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ABSTRACT 
Counterfeit and substandard medicines are a grave public health concern that 
comprises a $75B black market and claims over 100,000 lives every year. The World 
Health Organization estimates that 10-50% of medicines in countries around the world 
are adulterated, and their presence imposes serious financial and economic burdens while 
also contributing to the rise of drug-resistant pathogens. Although a plethora of 
technologies are available for field-based quality screening, none reliably quantify active 
pharmaceutical ingredient (API) content or kinetic release from a dissolving tablet. The 
United States Pharmacopeia, a global leader in medicines standards for over 150 years, 
. . 
indicates that these quality measures are vitally important yet remain outside of the reach 
of existing screening tools. The current field standard relies on thin layer chromatography 
to only provide qualitative results that make it difficult to discern between tablets that 
contain 80% and 100% API. Meanwhile, international standards set the threshold for 
substandard medicines at 90%. This clear lack of appropriately quantitative and field-
ready analytical tools poses a serious problem for national and international policy-
Vl 
makers who are plagued with wildly variable information that prevents focused and 
deliberate action against the spread of these medications. 
This work presents an alternative analytical technique that can specifically and 
accurately quantify drug API content and kinetic release. PharmaChk provides an 
orthogonal approach to existing technologies using a portable, inexpensive, and easy-to-
use platform. We demonstrate that aptamers can provide a simple and effective way to 
target a wide range of APis, while maintaining high quantitative precision and accuracy. 
A microfluidic, flow-through system is employed to obtain valuable drug quality 
information using a single step procedure. Through our research, we demonstrate the 
development of the PharmaChk platform from the proof-of-concept stage to beta 
prototyping and field-testing. By providing a portable, robust, and quantitative approach 
to medicines testing, PharmaChk can enable the collection of important drug quality 
information throughout pharmaceutical supply chains and ultimately save the lives of 
millions that are not afforded safe and essential medicines. 
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Chapter 1: Introduction 
1.1 Problem 
A mother's steps pound the clay as she hurries her way to the local pharmacy. She 's 
greeted with a smile that aims to disarm the anxious mother's worried expression; the 
pharmacist hands her a box of malaria medicine, reassuring her as the mother whisks out 
the door. Days later, she buries her baby boy. 
Malaria kills a child every sixty seconds, yet lurking in this statistic lays a dangerous, 
unassuming, and growing culprit. Counterfeit and substandard medicines are on the rise 
around the world, and have been linked to millions of deaths over the last decade. 1 The 
inadvertent use of these drugs has led to widespread treatment failures, increased 
morbidity and mortality, and a rise in drug resistance cases.2•3 In countries such as 
Pakistan and Nigeria, over 40% of the local market comprises adulterated medication, 
and globally, the World Health Organization (WHO) estimates 10-50%. 1 Antimalarials 
are only a small p01tion of a $75B black market that is scaling with increasing global 
demand for essential medicines.4 
Cases of dangerous or harmful medication go back over a hundred years. The 
passage of the U.S. Biologics Control Act of 1902 was largely in response to the death of 
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13 St. Louis children who were victims of tetanus-contaminated diphtheria vaccinations.5 
The source of the contamination was traced back to the blood of a horse that had 
contracted tetanus, but was nevertheless used to extract diphtheria antitoxin.6 Further 
investigation found that almost no serum had been laboratory-tested before distribution 
and several individuals were aware of the contamination prior to bottling the vaccine. A 
secondary tetanus outbreak in Camden, New Jersey quickly followed and was also 
attributed to contaminated vaccinations, resulting in over 70 hospitalizations.6•7 These 
outbreaks quickly gained national attention and resulted in heightened regulation 
surrounding the manufacture and sale of antitoxins, serums, and vaccines. Unfortunately, 
the level of oversight was still not far-reaching enough. Indeed, thirty years later, tragedy 
struck again. The Massengill Company of Bristol, Tennessee had just bottled close to 240 
gallons of a new liquid dosage form for sulfanilamide. This new compound was one of 
the first synthetic antibiotics and had been shown to be extremely effective.6 However, its 
unpleasant taste as a powder or tablet resulted in a high demand for a more palatable 
form, pmticularly for children. Harold Cole Watkins, chief chemist at the Massengill 
Company found that the active ingredient readily dissolved in diethylene glycol (DEG), a 
solvent attributed with a slightly sweet flavor. Minor testing of the formulation was 
conducted to check for taste, appearance, and fragrance before bottling the syrup for 
distribution. Within a month, the death toll began to climb.6 Apparently, DEG-a 
common component of antifreeze-was lethally toxic. By the time word had spread and 
recalls were put in place over 100 people had died. 8 This spurred quick government 
action, resulting in the passage of the Federal Food, Drug, and Cosmetic Act of 1938. 
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This new piece of legislation enacted even stronger oversight and regulation, and placed a 
mandate on companies to perform product-safety testing prior to marketing.8 
In spite of seizing global attention, the DEG tragedy of 1937 did little to curtail 
future incidents. Another 30 years later on the other side of the world, seven children in 
Cape Town, South Africa succumbed to renal failure. Post-mortem analysis and further 
investigation found traces of DEG in over-the-counter sedatives that were ingested by all 
seven children. The molecule was found to have been a substitute for propylene glycol9, a 
commonly used excipient that acts as a drug solubilizer in topical, oral, and injectable 
medication.10 In 1985, 5 patients at a hospital in Spain received topical treatments for 
bums and died due to DEG contamination.8 The following year, 21 people died at a 
hospital in India due to the administration of glycerine that was later found to contain 
18.5% (v/v) ofDEG.9 In 1990, PEG found its way into the headlines again: 47 children 
in Nigeria died as a result of ingesting acetaminophen syrup to treat malaria-related 
complications9. Nigeria has since suffered a second epidemic of DEG poisoning, this 
time killing 84 infants and children in 2008 after finding its way in teething syrup8. 
Similarly, disaster has struck India again, killing 33 in 199811 • Nearby Bangladesh also 
suffered hundred of casualties, where DEG poisonings between 1990-92 were 
responsible for 235 deaths12• In these cases, DEG was again found as a contaminant in 
acetaminophen syrup and cough expectorant. After the incident in Bangladesh, which 
took two years of investigation to identify, a ban was placed on all acetaminophen elixirs, 
subsequently seeing a 53% decrease in overall hospital admissions for renal failures, and 
an 84% decrease in hospital admissions for unexplained renal failures. 12 Unfortunately, 
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the story did not stop there. In the years to follow, Argentina (29 dead), Haiti (88 dead), 
China (12 dead), and Panama (78 dead) would all see fatalities due to medication-related 
DEG poisoning.9 In total, over 750 people were. victims of DEG poisoning over the past 
80 years across five major continents. While evidence was not found identifying the 
cause of this contamination in many of these cases, several were linked to deliberate 
substitutions, including the 2006 outbreak in Panama.13 
Unfortunately, the global DEG crisis represents only the tip of the iceberg. 
Numerous reports of other counterfeit and substandard medicines activity have been 
reported over the last twenty years. 
Africa 
In 1995, 88K meningitis vaccines were donated to Niger from neighboring Nigeria, as the 
country suffered from a meningitis outbreak that resulted in over 41K reported cases.14 
Upon receiving the consignment, the vaccines were noted to have an unusual color, 
launching an inquiry that eventually found no traces of active product. Unfmtunately, the 
finding came too late. With over 50,000 vaccines already used for inoculation, an 
estimated 2,500 deaths were attributed to these fakes. 15 More recent large-scale studies 
conducted in 2009 have shown that 35% of antimalarials sold in six major African cities 
were found to be substandard or counterfeit. 16 Moreover, this study found varying 
numbers based on tests using different medicines quality screening tools, suggesting that 
the precise prevalence of these poor quality drugs is large, but still elusive. A separate 
study of antimalarials in Burkina Faso showed a failure rate of 42% among samples that 
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were tested. 17 While these numbers vary from country to country, and even from city to 
city, a comprehensive 2012 review summarizing results from 21 surveys covering 21 
countries indicated that indeed, one third of antimalarial medication is falsified on the 
African continent. 18 
Asia 
Surveys in the Phillipines conducted in 1999 indicated that 8% of purchased medicines 
were counterfeit. A similar countrywide survey conducted around the same time in 
Cambodia showed that 60% of sampled antimalarials contained a substitute API that was 
less effective, or contained no API at all. In mainland Southeast Asia, surveys indicated 
that 38% of antimalarials sold as artesunate were fake. 19 Summarizing these results in a 
comprehensive 2012 review, Nayyar et al. presented a figure of roughly 36% for falsified 
antimalarials within Southeast Asia. 18 This points to a problem of equal if not greater 
magnitude for antimalarials in Southeast Asia when compared to Africa. It is estimated 
that 25% of all medicines purchased in malaria-endemic countries are antimalarial drugs. 
This poses a grave problem for millions who seek treatment and safety in these areas.18 
South and Central America 
Reports of counterfeit and substandard medicines in South and Central America are less 
frequent, but still problematic. In 1998, over 200 unwanted pregnancies occurred in 
Brazil due to counterfeit contraceptive tablets?0 DEG poisoning cases were also seen in 
Argentina, Haiti, and Panama. Later, m 2009, Brazil seized 316 tons of fake 
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pharmaceutical products. The following year, Argentina discovered and confiscated 
almost 400,000 counterfeit pills for the treatment of erectile dysfunction.21 While 
published reports of substandard medicines in this part of the world are scarce, there is 
significant anecdotal evidence that suggests that the problem is very real.8 
Europe and the US. 
Although the majority of substandard and counterfeit medicines cases are reported in 
developing regions, there has been a steady rise in the number of repotts documented in 
more industrialized nations. Close to 250K units of counterfeit medications were found in 
Italy in 2000, and in Russia, the counterfeit market was believed to represent 5-10% of all 
drug sales?0 More recent European estimates in 2010 indicated that the number of fake 
drugs identified by random samples from European Union borders increased by 400% 
from 2005.22 In the United States, the problem has also seen an increase. Between 
January and August of 2002-a period of 8 months-16 reports of drug counterfeiting 
and tampering were recorded?0 According to the broadcast provided by the National 
Public Radio, these cases dealt with fake AIDS and cancer medication, anemia 
treatments, and Viagra pills.23 By 2006, the FDA saw an 800% increase in the number of 
new counterfeit cases over the last six years?4 Two years later, 149 Americans tragically 
fell victim to fatally contaminated heparin sourced from China.8 In 2011-12, counterfeit 
cancer medications found themselves in distribution again, resulting in several FDA 
announcements that went out to physicians and doctors across the country_25-27 That same 
year, tainted steroids killed 64 people and affected hundreds more in Massachusetts? 8 
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The majority of these examples represent medicines that were mostly obtained through 
typical distribution channels. However, the presence and use of online retailers in 
. industrial nations further complicates the landscape. For . drugs sold through these 
channels, it is estimated that over 60% are fake. 29 
These reports paint a grim picture for the state of the pharmaceutical market and the 
penetration of adulterated medication within the past three decades. While a definitive, 
quantitative grasp on the problem remains elusive due to inconsistent study and survey 
results, one thing that is very clear is that the prevalence of fake and substandard 
medicines is on the rise. A quick glance at the number of annual overseas counterfeit 
drug cases that have been opened by the U.S. FDA shows a steady increased from 9 in 
1997 to 72 in 2010.8 Furthermore, the ambiguity of international law in many of these 
cases makes it difficult to prosecute manufacturers of adulterated drugs. As important as 
analytical tools are in defining and characterizing the problem, national and international 
policy also play a large hand in shaping the landscape for the global medicines market. 
Indeed, in order to affect this problem, these actors will need to play that hand to preclude 
the spread of poor treatment outcomes and ultimately save lives. 
1.2 Incentives and circumstances 
To formulate a deliberate and strategic policy against adulterated medication, it is 
important to understand the incentive structure and causes that lead to the global 
distribution of these products. While in some instances, there is evidence of clear 
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malicious intent, in others it is simply a story of poor manufacturing processes. 
As many suspect, profit is a major driving force in the production of both 
counterfeit and substandard medication. According to one report, the counterfeit drug 
market is 25 times more lucrative than heroin and 5 times more lucrative than tobacco.22 
While research, development, and production of a drug product can cost billions of 
dollars, the manufacturing of a knock-off product simply requires the formulation of a 
pill that has the same, shape, size, color, and weight as the original. Simply neglecting to 
add the API yields significant cost savings, and even substituting the API for similar 
molecules that are substantially cheaper can oftentimes be undetected. One example of 
this was the U.S. heparin scare in 2008. After the death of 149 people, detailed analysis 
of the heparin revealed the use of over-sulfated chondroitin sulfate (OSCS). This 
molecule cost over 100 times less than heparin and was virtually undetectable using high 
performance liquid chromatography-the laboratory gold standard. As a result of the 
incident, new tests were developed using sophisticated magnetic resonance techniques 
that had never before been used for heparin testing. 8 This example underscores the extent 
to which counterfeiters are willing and able to go to increase their bottom line in one of 
the most profitable markets in the world. Similar cost-savings in the way of infrastructure 
·are also a tremendous draw. Manufacturing technologies for tablets are readily accessible 
and operations for tablet production have been cited in facilities as small as ordinary 
houses, back-yards, and small cottages.30 With improvements in digital printing 
technologies, these counterfeiters can also copy labeling from readily available authentic 
medication with relative ease; in most developing areas of the world, medication is 
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simply available over-the-counter due to poor regulatory oversight and practices. These 
operations are particularly prevalent in areas where government corruption is an equally 
challenging problem.30 
Like outright fakes, poor regulatory oversight and practices are also responsible 
for the manufacture and sal~ of genuine, poor-quality medicines. In fact, much research 
shows that substandard medicines comprise a much larger proportion of failed quality 
tests than outright fakes. 30•31 However, in addition to the failure of regulators to enforce 
good manufacturing practices (GMPs), the causes of poor-quality medicines are 
essentially the same as those for counterfeits. Many small-scale productions have poor 
quality-control practices and are unable to guarantee batch-to-batch consistency of their 
drug product.31 This can be due to both lack of knowledge as well as lack of local 
resources. Many of these manufacturing facilities are located in low- and middle- income 
countries where systemic infrastructure is poor and there is lack of appropriately trained 
staff. Furthermore, these operations have limited options in the way of fmding and 
sustaining the financial resources necessary to operate a quality production.32 On the 
other hand, poor quality medicines can also be unknowingly or accidentally 
manufactured. Several instances of mislabeling have been cited, which illustrate cases in 
which genuine medicine was produced, but downstream testing for the inappropriately 
marked API would reveal no API content, marking the product as fake? 1 Another 
scenario is one in which poor quality API is acquired and used for manufacturing. While 
under strict GMP guidelines these ingredients should be tested, facilities with minimal 
· resources cannot afford to conduct such analysis. 
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Unfortunately, regulatory authorities in low-income countries are often in the 
same financial position as many small-scale manufacturers. Surveys administered to 26 
African regulatory authorities revealed an ongoing problem with sustained funding, 
chronic shortage of trained staff, and minimal operational resources. Furthermore, among 
the malaria-endemic countries on the African continent, only Kenya, Tanzania, and South 
Africa have WHO prequalified laboratories that are equipped to analyze drug samples. 18 
With such limited resources, regulatory authorities often do not have the ability to 
execute strict GMP oversight on local manufacturers. For medicines that are imported, 
minimal infrastructure for quality testing prevents sufficient sampling and verification for 
good quality products. Tragically, these restraints on both the manufacturers and 
regulators ultimately hurt the consumer. 
Tipping the scale and scrutinizing the other side, the high cost of genuine 
medicines around the world can also be named a culprit. 19 If it were not for these often 
unaffordable prices, there would be considerably less profit potential for counterfeiters 
and deliberate substandard manufacturers. 19 This problem is exacerbated by the relative 
poverty of individuals in resource-limited settings. If seemingly identical products are 
available for wildly different prices, the tendency exists in these areas to side with the 
more affordable product. Many consumers also actively seek these cheaper medicines 
outside the normal supply chain. In addition to a higher prevalence of fake or substandard 
drugs, medicines sold through these channels are typically provided without a 
prescription, at inappropriate dosages, and without package instructions and warnings.30 
Beyond simple price-structures, public demand for medicines that treat tropical 
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illnesses in low-income areas is also quite high. However, smce the 1980s, many 
pharmaceuticals have begun to focus their attention to more profitable market segments.33 
One example of this is the reduced production of chloroamphenicol, a medicine that was 
shown to be equally effective and significantly more affordable than ampicillin for the 
treatment of bacterial meningitis. Production of the medicine significantly decreased after 
1995, despite the occurrence of numerous meningitis epidemics in West Africa and other 
areas over the following ten years. 14 As pharmaceutical companies scale back their 
production, counterfeiters and substandard manufacturers can quickly replace the 
medicines market with poor quality drugs, as the supply for genuine medicines in these 
cases dwindles in spite of a high public need. 
1.3 The not-so-secret source 
Popular knowledge sides with the facts when it comes to susprcrons for where the 
majority of counterfeit and substandard medicines originate. India and China are two of 
the most prevalent sources for adulterated medication in the world.8•34•35 However, Indian 
and China also represent two of the largest manufacturing sites for all medication in the 
world; close to 80% of genuine API product is manufactured in these countries.8•18 Still, 
the problem is both serious and widespread. In 2006, Chinese police seized 24,000 blister 
packs of fake artesunte, but only after the majority had already been sold on the Myanmar 
border.35 In 2008, the European Customs Union reported over 3,200 attempts to import 
fake drugs, over half of which originated from India. Figure 1.1 provides an illustration 
of the major trafficking routes for fake and substandard medicines originating from these 
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two countries. 
Numerous schemes exist within these countries to produce and package poor-
quality medicines. In India, there are typically three classes of producers. The first are 
unlicensed manufacturers that produce tablets in small homes and backyards. The second 
are licensed manufacturers who produce poor quality product alongside their legitimate 
medicines. Evidence has been found of manufacturers that produce good quality tablets 
during the day, but continue night operations focused on substandard medication 
production.8•35 Others still simply use street chalk or other fillers to produce falsified 
medicines. The third are simply importers that bring in product from China and simply 
repackage it to make it pass as authentic medication.35 
In addition to China and India, Nigeria and Pakistan are also countries that have 
substantial manufacturing capabilities. In fact, some reports indicate that after India, the 
two largest producers of substandard medicines are Nigeria and Pakistan, quickly 
followed by China.36 To mitigate the growth of adulterated medicines in these countries 
and thwart their production in other emerging markets, the development of strong 
regulatory programs is essential. 
1.4 International response 
In an increasingly global market, the problem of counterfeit and substandard medication 
is far from contained to particular countries. As we saw in the previous section, a 
majority of adulterated medication is manufactured in India and China, yet those same 
medicines are used through areas in Africa, Europe, and the Americas. While national 
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medicines regulatory authorities such as the U.S. FDA are crucial players for the proper 
oversight of genuine medicines manufacturing, international bodies are equally vital to 
the process. They are essential to facilitating a global dialogue using common language 
that can be used to enact firm policies against adulterated medicines and strict guidelines 
for the production of safe and reliable medication. 
Fortunately, this idea has been cultivated since the inception of the World Health 
Organization in 1946. The first discussion on the problem of counterfeit medication was 
initiated at a 195 8 conference of Experts on the Rational Use of Medicine3• Since then, 
countries and independent researchers from around the world have collected data on the 
extent of the local and global fake medicines problem. In more recent years, countries 
such as India, China, the Philippines, Nigeria, and the United States have taken firm steps 
toward mitigating the spread of poor-quality drugs and increasing global access to 
essential medicines.3 
[n an effort to consolidate data, the WHO developed the Counterfeit Drug 
Database in 1 982. While the database provided a central store for individual reports of 
fake drugs, it also provided a useful tool to help understand the problem. In a 1999 report, 
the WHO released information from the database that showed that from 771 confidential 
reports received between 1982-1999, almost 50% of cases were reported by the WHO 
Western Pacific regional office, 20% by the WHO Africa regional office, and just under 
15% by the WHO Europe regional office. Furthermore, they indicated that almost half of 
the reported cases dealt with life-saving antibiotics.2 
During this time, a separate non-profit institution known as United States 
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Pharmacopeia (USP) began a joint partnership with the United States Agency for 
International Development (USAID). The resulting program, known as the Drug Quality 
and Information (DQI) program began in 1992 and aimed to support developing countries 
address local problems with adulterated medicines. As a leader in setting medicines 
quality standards in the U.S. for over 170 years, the USP provided expert knowledge in 
analytical methods, protocols, quality assurance, and quality controls systems. The 
program lived until 2009, when the USP was awarded $35M to expand the program over 
the following five years. Since then, that support was raised to an additional $11OM to 
last until 2019. The USP now operates in more than 35 countries, under a new program 
titled Promoting the Quality of Medicines (PQM). The PQM program has four key 
objectives: 
1. Strengthen quality assurance and quality control systems 
2. Increase the supply of quality assured medicines 
3. Combat the availability of substandard and counterfeit medicines 
4. Provide technical leadership and global advocacy 
Domestically, the USP is still responsible for setting drug quality standards and develops 
reference standards that are used by pharmaceuticals to comply with FDA regulations and 
GMPs. 
Together, the WHO and USP have years of experience in the counterfeit and 
substandard medicines space, and have gained valuable insight into the extent of the 
problem and how it may be addressed. 
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1.5 Counterfeit vs. substandard 
The formation of international programs and the development of unified efforts against 
adulterated medication is a major step in developing global policies that can improve 
worldwide access to good quality medicines. However, a major problem in developing 
these policies and determining strategies for moving forward is the Jack of clear and 
quantitative evidence regarding the medicines quality problem. Over the last thirty years, 
hundreds of studies and reports have been published that document the occurrence of 
poor quality medication. Yet much of this work uses different language and inconsistent 
definitions. While some use the term counterfeit more generally to refer to any 
medication that was manufactured with mal-intent or does not contain what it indicates35 , 
others use it to mean medication that is strictly mislabeled and branded as another 
product. These minor differences in semantics result in inconsistent findings and 
imprecise numbers when determining the prevalence of various classes of poor quality 
medication in areas around the world.3 
The original definition for a counterfeit drug was formulated in 1992 by the WHO 
in conjunction with the pharmaceutical industry: 
"A counterfeit medicine is one which is deliberately and fraudulently mislabeled 
with respect to identity and/or source. Counterfeiting can apply to both branded 
and generic products and counterfeit products may include products with the 
correct ingredients or with the wrong ingredients, without active ingredients, with 
insufficient active ingredients or with fake packaging. "2 
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While this definition continued to be officially used by the WHO, it was understood that 
in spite of this, independent reports and investigations continued to use varying 
definitions. Furthermore, some countries such as Nigeria and the Philippines operated 
under their own official definition of counterfeit. What most eventually understood of the 
term is that a counterfeit drug referred to a medicine that was an imitation of something 
else with the intent to deceive.3 
Substandard medicines, in contrast to counterfeits, simply refer to medicines that 
are of poor quality. The WHO defmes a substandard medicine as: 
" ... genuine medicines produced by manufacturers authorized by the NMRA 
[national medicines regulatory authorities] which do not meet the quality 
specifications set for them by national standards. "37 
Substandard medicines may refer to tablets with more or less API than expected, or they 
may refer to a drug that has no API at all. In this way, substandard medicines encapsulate 
all counterfeit medication, with the exception of good quality counterfeits that contain the 
appropriate amount of API. While this exception almost never exists, it highlights the key 
difference between a counterfeit medicine and a substandard one-counterfeits are 
always branded with the intent to deceive. 
Throughout the remainder of this writing, these defmitions will be used for both 
counterfeit and substandard, although a heavy focus is placed on substandard medicines. 
The word fake shall be used synonymously with counterfeit, while adulterated may be 
used to encapsulate all of these classes of medicines. 
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1.6 Implications 
Despite all of the confusion surrounding the definitions of counterfeit and substandard 
medicines as well as the true extent of the global problem, the one thing that remains 
bitterly and piercingly clear is the devastating health impacts these medicines have 
worldwide. For malaria alone, 3.3B people are at risk in over to 50% of the countries in 
the world where the parasite is endemic.18 Meanwhile, close to a third of antimalarial 
medication in these areas are counterfeit or substandard. As reviewed in the previous 
sections, thousands of individuals have died due to adulterated medication, and thousands 
more die each year as victims of illness continue to seek help but are instead greeted by 
empty pills. 
In addition to the burden borne by the loss of life, the economic implications of 
this global problem are staggering. In some areas, up to 90% of the population have to 
pay out of pocket for their medication, which oftentimes account for a significant portion 
of the household income.31 These financial and health-related burdens quickly translate to 
substantial decreases in national productivity and labor force. As many of the affected 
areas represent emerging markets, responding swiftly and deliberately to the medicines 
quality problem will be critical for sustained economic progress. 
Finally, one of the most potentially devastating implications for substandard 
medication is its ubiquitous cultivation of drug-resistant pathogens. History has already 
seen both drug-resistant malaria and tuberculosis evolve in response to medical 
treatments. For malaria, chloroquin resistance grew rampant in the 1990s, eventually 
leading to the use of artemisinin-combination therapies (ACTs)? 8'39 While ACTs have 
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proven immensely effective, uneasiness over the development of drug resistance for this 
I f d. . . . 18 40 41 Th" . f . . 1 I b new c ass o me 1cmes ts mountmg. ' ' IS IS o grave concern partlcu ar y ecause 
there are few other treatment options available. Similarly, drug-resistant tuberculosis has 
been a problem for decades. It is estimated that one third of the world is infected with 
latent tuberculosis infection. While the treatment of active TB due to these infections is 
already long, cases of drug-resistant and multidrug-resistant (MDR) TB are even more 
complicated and grueling, sometimes taking up to 2 years to treat.42 More recently, 
extensively drug-resistant (XDR) TB has also become a problem, showing resistance to 
both first- and second-line treatments. While the development of many of these strains is 
due to poor drug adherence, substandard medication has virtually the same effect. 
Especially considering treatment lengths such as those for TB, the regimented use of 
substandard medicines can quickly result in the development of drug-resistance. While in 
past years the link between substandard medicines and drug-resistance was speculation, 
the connection has turned out to be very much true. 18•31 •43•44 
1. 7 Lifting the fog 
In this chapter, we have reviewed numerous cases of substandard and counterfeit 
medication. We have seen that they are flourishing in global markets, sometimes 
comprising up to 50% of accessible medicines; that they are responsible for hundreds of 
thousands of deaths every year; that they have pattially led to the development of drug-
resistant malaria and tuberculosis; that they have significant financial implications for 
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victims of illness that see no benefit from their purchases; and that they can ultimately 
bear grave capacity-based and economic burdens on afflicted nations. 
Fortunately, we have also seen countries across the globe mobilize in the face of 
this threat. Numerous international alliances and programs have been designed and 
executed to help provide a strategic step forward based on expert knowledge and 
experience. Several countries including Nigeria and China have also begun to crack down 
on local sources of poor-quality medication. Public awareness is also on the rise as more 
reports of poor-quality medicines are making headlines. 
Yet in the face of literature, what we currently see is a problem landscape that is 
thick with fog. While hundreds of reports and studies provide pages of numbers and 
statistics, we are finding that many of these results are not directly comparable and make 
it difficult to gain a comprehensive understanding of the extent of the problem. Being 
aware to the fact that the crisis is of different proportions from country-to-country and 
continent-to-continent, more evidence is needed in order to devise problem-specific 
solutions that account for local logistical and political factors; the cause and spread of 
adulterated medicines is by no means the same in every country. In order to provide clear 
guidance to international efforts to enact policy changes, more analytical testing is 
urgently needed. These tests must extend beyond post-market samples to include analysis 
of medicines quality up and down local supply chains. Only by performing these 
comprehensive examinations can we be certain of where adulterated medication are 
penetrating the market or why good quality product is deteriorating or expiring. 
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Fortunately, there are a plethora of analytical methods that are available and have 
even see prolific use. However, as we will see, these methods all provide only a subset of 
quality information. A more quantitative and comprehensive methodology is desperately 
needed to augment the current set of tools. Before we entertain that idea, the next chapter 
will first begin with a look at what's available and how it's used. 
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1.8 Figures 
Figure 1.1 Presents an overview of the general counterfeit medicines trafficking 
routes from India and China. India and China are the two largest producers 
of substandard and counterfeit medication. As the diagram indicates, the 
majority of these poor quality products travel to South East Asia and 
Africa. Figure taken from the 2010 report from the United Nations Office 
. 35 
on Drug and Crime. 
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Chapter 2: Testing Approaches and Current Status 
2.1 Testing Approaches 
The United States Pharmacopeia (USP) outlines four attributes that are used to 
characterize the quality of medicines: 
1. Active pharmaceutical ingredient (API) identity - verification of the correct 
API in the drug tablet. 
2. API quantity - measurement of how much of the correct API is present in the 
tablet. 
3. Tablet dissolution- analysis of how the API is released from the tablet over time 
as it dissolves in solution. 
4. Impurities- assessment of what impurities and/or other toxic agents may also be 
present in the tablet. 
In practice, there are three modes of testing that are used to analyze one or more of these 
attributes, either directly or by proxy: visual inspection, field analysis, and laboratory 
testing 
2.1.1 Visual Inspection 
Visual inspection often serves as the first line of screening in many countries due to its 
inexpensive nature. The process involves packaging and labeling inspection, and is 
intended as a proxy for the USP quality attributes. Any anomalies flag the drug for 
further testing, which can either be done onsite or at a central testing facility. Visual 
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inspection is performed for two reasons. If the medicine is substandard, poor packaging 
can imply crude manufacturing processes for the tablets themselves. On the other hand, if 
the medicine is counterfeit and designed to resemble a brand name, visual inspection 
focuses on direct comparison of the packaging and labeling with that of an authentic 
package. Aspects that are focused on include inconsistent print fonts , logos, and print 
quality. 
2.1.2 Field Analysis 
Field analysis involves onsite physical testing of medication. Tablets are interrogated 
using a number of technologies and often after a visual inspection. These tests aim to 
determine one or more of the four USP quality attributes, however none analyze all. 
While field-based methods continue to improve over the years, most focus on API 
identity and impurities. Some devices such as Raman and near-infrared (NIR) scanners 
also provide semi-quantitative information regarding API content. However, none 
currently attempt to provide any dissolution information. 
2.1.3 Laboratory Testing 
Laboratory testing of drug tablets typically makes use of high-performance liquid 
chromatography (HPLC), which provides reliable and accurate test results. This approach 
provides a definitive analysis, and is often used for confirmatory testing after field 
analysis of specific tablets. While laboratory testing is used as the gold standard, the cost 
of necessary instruments prohibits extensive sampling. For this reason, there is a major 
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push towards developing more reliable and accurate field-based methods for medicines 
screening that can allow for rapid analysis of more tablets at a lower cost. 
2.1.4 Dissolution 
Dissolution testing is commonly performed in the pharmaceutical industry to determine 
batch-to-batch variability in tablet pressing and verify therapeutic value based on 
comparisons to bioequivalence assays. It serves as the one of the key tests for quality 
assurance of medicines as they leave the manufacturer. 
Dissolution testing is typically performed using one of four USP certified 
dissolution apparatuses. They are referred to as USP Dissolution Apparatus 1-4. The 
principle of the test is to determine how the API is released from a tablet over time. The 
apparatuses provide a mechanism by which the tablet is slowly dissolved, and samples 
are analyzed for the API concentration at a specific time interval. The results are plotted 
to provide a chart of API concentration over time. A typical plot starts with a zero signal 
that slowly rises and then plateaus once the tablet is fully dissolved. Each apparatus 
provides a different method for dissolving the drug tablet. 
The USP Dissolution Apparatus II is the most widely used apparatus and is often 
referred to as the paddle test. The system uses a paddle to stir a solution containing the 
drug tablet (Figure 2.1). In recent years, numerous studies have been performed that 
analyze the perfonnance and variability of the system, indicating a high dependence of 
dissolution time on tablet position within the vessel.45-47 However, this problem is 
typically circumvented by standardizing the tablet position from test to test. 
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While dissolution testing is performed frequently as part of the manufacturing 
quality assurance process, the analysis is largely neglected in medicines quality 
screenings. As emphasis continues to shift from laboratory to field-testing for counterfeit 
and substandard drug screening, there is a growing need for technologies that are able to 
perform dissolution in addition to determining API identity and content. There are 
currently no technologies that meet these criteria. 
2.2 Existing Technologies 
Numerous devices are currently available for analyzing tablets both in the field and in the 
laboratory. These instruments are detailed below to provide a summary of the current 
landscape for counterfeit and substandard medicines screening. 
2.2.1 HPLC 
High performance liquid chromatography (HPLC) has remained a mainstay in analytical 
chemistry since the 1960s. The technology relies on a column of packed beads or 
granular materi.al through which a sample is driven using high pressure. As the sample 
passes through the column, different molecules interact uniquely with the pack material. 
Consequently, these molecules are separated and exit the column in a time-dependent 
manner that is based on the strength of the interaction. Molecules that interact strongly 
with the beads remain within the column for longer, while those that interact weakly exit 
quickly. A variety of detectors are used at the column egress to analyze the departing 
molecules; the most common include UV -vis and mass spectroscopy detectors. As 
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molecules leave the column and pass through the detector, a signal is generated that is 
proportional to the concentration of the molecules. This signal is recorded throughout the 
test, resulting in time-resolved peaks that represent the various components that 
comprised the initial sample. The time at which a peak appears is known as the residence 
time, referring to how long the molecule remained within the column. A sample 
chromatogram is provided in Figure 2.2. 
Once a chromatogram is generated, the residence time and peak intensities from 
UV -vis or mass spectroscopy analysis can be used to determine which molecules were 
present in the sample mixture. After an initial determination has been made, the results 
can be verified by spiking additional samples with a known amount of each analyte. The 
presence of the same peak with a higher peak value confirms the molecule. The presence 
of an additional or split peak indicates a false result. Once molecule identities have been 
confirmed, the amount of each component within the original sample can be calculated 
based on the area of each peak. These areas are compared to a reference peak of a known 
quantity to calculate the absolute mass of each component. 
For pharmaceutical testing, HPLC is the gold standard as it can be used to 
determine all four USP quality attributes with high precision and accuracy. 
Chromatograms generated from reference samples ~an be used to verify API content and 
identity from a sample tablet. The presence of any impurities at significant concentrations 
will also result in additional peaks that are not present in reference chromatograms. The 
resulting peaks can be analyzed again to determine the identity of the impurity. Finally, 
dissolution information can be gathered by dissolving a tablet and sampling at specific 
26 
time intervals. These samples can be analyzed using HPLC to obtain accurate readings of 
API concentration over the course of tablet dissolution. 
2.2.2 GPHF-MiniLab® 
The GPHF-MiniLab® serves as the current WHO recommended standard for field-based 
screening of prescription drugs in developing regions. The kit consists of two briefcases 
that contain reagents and reference standards to perform field-based medicines quality 
testing (Figure 2.3) . MiniLab® analyzes drug quality attributes in four stages. 
1. Visual Inspection - Counterfeit medicines oftentimes are not packed appropriately or 
are packaged differently from those produced by authentic manufacturers. Although a 
simple procedures, many drugs are actually eliminated in this way. 
2. Disintegration Testing - Drugs that pass the visual inspection are then placed in 
solution to identify whether the formulations actually dissolve. Again, this is a 
rudimentary screening protocol that provides a simple yes or no answer. Despite this, 
it plays an important role in screening out medicines that use inappropriate 
formulations and lead to incomplete drug delivery. 
3. API Identity -A drug tablet is crushed and dissolved in an appropriate solvent. A 
quick colorimetric test is then used to verify the presence and identity of the active 
ingredient. 
4. Chemical Analysis - Thin layer chromatography (TLC) is finally used to assay the 
potency of the drug. The dissolved drug solution is used to spot a TLC plate. The 
separated components can then be analyzed to determine the presence of impurities. 
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The amount of active ingredient can also be deduced from the size of the 
corresponding spot, although this provides only a semi-quantitative measure. 
The strength of the MiniLab® system rests in its use of TLC. TLC has long been used as 
a simple, yet effective technology for · chemical separation48, quantification48, and 
extraction49 as well as drug analysis, screening, and quality control.50-52 In the low 
resource environments of developing countries, TLC has emerged as a useful technique 
to assay drugs for the presence or amount of active ingredient. In addition to the 
simplicity of the TLC approach, the portability and relatively cheap production costs 
make MiniLab® a very attractive tool for medicines quality screening in resource-poor 
settings. However, TLC-dependent testing also presents a number of significant 
challenges: 
1. TLC testing may produce similar separations for chemicals of varying structure.48 
2. Similar color responses can occur between true active ingredients and other 
analytes.49 
3. TLC testing shows poor sensitivity to low-level impurities. 
For MiniLab®, these problems quickly compound, leading to an error in API 
quantification of approximately 20%. Poor quality medicines can have tremendous 
effects on drug efficacy and safety, yet the GHFP-Minilab® protocol still accepts 
medicine samples that have at least 80% of the labeled active ingredient(s). 16 
Overall, MiniLab® provides an extremely inexpensive option for analyzing drugs 
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in the field and packages the system in two suitcases that can be transported much more 
easily than a full lab; however, despite these advantages, MiniLab® provides poor 
accuracy and is far from being a truly portable, robust, or dependable system for 
medicines quality screening. While being comprehensive and self-contained, the kit 
weighs 100 kg, making it difficult to transport. Furthermore, the system does not perform 
dissolution testing. While the kit may determine whether or not a given drug may 
disintegrate, it provides no measures for determining whether the active ingredient is 
released from the tablet in a consistent and timely manner. In short, the system provides 
only semi-quantitative results that, at best, provide only a cursory analysis of medicines 
quality. 
2.2.3 NIR spectroscopy 
Near-field infrared (NIR) spectroscopy offers another method for chemical analysis that 
is far more quantitative in comparison to TLC and has shoWn growing popularity in the 
area of medicines quality assessment. 53-56 On the market, Phazir™ is commonly used for 
this analysis (Figure 2.4). NIR spectrometry stimulates the molecules of a sampled 
medicine with near-infrared light and measures vibrations to obtain a unique fingerprint 
of the compound, including the API(s), excipients, and fillers. Portable NIR 
spectrometers are advantageous in that they are light and robust, eliminate sample 
preparation by testing through packaging, and the test results can be read within seconds. 
The disadvantage is that NIR depends highly on the formulation of the drug, being very 
accurate in some cases and unreliable in others16. Additionally, NIR is generally not very 
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accurate for quantitation, which is vital to the measurement of impurities. In order to be 
more quantitative, NIR requires a large number of training set that capture the batch-to-
batch variance in good quality drug formulations produced by pharmaceuticals. 
2.2.4 Raman spectroscopy 
Raman spectrometry represents another avenue for drug analysis that provides 
information similar to NIR. In the field, this technology is more commonly know as 
TruScan (Figure 2.4). Raman spectrometry also stimulates the molecules of a sampled 
medicine with a laser and measures vibrations to obtain a unique fingerprint of the 
compound. As is the case of their NIR counterparts, handheld versions of Raman 
spectrometers are light and robust, eliminate sample preparation and produce simple test 
results within seconds. An important disadvantage to Raman is that its use is problematic 
for medicine compounds that exhibit high fluorescence. 16'57 Raman is also less accurate 
as a quantitative tool, which is critical for quantifying the API(s) and measuring the 
levels of impurities. Certain molecules are also not Raman active and cannot be 
adequately detected. 
2.2.5 CD3 
CD3 is a recent addition to the list of medicines screening tools, and is still in the pilot 
phase (Figure 2.5). The instrument is a handheld scanner, much like NJR or Raman 
scanners. However, instead of providing a chemical fingerprint for the tablet, CD3 uses 
spectral analysis to interrogate physical features of drug tablets such as their shape, 
roughness, and color. The instrument can also be used to analyze the tablet packaging. 
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The device itself uses light-emitting diodes (LEDs) of various wavelengths to 
shine light onto the sample. Due to the way materials interact uniquely to these lights, 
counterfeit medicines that are made with different materials may absorb light or glow 
differently when compared to an authentic medicine (Figure 2.5). Any anomalies can be 
used to flag the drug as a suspected counterfeit. 
Studies comparing CD3 to other technologies are ongoing, but the device has 
successfully been used at US border crossings over the past several years. 58 However, the 
instrument only provides an enhanced mechanism for visual inspection; it is not able to 
verify API identity and content or provide dissolution information. 
2.3 Continuing challenges 
The current landscape of field- and laboratory-based testing platforms has made 
important contributions to defming and addressing the problem of poor quality 
medicines. However, laboratory-based methods severely limit the number of drug 
samples that can be rapidly and accurately screened, and field-based technologies still do 
not provide comprehensive and dependable results to offset this challenge. What this 
landscape still lacks is a comprehensive and quantitative testing platform that can provide 
definitive analysis of API content and kinetic release in the field. 
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2.4 Figures 
Figure 2.1 USP Apparatus II dissolution device, also referred to as the paddle 
method. This apparatus uses a paddle with the specified dimensions to stir 
a solution that contains a tablet. Samples of the solution are then taken at 
specified time intervals and analyzed for API content. This is used to 
generate a dissolution profile or plot of dissolved API over time. The 
bottom of the stir blade is specified to be 25 ± 2 mm from the bottom of 
the vessel, and the tablet is added to the solution and allowed to sink to the 
bottom before the blade is started. If the tablet is buoyant, appropriate 
sinkers can be used such as wire or helical glass. 59 
102±4 
(Internal 
diameter) 
35.8 
42.0 ± 1 
74.5±0.5 
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Figure 2.2 Sample HPLC chromatogram for the separation of J' Adore perfume water. 
0 
The separation was conducted using a C 18 column using a 5-l 00% 
acetonitrile-water gradient. The plot demonstrates absorbance of a 
separated mixture over time, and each peak represents a separated 
component from the original solution. The time at which the peak is 
·observed denotes the residence time.60 
10 20 30 40 50 60 
min 
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Figure 2.3 Global Pharma-Health Fund (GPHF) MiniLab® system. (top) Image of the 
full system fit into two suitcases. Suitcases contain all of materials 
required to complete a test including glassware, paper, pencils, and an iron 
for heat development of TLC results.6 1 (bottom) GPHF MiniLab® 
presented by Merck to the head of the Tanzanian Food and Drugs 
Authority. Provides a reference for the size of the system.62 
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Figure 2.4 Images of handheld scanning technologies for substandard and counterfeit 
medicines screening. (top) Phazir™ NIR scanner.63 (bottom) TruScan 
Raman scanner. 64 
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Figure 2.5 (top) Counterfeit Detection Device 3 (CD-3) device developed by the U.S. 
Food and Drug Administration. Tool uses lights of various wavelengths to 
illuminate and photograph samples and note any surface differences in the 
way packaging and tablets respond. Samples are compared against 
standard images to identify the differences.58 (bottom) Example of 
counterfeit Alii capsules identified by the CD3 device . Image shows the 
authentic sample on the right and the counterfeit product on the left.65 
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Chapter 3: Current Needs and PharmaChk Approach 
3.1 Ongoing needs 
Given the multitude of technologies reviewed in the previous chapters, there are many 
ways that improvements to API quantitation can be made. However, as aforementioned, 
none of the current approaches address API kinetic release. The MiniLab® test begins to 
interrogate this quality attribute by conducting a disintegration test. However, this simply 
checks to see if the tablet dissolves within an expected time frame; no further analysis of 
API concentration is performed. 
A more detailed look at other technologies for substandard medicines screening 
would reveal that most of them are based either on chromatography or spectroscopy. 
Truthfully, these are two of the most appropriate analytical techniques for tackling 
medicines quality screening. However, few improvements are being made that truly 
address the biggest problems in drug analysis-quantitation and kinetic release. 
Furthermore, many of these technologies are too limited by their protocol to provide an 
easier method of testing. Ease-of-use is an important factor for field-based technologies, 
yet some techniques still require laborious sample preparation. 
In order to elegantly and deliberately solve the ongoing problems in medicines 
quality testing, a fresh and holistic perspective is desperately needed. By taking this more 
systems-based approach, a streamlined, direct, and deliberate strategy can be formulated. 
To this end, we began with a list of needs as a starting point for designing a new field-
based system that addresses the existing challenges that face field-based screening tools. 
To help isolate those needs, we engaged with a party that had close to 200 years of 
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experience in the area of medicines quality and drug analysis- the USP. Due to their 
DQI and newly established PQM programs, USP had first-hand experience with each of 
the existing field-based analyses; they also had first-hand experience with all of their 
associated challenges. With that insight and experience, we identified the following list of 
key needs for a new field-based approach, which should provide: 
1. Quantitative information for API content 
2. API kinetic release in solution 
3. High specificity and sensitivity 
4. Easy-to-use components and protocols 
5. High portability 
6. Low power consumption 
7. Minimal user training requirements 
8. Affordability 
Using these key requirements, we began to devise a new testing strategy that approached 
adulterated medicines screening from a completely orthogonal direction. The thesis of 
this work presumes that this testing strategy could provide enhanced API quantitation 
over existing methodologies in addition to kinetic release, while remaining field-
deployable and easy to use. The outcome of that work is what we now call PharmaChk. 
3.2 PharmaChk Approach 
The concept for the PharmaChk system was inspired by a single question-how can you 
make a system that is specific and sensitive to an endless number of different molecules? 
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The simple answer was, you can' t. The very notion of specificity is exclusive. In order to 
have a specific test for a wide range of molecules, something has to change from test to 
test. When applying this to the development of a single system capable of quantifying all 
classes of drugs, some dynamic component of the static device has to make it specific. 
The question then became, what part? 
Binding assays have been a staple of cellular and molecular biology for decades. 
Cells are often stained with dyes that are specific only to patiicular components. The first 
example of this was the use of saffron by Anton van Leeuwenhoek in the 1600s to visual 
muscle fibers.66 Saffron is still commonly used today as a component in the more 
contemporary hematoxylin phloxine saffron (HPS) stain, which is used to differentiate 
between common connective tissue such as collagen and muscle.67 While early stains 
made use of molecules such as saffron with strong color for visualization, the emergence 
of fluorophores as an alternative for visualization was quickly changing that landscape. 
3.3 Fluorophores and Fluorescence 
Fluorophores are a class of molecules with specific structures that bestow them with a 
very unique property; when they are illuminated or excited by light of a particular color, 
they glow or emit light of a different color. All fluorophores share this chromatic shift, 
more formally referred to as the Stokes shift. In the biological sciences, the use of 
fluorescent molecules has become ubiquitous, but in order to consider their use in our 
approach for counterfeit and substandard medicines detection, it is important to 
understand their origin and the factors that affect them. 
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The fundamental basis for fluorescence is rooted in quantum mechanics and is a 
consequence of the Schrodinger equation. The Schrodinger equation represents a physical 
description of matter that is based on the supposition that it can be treated as both a 
particle and wave. While classical mechanics describes matter in terms of particles, the 
Schrodinger equation provides a basis for the investigation of its wave-like properties. 
Indeed, the wave nature of matter has been repeatedly substantiated over the past century 
and has been used to explain phenomena such as diffraction, atomic and molecular 
orbitals, and quantum tunneling.68 It is this wave description that also provides a more 
complete understanding of fluorescence. A fundamental understanding of its mechanism 
begins with the implications of the Schrodinger equation on atomic structure and energy 
levels. 
3.3.1 Atomic structure and energy levels 
The time-independent form of the Schrodinger equation is central to the description of 
atoms, and more specifically the distribution and energies of electrons within atoms. The 
relation can be used to solve for the wave description of matter, or wave equation, and 
states that, 
El/J(r) = [ ;~ V2 + V(r) ]l/J(r) , 
where l/J(r) is the position-dependent wave equation, his the reduced Planck constant, 
m is the mass, and V(r) is the position-dependent potential energy function. A quick 
analysis of the relation reveals that it is an eigenvalued function, which yields one of the 
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most fundamental finding in atomic theory-energy within atoms is quantized. This 
implies that components such as electrons that impart atoms with a specific energy must 
be configured in such a way that only a discrete set of energies is possible. 
Configurations that don ' t provide those energy values are forbidden and do not exist. 
These findings can be extended beyond atoms to molecules. Within molecules, two 
contributors to the overall molecular energy are its electronic configuration and 
vibrational states. 
3.3.2 Electronic configuration 
In atoms, the electronic configuration is determined by the specific arrangement of their 
electrons. These electrons reside in distinct orbitals that are grouped into subshells, which 
in tum are grouped into shells (Figure 3.1). In addition to their orbital or position, 
electrons also have a property known as spin. This property has two potential values: +Yl 
or. -Yl. Together, the shell (n), subshell (I) , orbital (mt), and spin (ms) of an electron denote 
4 quantum mechanical properties that together must be unique for each electron in an 
atom. This principle is commonly referred to as the Pauli exclusion principle. 
Electrons within molecules must follow the same principle, but have orbitals that 
include hybrids from the original bonding atoms. These orbitals and associated subshells 
are filled with electrons from the innermost shells outward. Each orbital can contain a 
maximum of only 2 electrons, and due to the Pauli exclusion principle, these electrons 
must have opposite spin. Coming back to the concept of energy, each orbital has a 
defined energy, and as their subshells grow in size or move outward to shells further from 
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the nucleus, this energy increases (Figure 3.2). 
3.3.3 Vibrational states 
In addition to energy levels imparted by the specific electronic configurations, molecules 
also have additional energy levels due to vibrations of their bonds. Again, solutions to the 
Schrodinger equation stipulate that these vibrations can only be of specific frequencies. 
The amount of energy required to move from one vibrational state to another is 
significantly smaller than what is required to move from one electronic configuration to 
another. 
The combination of electronic and vibrational states paints a complex energy 
landscape that provides numerous energies for a molecule to exhibit. Furthermore, 
different combinations of electronic and vibrational states may overlap in total energy 
values, providing opportunities for molecules to shift between these different 
configurations with little change in energy. As we shall see shortly, this phenomenon is 
key to fluorescence. 
3.3.4 Absorption and relaxation 
Molecules naturally reside in the lowest-energy configuration termed the ground state. 
However, by absorbing energy from the environment, molecules can shift their electronic 
and vibrational configuration to a higher energy level. When this energy is provided by 
electromagnetic radiation, this event is called absorption. Absorption can only occur if 
the energy of the radiation exactly matches a molecular transition from one energy level 
to another (Figure 3.3). The dependence of energy on the wavelength of radiation is well 
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defined and famously related by the equation, 
he 
E=;:· 
Here, E is the energy, h is Plank's constant, c is the speed of light, and A is the 
wavelength of light. In the range of 400-700 nm where the majority of fluorescence work 
is performed, the energy of light is significant enough to result in changes in both the 
electronic and vibrational configuration of a molecule. Transitions in the electronic 
configuration specifically involve the promotion of an electron to a higher energy orbital. 
When an electron is promoted, it may either keep its spin state or invert to the 
opposite spin state. The most common transition preserves the spin, and is known as 
singlet state excitation. However, on rare occasions, the spin can be inverted, resulting in 
a lower energy triplet state excitation. Since a flip in the spin state is first required for 
triplet state excitation, this process is typically less probable and occurs on a time scale 
that is several orders of magnitude higher than singlet state excitation. However, on 
certain occasions, the chemical structure of a molecule can result in a high probability of 
triplet state excitation. This is particularly true when the energy levels of the triplet state 
overlap with those the of excited singlet states. In these cases the spin inversion is 
facilitated either by the presence of heavy atoms within the molecule or the presence of 
I I . I . 69 mo ecu ar oxygen m so utwn. 
Once a molecule has been excited, there are several pathways available for it to 
return to the more stable ground state. These include vibrational relaxation, internal 
conversion, external conversion, intersystem crossings, dissociation, and radiative decay; 
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fluorescence is a specific form of radiative decay. 
3.3.4.1 Vibrational relaxation 
Vibration relaxation is the fastest of these processes and typically occurs on the time 
scale of less than 10-12 s.70'71 The process involves stepwise decreases through the 
vibrational energy levels for a given electronic configuration. As the molecule relaxes 
through these states, the excess energy is released as heat. Vibration relaxation occurs so 
quickly that it almost always results in relaxation of the molecule to the lowest 
vibrational energy state for the excited electronic configuration (Figure 3.4). 
3.3.4.2 Internal conversion 
While vibrational relaxation is occurring, there are oftentimes similar, overlapping energy 
levels that represent lower energy electronic configurations with higher vibrational states 
(Figure 3.4). If these energy levels are close enough to one another, there can be a 
conversion from one electronic configuration to the other. This is known as internal 
conversion. Once this occurs, vibrational relaxation can continue to proceed to an even 
lower energy level that represents the lowest vibrational state for the new electronic 
configuration. The more overlap there is between the vibrational energies of the two 
electronic configurations, the higher the likelihood for internal conversion. Internal 
conversion typically occurs on time scales similar to vibrational relaxation. 70'71 
3.3.4.3 External conversion 
In contrast to these internal methods of relaxation, external conversion involves 
relaxation via collisions with other molecules m solution. These collisions facilitate 
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energy transfers in the form of kinetic energy or heat. Due to this nature of external 
conversion, the process is highly affected by environmental factors. Temperature and 
viscosity are two examples of environmental variables that directly impact the frequency 
of molecular collisions and thus affect the rate of external conversion. Increasing the 
temperature or decreasing the viscosity of the solution enhances external conversion by 
increasing collision rates. 
3.3.4.4 Intersystem crossing 
Intersystem crossing represents yet another relaxation mechanism by which the excited 
singlet state transitions to a lower energy triplet state (Figure 3.4). Again, this process is 
typically unfavorable due to spin inversion. However, once this transition has been made, 
the excited molecule may remain in this state for l o-8 to l o-3 s due to a similarly low 
probability of a triplet to singlet state transition.72 External conversion and 
phosphorescence (a form of radiative decay) are two mechanisms by which molecules in 
the triplet excited state may return to the singlet ground state. In phosphorescence, this 
transition is accompanied by the release of a photon with a wavelength characteristic of 
the transition energy. 
3.3.4.5 Dissociation 
In addition to the myriad of processes by which excited molecules may return to the 
ground state, a second option is dissociation of the bond originally held together by the 
newly excited electron. When a molecule is excited, electrons are promoted to 
antibonding orbitals that have a higher energy but also represent Jess stable bonds. These 
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bonds can spontaneously dissociate, or in the presence of other molecules, may react to 
form different bonds. Either way, the original molecule becomes altered and takes on 
new .properties. Dissociation is the primary mechanism underlying photobleaching. 
Photobleaching describes the process by which fluorophores become deactivated and no 
longer emit fluorescent light. A common cause of photo bleaching is oxidation of excited 
molecules by 0 2•73 
3.3.4.6 Radiative decay 
The final method of relaxation is radiative decay, which involves a transition to the 
ground state via the emission of a photon with an energy equal to the transition energy. 
Fluorescence and phosphorescence are two specific forms of radiative decay. As 
phosphorescence is not a focus of this work, we will focus on fluorescence exclusively. 
Fluo~escence typically occurs on the time scale of less than 10-7 s.74 As this is orders of 
magnitude slower than vibrational relaxation and internal conversion, fluorescence 
energy transitions always occurs from the lowest vibrational state of an excited electronic 
configuration (Figure 3.4). The energy that is lost to reach this lowest vibrational state is 
what is responsible for the Stokes shift of a fluorophore; by the time a photon is emitted 
through radiative decay, the energy difference required to return to the ground state is 
less than the energy that was initially absorbed. In practice, this is seen as a red shift, as 
lower energy photon have longer wavelengths. Fluorescein, a fluorophore commonly 
used in biological sciences absorbes blue light with a peak wavelength of 494 nm and 
emits green light with a peak wavelength of 521 nm, representing a Stokes shift of 27 nm. 
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In addition to the Stokes shift, the presence of multiple vibrational states in both the 
ground state and the excited state is the reason why fluorophores have broad excitation 
and emission peaks. Wider peaks are indicative of molecules that contain more energy 
levels (Figure 3.5). 
3.3.5 Quantum yield and fluorescence lifetime 
For a large population of excited molecules, the processes outlined above all occur 
simultaneously but with different rates. It is the relative speed of these rates that 
determines the dominant relaxation mechanism. For most species, the existence of so 
many relaxation paths means that fluorescence is not a common observance. However, in 
fluorophores, fluorescence becomes a dominant pathway due to a higher efficiency in 
radiative decay from the singlet excited state. This efficiency can be described as the 
quantum yield and represents the ratio of emitted photons to absorbed photons. A more 
rigorous definition defines the quantum yield in terms of rate constants: 
where k1 is the fluorescence rate constant, kv is the vibrational relaxation rate constant, 
kic is the internal conversion rate constant, kec is the external conversion rate constant, 
kisc is the intersystem crossing rate constant, and kd is the dissociation rate constant. 
Molecules with a higher quantum yield have a larger k1 in comparison to the sum of the 
remaining rate constants. This may be due to intrinsic properties of the molecule, which 
affect k1 and kd, or due to external factors such as solvent viscosity and temperature, 
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which have a significant influence on kv, kic' kisc' and kec· 
The relative competition of fluorescence against nonradiative relaxation 
mechanisms can be teased out by observing the fluorescence lifetime of a fluorophore. 
The fluorescence lifetime describes the average length of time a fluorophore remains in 
the excited state before relaxing to the ground state by emitting a photon. This process 
can be observed by exciting a population of fluorophores with a short pulse of light and 
recording how fluorescence decays over time. Fluorescence is considered a first order 
process, where 
-t 
I= I0 e""""T. 
Here, I is the fluorescence intensity, Io is the initial fluorescence intensity immediately 
after excitation, t is time, and r is the fluorescence lifetime. The fluorescence lifetime is 
further related to the rate constants by 
1 
r =--------------------------
kt + kv + kic + kec + kisc + kd 
As the rate constant k1 is an intrinsic property of the molecule, changes in the measured 
fluorescence lifetime due to solvent or temperature can indicate increased or decreased 
competition of fluorescence with nonradiative relaxation mechanisms such as external 
conversion or intersystem crossings. 
3.3.6 Fluorescence intensity 
The use of fluorescence in quantitative studies has grown traction over the past century75-
80
. This is possible in part due to an understanding of fluorescence as a function of 
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quantum yield, molar absorptivity, path length, and fluorophore concentration. These 
parameters are related by the equation 
where I is the fluorescence intensity, k is a proportionality constant, q> is the quantum 
efficiency, ! 0 is the intensity of the excitation light, c is the molar absorptivity, l is the 
path length of the excitation light through the fluorophore medium, and c is the 
concentration of the fluorophore. This equation is derived from the Beer-Lambert law, 
which relates absorption to molar absorptivity, concentration, and path length. The molar 
absorptivity is another intrinsic property of a molecule that determines with what 
readiness light of a specific wavelength is absorbed by a molecule. In most practical 
applications, both c and l are constant, leaving an exponential dependence of fluorescence 
intensity on fluorophore concentration. However, if the fluorophore concentration is 
sufficiently small and de < 0.05, the equation approximately reduces to 
I = kcf110 Elc. 
In this regime, we see a linear dependence of fluorescence intensity on fluorophore 
concentration. It is this relation that is the foundation of most quantitative fluorescence 
work and is proposed here as a strategy for API quantification. Through the use of 
fluorescent reporter molecules that can bind specifically to a target API and provide a 
linear fluorescence response, the concentration of the API can be easily determined. 
However, to determine API concentration rather than fluorophore concentration, the 
reporter molecule must exhibit an increase or decrease in fluorescence upon binding. In 
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the next subsections, we shall explore what factors can be controlled or exploited to 
achieve this change in fluorescence behavior. 
3.3.7 Fluorescence enhancement 
Given the multitude of relaxation mechanisms that depend on internal and external 
factors, there are a number of ways in which the quantum yield of a fluorophore can be 
enhanced to provide a higher fluorescence signal. One way is by simply decreasing the 
temperature of the solution or increasing its viscosity. Both of these changes reduce the 
likelihood of intermolecular collisions, providing fewer opportunities for external 
conversion to occur. Another method is by increasing molecular rigidity. Numerous 
studies have shown that nonplanar molecules with many degrees of freedom can gain 
dramatic increases in quantum yield through additional bonds that force a more rigid 
structure.81 Qualitatively, this can be explained by the fact that more rigid molecules have 
fewer rotational degrees of freedom that limit the number of energy states available to the 
molecules. As a result, there is a decreased likelihood of overlapping energy states which 
both decrease the probability of internal conversion . and intersystem crossing. This has 
the effect of increasing quantum yield by decreasing the associated rates. An example of 
this phenomenon involves the molecule tetracycline. In deionized water, tetracycline 
exhibits a quantum yield of0.002.82 Recently, ribonucleotide sequences with a specific 
binding capacity for tetracycline have been dev~loped and investigated. 83-85 Studies of the 
tetracycline-aptamer complex reveal significantly enhanced fluorescence of the 
tetracycline molecule ·itself, with over a 100-fold increase in overall fluorescence 
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intensity. While one study found the average fluorescence lifetime oftetracycline in pH~ 
buffered solution to be 0.37 ns86, experiments by Forster et al. revealed a marked increase 
in fluorescence lifetime, measuring 4.37 ns for the bound complex.83 This result indicated 
a reduction in nonradiative relaxation processes, allowing fluorescence relaxation to 
become more dominant. Further investigation of the bound complex in the same study 
· showed that tetracycline was locked into a rigid position within the aptamer. 
Furthermore, these fluorescence readings were taken at the same excitation and emission 
wavelengths, indicating that there had not been any change to the absorption wavelength. 
This demonstrates that the confinement of the molecule to a more rigid structure resulted 
in fluorescence enhancement. In Chapter 5, we shall see how this result was used with the 
PharmaChk system to quantify tetracycline concentration in solution. 
3.3.8 Fluorescence quenching 
In addition to fluorescence enhancement, fluorescence quenching also has a number of 
useful applications.87-89 Quenching is typically split into two main categories: dynamic 
and static. Dynamic quenching involves suppression of fluorescence emission by 
increasing the rate constants of competing relaxation methods. This has the effect of 
decreasing fluorescence lifetime, but does not affect the absorption spectrum of the 
fluorophore. Static quenching on the other hand involves the formation of a complex 
between the fluorophore and a secondary molecule. In contrast to dynamic quenching, the 
formation of the complex results in a direct change to the spectral behavior of the 
fluorophore. 
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Examples of dynamic quenching again include increasing the solvent temperature 
or decreasing its viscosity. This will increase intermolecular collisions and nonradiative 
relaxation of excited molecules, resulting in a decrease in both the quantum efficiency 
and fluorescence lifetime, while leaving the absorption properties of the molecule intact. 
Another method of dynamic quenching is the introduction of molecular oxygen and 
paramagnetic molecules. These species have properties that promote intersystem 
crossings by facilitating spin inversion.69 The result is movement from singlet excited 
states where fluorescence is observed to triplet excited states where either 
phosphorescence or other nonradiative processes result in relaxation of the molecule to 
the ground state. 
Another method for dynamic quenching involves a completely new mechanism 
known as Forster resonance energy transfer (FRET). FRET is a nonradiative energy 
transfer between two molecules that results in the relaxation of the excited state donor 
molecule and excitation of the secondary acceptor molecule. The underlying mechanism 
of FRET is a dipole-dipole coupling that results in a heavy dependence of the energy 
transfer on distance (llr6). In addition to the distance, there must also be spectral overlap 
between the emission of the donor and the absorbance of the acceptor. Finally, because of 
the dipole-dipole nature of the phenomenon, the relative orientation of the two molecules 
is also a factor. Together, these aspects inform a new rate constant for FRET that can be 
incorporated into the fluorescence quantum efficiency description. The same formulation 
can furthermore be used to define the FRET quantum efficiency. FRET has been used 
substantially in a number of investigations that range from analysis of binding and rate 
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kinetics90•91 to probing the distance dependence of molecular processes.92.94 As a dynamic 
quenching method, FRET again results in a decrease in the fluorescence lifetime. 
In contrast to dynamic quenching mechanisms, static quenching involves the 
formation of a complex between the fluorophore and another molecule. While in some 
instances this may cause fluorescence enhancement (as we saw with the tetracycline-
aptamer complex), in other cases this results in quenching due to the rise of new spectral 
behavior. · This behavior manifests as either a loss of absorbance at the excitation 
wavelength, a shift in the excitation wavelength, or a shift in the emission wavelength. 
These outcomes result in a dramatic decrease in observed fluorescence intensity. 
One example of static quenching is the quenching of biotin-4-fluorescein (B4F) 
by streptavidin. While free B4F exhibits strong fluorescence due to the fluorescein 
moiety, studies indicate a dramatic quenching effect upon streptavidin binding that has 
been observed to approach 88%.95 Furthermore, streptavidin contains four binding 
locations for biotin, and a close analysis of the quenching data reveals that as lhe average 
number of bound sites on · streptavidin increase, the degree of quenching also increases. 
While this can result in inconsistent fluorescence intensities for concentrations of B4F 
that do not saturate streptavidin binding pockets, data from Kada et a/. shows a linear 
increase in fluorescence as a function of B4F concentration once streptavidin saturation 
occurs.95 These studies demonstrate how this result can be exploited to quantify 
streptavidin concentration and highlight the use of a linear fluorescence response to 
perform analyte quantification. Indeed, we shall also exploit this behavior in Chapter 5, 
ultimately demonstrating that the PharmaChk platform can operate on both fluorescence 
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enhancement and fluorescence quenching. 
3.3.9 Fluorescent reporters and analyte quantification 
Returning to the concept of binding assays, fluorescent markers have commonly been 
used to identify and even quantify analytes. These molecules make use of binders that 
exhibit strong affinity for a target of interest, and are then attached to a fluorophore to 
provide a method of visualization. This principle has often been applied to cell stains, but 
these markers do not exhibit a change in fluorescence upon binding. Consequently, even 
markers that do not bind to anything emit light with the same intensity as those that do 
bind. This is typically dealt with by using wash steps that carry away any unbound 
molecules. However, the need for wash steps requires discrete sampling that in the case 
of medicines testing would preclude API kinetic analysis. While multiple discrete 
samples could be taken and quantified to generate a release profile, this method has both 
poor resolution and excessive sample preparation requirements. Both of these fail to meet 
the needs previously outlined for a quantitative and easy to use system. 
A more streamlined and effective method to obtain a release profile is via 
continuous sampling. Fortunately, flow-through designs are excellently positioned for 
this mode of data collection, as small samples can be continuously pumped from a drug 
solution and mixed with fluorescent molecules for quantification. However, while this 
would generate a smooth API profile as the tablet continues to dissolve, the absence of a 
wash step requires a shift in fluorescence behavior upon binding in order to maintain 
quantitative power. F01tunately, our understanding of fluorescence enhancement and 
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quenching provides a basis for developing specific molecules with this behavior. 
Reporter molecules could be designed to contain both a binder tuned to a specific API 
and a fluorophore that changes intensity upon binding. 
Using this concept, two conditions must be met in order to produce a practical 
testing platform. First, a cheap, easy-to-use system would be necessary to accommodate 
flow-through analysis and mixing using extremely small fluid volumes. This would 
ensure that API content could be monitored for an extended period of time without 
depleting the drug solution. Second, reporter molecules that take advantage of 
fluorescence enhancement or quenching upon binding must be designed. This is critical 
to quantification, as flow-through systems cannot accommodate wash steps. Fortunately, 
the emergence and ongoing development of micro fluidics and aptamers are two platforms 
that are petfect for meeting these conditions. 
3.4 Microfluidics 
Microfluidics is a relatively new platform that enables extremely small fluid handling on 
miniature chips. These chips are smaller than credit cards yet encompass complex 
analysis and testing that provide similar results to bench-top systems. The chips 
themselves contain miniature channels that direct the flow of solutions that are pumped in 
and through them. Figure 3.6 provides an example of a microfluidic chip that is capable 
of analyzing blood and counting T -cells to diagnose HIV. The beauty of microfluidics is 
that it is a generalized platform that enables the design and implementation of practically 
any test-all in a miniature chip. 
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3.4.1 Platform advantages 
Microfluidic technologies have seen widespread growth over the past decade, particularly 
in the development of point-of-care devices targeted for use in developing regions. A 
large portion of these devices have been aimed toward affordable, robust, yet accurate 
diagnostic systems for illnesses such as tuberculosis, malaria, and HIV/AIDS.96-99 The 
technology as a platform offers a number of advantages beginning with reduced resource 
consumption. While traditional assays and tests use volumes of milliliters and higher, 
microfluidic technologies enable fluid handling of pico- to nanoliter volumes. This helps 
with reducing the costs associated with solvents and makes the system more portable as 
smaller reagent volumes need to be transported. A second advantage to microfluidic 
technology is rapid prototyping. Traditionally, microfluidic devices are made from 
molded polydimethylsiloxane (PDMS) elastomer, making fabrication of these chips swift 
and trivial. 100 The molds themselves can be fabricated using soft photolithography, which 
provides incredible flexibility in chip designs and allows a single process to be used for 
developing of an abundance of assays and analytical tests. Beyond diagnostics, 
microfluidics have consistently proved useful in areas as diverse as chemical 
• 101 102 b. d. d k. . I . 1o3 d . 1o4 1os d separation ' , m mg an metlc ana ys1s , rug screenmg ' , an organ 
modeling.100•106-108 This incredible versatility and convenience makes microfluidics an 
ideal choice for the development of a low-cost, robust, portable, and accurate system for 
API quantification and kinetic release in the field . 
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3.4.2 Mixing challenges 
In order to accurately quantify the API in a tablet, the drug solution will need to be 
thoroughly mixed with the reporter solution. Mixing these solutions on a microfluidic 
chip would minimize resource usage, particular of the fluorescent tag; however, 
microfluidic mixing has proven to be a significant design challenge. Considerable 
research has gone into the development of both passive and active micromixers. Passive 
mixing relies solely on diffusive phenomena, while active methods introduce energy into 
the · system to facilitate mixing. While active mixing is generally quicker, it requires 
powered components that utilize valuable energy in a portable system. As a result, the 
review below only focuses on passive mixing strategies. 
On the macro scale, mixing of fluid components of low viscosity typically occurs 
through convective currents that result from mechanical agitation. In this regime, inertial 
forces dominate fluid behavior, enabling efficient mixing. As we reduce to the micro 
scale, we see strikingly different behavior from the same fluid. In this regime, inertial 
forces are too small to dominate fluid motion, and we instead see the emergence of 
viscous force dominance. Consequently, fluids in this regime typically observe laminar 
flow, dramatically hampering transverse fluid motion and limiting fluid mixing to simple 
diffusion. Figure 3.7 clearly depicts this phenomenon, where two fluid streams remain 
distinctly separated after their initial junction. 
The Reynolds number is an important indicator that can be used to determine the 
tendency for a fluid system to exist in laminar or turbulent regimes. It is defined as: 
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where Dh is the hydraulic diameter of the channel (cross-sectional area divided by wetted 
perimeter), U is the mean velocity, and vis the kinematic viscosity of the fluid. The 
dimensionless property describes the ratio between momentum and viscous forces . High 
Reynolds numbers (above ~2300) are indicative of turbulent flow, while low Reynolds 
numbers are indicative of laminar flow. In a microfluidic system, fluids almost always 
exist in the low Reynolds number regime as the hydraulic diameter is extremely small. 
Fluid velocities are also typically smaller as the amount of pressure required to drive a 
fluid at a particular flow rate scales 14 , where r is the channel radius. Thus, high fluid T 
velocities in microfluidic systems require tremendous pressures that can often exceed the 
limits of the system. 
Given the dominance of viscous forces in laminar regimes, transverse mixing of 
two fluid streams is now limited only to molecular diffusion. Since the time required for 
this process to occur scales with the square of the distance traveled, mixing of two 
laminar fluid streams requires impractical time scales and thus impractical channel 
lengths for a microfluidic system. 
One of the earliest passive mtcromtxers addressed the problem of diffusion 
distance by increasing the contact area of the two fluid streams. Branebjerg et a!. 
developed a system that produces this effect through a process called lamination. 109 In 
this process, two adjacent streams are joined one atop the other in order to decrease the 
diffusion length and increase the contact area. A schematic of this is provided in Figure 
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3.8. A number of other groups have made further improvements to this concept, resulting 
in mixers with multiple parallel lamination 11 0-11 2 streams and others that use serial 
lamination. 113•114 Another method used to decrease diffusion distance is fluid injection 
through micro-nozzles. Miyake et al. were one of the first groups to introduce this type of 
micromixer, in which four hundred nozzles spaced 10011m apart were used to introduce 
one fluid into a chamber of another fluid . 115 
Although these methods produced very promising results and fast mixing times, 
they often require complicated fabrication techniques and utilize 3D structures that are 
not suitable for simple PDMS microfluidic chips. While groups such as Cha et al. have 
demonstrated 3D fabrication in PDMSm, these chips require many more steps than a 
single molding procedure and would ultimately increase the cost per chip. Again, these 
options become counter-productive for a system targeted for low-resource settings. 
Rather than focus on lamination schemes, many other groups chose to explore 
methods to utilize chaotic advection for efficient mixing. Chaotic advection relies on the 
formation of advective currents that transport fluid particles transversely, even in laminar 
flow regimes. At higher Reynolds numbers, this can be achieved by introducing obstacles 
in the flow path.11 6 These obstacles induce eddy' s that generate transverse mass transport 
and facilitate mixing. Inhomogeneous placement of these obstacles can greatly increase 
mixing efficiency. Wang et al. have done extensive computational work to optimize the 
layout of these obstacles. 1 17 Further work has also been done to use obstacles efficiently 
at lower Reynolds numbers. 11 8• 11 9 
In addition to the use of obstacles, other groups have used serpentine channels and 
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other 2D and 3D curved surfaces to induce recirculation currents to increase mass 
transport. 120-123 Considerable computational work has also been done to characterize 
these designs. The results of these studies show that mixing efficiency in these 
micromixers drops precipitously with Reynolds numbers below a moderate critical value. 
Yet another method that has been developed for enhanced mixing is the 
generation of helical flow through a microfluidic channel. Stroock et a!. first 
demonstrated this in the Whitesides lab.124' 125 A slanted-groove pattern was added to the 
surface of the channel to create lateral pressure differentials induced by viscous resistance 
to the patterns. The result is the generation of a helical flow path. This is demonstrated in 
Figure 3.9. Mixing was further enhanced by the use of a staggered herringbone structure. 
This layout results in continuous stretching and folding of the fluid, exponentially 
increasing the contact area between the two fluids and significantly enhancing mixing. A 
computation analysis of this design was conducted by Hassell et a!. The results suggested 
a low degree of helical flow in the designs analyzed and increased dissipation of inertial 
forces when using conditions that led to more helicity. 126 Further work has been done to 
increase this motion and further facilitate chaotic advection by adding patterned surfaces 
to the walls and roof of the channel. Howell et al. first added patterns to both the top and 
bottom surfaces of the channel to increase the formation of vortices and chaotic flow 127 • 
Similarly, Yang et a!. added a zigzag pattern to the roof of a patterned channel using a 
second layer of PDMS. A schematic of the design is shown in Figure 3.10. Their 
computational and experimental results demonstrated superior mixing in comparison to 
the slanted-groove micromixer. Further work by Yang et a!. explored the effect of adding 
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patterns or notches to the walls of the micromixer.128 A schematic of their connected-
groove micromixer (CGM) is also provided in Figure 3.10. With higher viscosity fluid 
flows, the CGM was able to boost helical flow intensity by 20%. 
A final, and rather unique departure from more traditional micromixers, is the use 
of droplet microfluidics to create chaotic advection and facilitate mixing. Droplet 
microfluidics makes use of multi phase solutions to create plugs in microfluidic channels. 
These are bubbles of one fluid phase that are transpmied in a second fluid phase. 
Typically this is achieved using both an aqueous solution and an oil phase. Bringer et al. 
first demonstrated plug formation and mixing for the purpose of determining chemical 
kinetics. 129 Their design used an aqueous phase channel that met perpendicularly with a 
carrier phase (oil) channel. The relative flow rates of these two channels can be modified 
to produce aqueous plugs within the carrier phase of particular size and separation. The 
formation of these plugs is depicted in Figure 3.11. By sending these plugs through 
curved channels, shear forces between the carrier fluid and the plugs cause recirculation 
flow that facilitates mixing. This is shown Figure 3.12. The advantages of this system are 
that by localizing the aqueous solution to finite plugs, there is no fluid dispersion as 
compared to pure aqueous flow through a microchannel. Furthermore, by relying on 
shear stress to induce mixing, there is no need for complicated patterning of the channel 
walls. However, this method also introduces a different carrier phase that can lead to 
chemical separation of hydrophobic particles that may exist in the aqueous fluid phase. 
This presents an additional challenge when performing tests on dissolved drug tablets, as 
these tablets can often include hydrophobic species. Many APis themselves can also 
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often contain aromatic components. 
The vast array of microfluidic m1xmg strategies presented above affords 
numerous options for moving forward. However, some are more complicated to fabricate 
than other. While a trade-off exists between complexity and perfmmance, the appropriate 
strategy is one that provides enough liberty from chip fabrication while still offering a 
practical solution. Of the designs considered, the staggered herringbone mixer (SHM) 
provides one of the simplest designs while still providing sufficient mixing using 
practical device real estate. As discussed above, the droplet-based micromixer affords 
some advantages, however it also introduces much room for error and also requires an 
additional oil solution to operate. 
3.4.3 Design challenges and electronics analogy 
The design of many microfluidic chips is based on pipe flow described by the Hagen-
Poiseuille equation. 
811LQ 
l::.P=--
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This equation relates the pressure difference across a pipe to the length, L , radius, r, flow 
rate, Q, and dynamic viscosity; p.. While this equation describes fluid flow for pipes of 
any radius, it is particularly handy for understanding flow in microfluidic channels. As 
we saw in the previous sections, fluid behavior changes drastically as the length scale is 
decreased. This equation provides similar insight for fluid resistance and pressure drops 
across microfluidic channels. Due to the fourth-power dependence of this equation on the 
radius, as the radius becomes smaller, the pressure required to drive fluid flow increases 
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dramatically. While this may seem like a detriment at first, it is proves to be an extremely 
exploitable relationship for controlling fluid flow at those length scales. 
As microfluidic chip designs grow more complex, the analysis required to verify 
flow behavior becomes significantly more involved. The Hagen-Poiseuille equation 
provides an analytical analysis, but as the number of interconnected channels increases, 
the equations begin to pile up. Fortunately, a seemingly unrelated field has come to the 
rescue of many. Circuit theory has a history of over 15 0 years and has only become more 
intensively studied in modem times. In 1845 Gustav Kirchhoff described as set of laws 
that are used to this day by electrical engineers. These laws describe the behavior of 
current and electrical potential in electrical circuits. 
n n 
I~k = o Ivk=o 
k=1 k=1 
The first describes current at a node, stating that the magnitude of current that enters a 
node must be equal to magnitude of current that leaves a node. This is a conservation 
theorem. The second explains electrical potential in a closed loop. It states that the sum of 
all voltage drops within a loop must sum to zero. It describes electrical potential as a 
conservative force. 
It tums out that electricity and hydrodynamics are quite analogous. Similar to the 
way an electrical potential difference drives current, a pressure differential drives fluid 
flow. Furthermore, both current and fluid flow rate follow a linear relationship defined by 
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a resistance. In fact, the Hagen-Poiseuille law can be rewritten as, 
8J1L R --
h - rrr4 
In this form, it may bear a striking resemblance to Ohm's Law. 
LlV = IR 
By exploiting this analogy, Kirchhoffs laws may actually be used to analyze fluid 
networks. This provides a much stronger tool for designing and analyzing microfluidic 
circuits. However, a complication of using this analysis for microfluidic channels that due 
to the fabrication process, microfluidic channels are almost always rectangular. Many 
equations exist for approximating a radius for thi.s geometry, but due to this, conversions 
between circuit analysis using resistance and microfluidic design using channel widths 
and heights can become quite cumbersome. Nevertheless, the circuit analogy is an 
immeasurable asset for simplifying and analyzing microfluidic network designs . As we 
will see in Chapter 4, more work can be done to make the use of this analogy for larg~r · 
networks even simpler. 
3.5 Aptamers 
Aptamers are a stark departure from microfluidics that take us from the fabrication of 
synthetic material to fabrication and design of a completely different nature-biological. 
Rather than silicone and glass, their building blocks are nucleotides or peptides, 
components that comprise the DNA and proteins that we find in our bodies. Aptamers are 
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short macromolecules built from these components that form 3D conformations that bind 
specifically to target molecules. Typically, they take the form of RNA or single-stranded 
DNA (ssDNA). Interest in their utility first arose from HIV research, where investigators 
found that the virus made use of small, yet structured RNA molecules that bind 
specifically to viral or cellular protein targets. 130 Since then, a flurry of research has been 
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3.5.1 Uses and advantages 
Aptamers have been used for numerous applications, including therapeutics, however the 
majority of these have focused on targeted binding. Compared to other molecules that 
share similar functionalities such as antibodies and proteins, aptamers offer a number of 
advantages. 
First, they are considerably smaller and more stable. While both proteins and 
antibodies typically lose functionality after denaturing, aptamers can refold to their 
original conformation without any loss in binding affinity to their target. This has 
important implications for field-based applications where refrigeration of reagents is 
often not possible or practical. Furthermore, their small size means that for the same 
weight, aptam.ers can bind significantly more target than either pro.teins or antibodies. 
Second, aptarners are considerably cheaper to produce. While antibodies and 
proteins must typically be harvested from biological materials, aptamers can be 
. synthesized using automated processes once their sequences are known. In addition to 
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cost, this significantly increases production rates, meaning that more product can be 
produced faster for a lower cost. 
Third, aptamers can be easily modified and tethered to other molecules such as 
fluorophores. Moreover, they can be easily designed in a way that confers modified 
fluorescence behavior based on binding or external conditions. 
Finally, the single greatest advantage to aptamers is that they can be designed 
using a systematic procedure. Rather than antibodies, which require significant effort and 
resources to generate for a specific target, new aptamers can be produced for a target 
molecule with relative ease. For a concept such as PharmaChk that relies on unique 
reports that are specific to a plethora of APis, aptamers present an incredible opportunity. 
However, to exploit this property, we must first understand how they are produced and 
what factors are critical in that development process. 
3.5.2 Development process 
The immediate challenge in working with aptamers is developing one that will bind with 
high specificity and affinity to a particular target; the range of possibilities for such an 
aptamer is almost infmite. Rather than designing one based on protein interaction models, 
a brute force approach can be taken. Beginning with a pool of approximately 1015 random 
aptamers, selection methods can be employed to single out those that bind specifically to 
a target. Initial work in this area was conducted by both the Gold and Szostak 
groups. 137•138 Both groups employed a selection scheme that they applied to a pool of 
randomly synthesized oligonucleotides between 50-100 base pairs in length. These 
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oligonucleotides were also flanked with restriction sites and primer binding domains that 
enable easy amplification and ligation of the genetic material. The general selection 
process has come to be known as Systematic Evolution of Ligands by Exponential 
Enrichment (SELEX). The steps involved in the process are as follows: 
1. Generation of random DNA oligonucleotide pool 
2. Transcription of DNA pool to RNA pool 
3. Specific selection of RNA pool against target molecule 
4. Reverse transcription of selected group to ccDNA 
5. Repeat 2-4 for further refinement. 
Over the years, a number of selection platforms have arisen. Tuerk et al. originally used a 
protein target bound to nitrocellulose filters. 137 RNA molecules with affinity to the target 
would stay on the nitrocellulose filter, while the rest were simply washed away. These 
remaining molecules were then used for the remainder of the enrichment procedure. 
Ellington et al. instead used an affinity column for selection. 138 The initial pool of RNA 
molecules were run through a column of target protein tethered to agarose beads in high 
salt conditions. Molecules that bound to the target would remain in the column, while the 
rest flowed through. After several wash steps with high salt solution, the bound 
molecules are eluted from the column with water and used for further enrichment. 
Several groups have taken this idea further by using magneti~ beads.139•140 This facilitates 
easier separation of bound and unbound RNA. The limitation of these processes, 
however, is that they require a functional group on the target for tethering to the beads. 
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This may oftentimes not be available and also affects what functional groups are 
available to select the RNA against. 
Another selection scheme involves the use of capillary electrophoresis (CE). 141 •142 
Here, RNA molecules are mixed with the target and separated into groups of unbound 
RNA, free target, and RNA-target complex. Due to the high resolution offered by CE, 
this method provides much higher selection efficiency, requiring only two to four rounds 
of selection. In comparison, nitrocellulose filters typically require twelve. 130 A further 
advantage to this method is that the target molecule does not require tethering. Thus, full 
molecule interactions similar to native conditions are selected for. 
3.5.3 Improvements 
The selection schemes present_ed in the previous section provide numerous options for 
obtaining an aptamer for a specific target. However, in many cases they remain time 
consuming and labor intensive. In more recent years, this had begun to change with the 
emergence of microfluidic selection schemes. While automated selection have been 
achieved in the past143•144, microfluidic chips offer a more robust, efficient, and practical 
method of selection. Hybarger et al. were the first to work in this area, developing an 
automated microfluidic system for SELEX.145 However, their system still required bulky 
equipment similar to more traditional automated SELEX procedures. More recently, 
Huang et al. developed a more integrated system that brings the PCR module on-chip and 
uses magnetic beads for separating bound and unbound species. 146 This system further 
reduced the time required to isolate high affinity aptamers, needing only 60 min per 
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round rather than 160 min. Furthermore, reagent use was also decreased by 60%. Overall, 
this brought the time required to perform SELEX down from a few weeks to a day. These 
improvements only provide more support for aptamers as a superior option for the 
development of specific and stable reporters for API targets. 
3.6 Putting it together 
Given the multitude of advantages conferred by both microfluidics and aptamers, both 
platforms were established as the perfect basis for building a single system that was 
capable of quantifying API content and kinetic release with high specificity and 
sensitivity. Microfluidic chips permitted pico- to nanoliter fluid handling, enabling 
continuous sampling from a drug solution for hours. Aptamers permitted API 
quantification by providing a systematic approach to building specific reporter molecules 
that only fluoresce upon binding to their target. Bridging these ideas, a complete system 
was envisioned and conceptualized (Figure 3.13). 
PharmaChk has four major components that enable both API quantification and 
kinetic release. The first is the tablet dissolver. This provides a stirred container for the 
tablet to rest in as it dissolves. The second is the fluorescent tag or reporter molecule 
solution. This is the key dynamic component of the system that enables API quantitation 
with high specificity using a single system. The third is the microfluidic chip. This is 
where the dissolving tablet solution and fluorescent tag are pumped into and mixed. It 
provides a space for appropriate mixing of the two solutions so that fluoresce 
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measurements can be taken from the sample. The fourth is the signal detector. This is 
what collects the fluorescence signal and ultimately enables real-time API quantification. 
The true heart of the PharmaChk system is the microfluidic chip. A detailed 
schematic of the process is provided in Figure 3.14. The PharmaChk chip contains two 
inlets where the drug and reporter molecule solutions enter separately. Once on-chip, the 
fluids converge to a mixing channel containing herringbone patterns. These patterns 
promote mixing of the drug solution and the reporter molecules. Compared to typical 
microfluidic mixers, the mixing channel on the PharmaChk chip was extended, not only 
to promote further mixing, but also to provide sufficient time for the reporter molecules 
to attach to the API. Finally, a fluorescence reading is taken near the egress of the chip to 
quantify API concentration. This value can then be plotted over time to obtain a kinetic 
release profile. Furthermore, the same curve can be integrated to determine overall API 
content. This solution provides a single, streamlined process to obtain both pieces of 
information. 
The PharmaChk concept exemplifies a targeted approach to determining drug quality 
based on the identification of key needs in the field. However, a technology concept 
alone cannot be taken into the field to elucidate the pervasiveness of counterfeit and 
substandard medicines and solve the larger problem. In the subsequent chapters, we will 
demonstrate key steps that were taken to prove this concept and transform it from a 
glorified sketch to a real-world solution. 
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. 3. 7 Figures 
Figure 3.1 
shells 
Representation of atomic electron shells, beginning with the first shell and 
moving outward. Moving outward from the nucleus, each shell contains 
more subshells that have a specific number of orbitals that house a 
maximum of 2 electrons. As subshells grow larger, their arrangement of 
orbitals grows more complex. Only the s and p orbitals are depicted here, 
as larger subshells cannot be clearly and concisely depicted. 
s,p,d,f subshell orbitals max. electrons 
s,p,d s 1 2 
s,p p 3 6 
s d 5 10 
f 7 14 
nucleus 
orbitals 
71 
Figure 3.2 Diagram indicating the energy levels of various electron subshells, 
beginning with the lowest energy. Orbital energies typically increase by 
shell followed by subshell size; however in higher shells, the s orbital 
electrons oftentimes have lower energies than larger subshells in the 
previous shell. For instance, the 4s electrons have a lower energy than the 
3d electrons.147 
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Figure 3.3 Energy diagram indicating that only energy that exactly matches an 
internal transition can be absorbed by an atom or molecule. The lowest 
energy state in an atom or molecule is called the ground state, and higher 
energy levels are determined by factors such as electronic configurations 
and vibrational states. 
ground state 
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Figure 3.4 
En rgy 
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Ground State 
Energy diagram depicting light absorption and the numerous relaxation 
pathways available to atoms and molecules to transition from an excited 
state down to the ground state. Vibrational relaxation, internal conversion, 
external conversion, intersystem crossing, fluorescence, and 
phosphorescence are represented here. 148 
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Figure 3.5 Diagram showing the cause of width spectral bands as the presence of 
numerous vibrational energy states in both the ground and excited 
electronic states. Stokes shift is also depicted as a transition from the 
lowest vibrational state in the excited electronic state to various vibrational 
. h d 149 states m t e groun state. 
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Figure 3.6 Microfluidic chip that analyzes blood for HIV by counting T-cells. 150 
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Figure 3.7 Laminar flow of two fluid streams in a microfluidic channel. Taken from 
Kakuta et a/.151 
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Figure 3.8 Schematics of parallel and serial lamination for passive micromixers. 
(a) Parallel lamination of two fluid 
streams atop one another. Taken from 
Branebjerg et al. 109 
(b) Serial lamination of two fluid streams 
that are joined, split, and then re-joined. 
Taken from Nguyen et a/. 152 
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Figure 3.9 Schematics and cross-sectional images of unpatterned channels (a), 
slanted-groove channels (b), and staggered herringbone channels (c). 
Taken from Strook et a/.125 
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Figure 3.10 Schematics of top and bottom patterned surface channels (left) and slanted 
groove channels with patterned walls (right). Taken from Capretta et a/. 153 
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Figure 3.11 
(a) 
water 
oil 
Photo and illustration of plug generation using a two-phase system. The 
three images show the formation of plugs of different length and 
separation by control of fluid flow rates. Taken from Bringer et al. 129 
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Figure 3.12 Fluid mixing due to chaotic advection from shear stresses that develop as a 
result of channel bending. These bends cause internal circulation of fluid 
within the aqueous plugs. Taken from Bringer et a/. 129 
(a) 
(c) 
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Figure 3.13 Conceptualization of the PhannaChk system, containing four major 
components. A pill is dissolved in the tablet dissolver and samples are 
continuously pumped into the microfluidic chip, along with the fluorescent 
tag solution. These liquids mix on the chip, and a fluorescence reading 
from the tag is used to determine tablet API content. 
-----•1. Tablet Dissolver 
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Figure 3.14 Schematic of PharmaChk chip, with dissolved input, probe, mtxmg 
chamber and the CCD camera for determination of API concentration. 
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Chapter 4: Novel Web Application for Multivariate Analysis of Complex 
Microfluidic Networks 
4.1 Introduction 
As the field of microfluidics continues to explode, chip designs are growing in both 
sophistication and complexity. The us.e of computational fluid dynamics (CFD) 
calculations is becoming increasingly prevalent, and is often required to aid in the design 
of complicated systems that require mixing, hydrodynamic focusing, and particle 
manipulation. 154-159 However, these calculations are often cumbersome, computationally 
intensive, and require costly software. While they are critical for understanding local flow 
conditions, they are impractical for the design of large-scale microfluidic networks. 
The electrical circuit analogy provides a simple alternative for the design of these 
larger networks. 160 This approach takes advantage of age-old circuit analysis to 
understand fluid transport through vast channel complexes. Its use in concentration-
d d d . . . l l . 161-164 H fi l epen ent, pressure- nven systems IS part1cu ar y promment. owever, or arger 
networks, the number of equations becomes quickly unmanageable. In these cases, it has 
been commonplace to use tools such as PSpice165 , which provide quick and easy analysis 
of circuit designs. However, even the use of these systems requires conversion of 
hydrodynamic networks into electrical equivalents. Because hydraulic resistance is 
dependent on channel height, width, and length, understanding how changes in these 
parameters at affect device performance requires back-and-forth conversions between 
channel dimensions and hydraulic resistance. 
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To streamline this process, we .lay the groundwork for an interactive web 
application that enables rapid design and analysis of microfluidic networks based on a 
Hagen-Poiseuille flow model. This system allows for easy manipulation of channel 
parameters and one-click analysis of the resulting flow behavior. This eliminates the need 
to convert networks into equivalent circuits to solve flow rate problems. Additionally, the 
representation of microfluidic channels in this web-based model enables automated, 
multivariate analysis of chip behavior based on variations of a single parameter. Chip 
performance can be evaluated through a user-defined function, allowing a high degree of 
flexibility. One example of the use of this feature is in understanding how slight 
variations in channel height across a chip may affect the dilution factor of a resistance-
driven dilution chip. This type of multivariate analysis has not been demonstrated in 
literature and signifies a major gap in the design of robust microfluidic networks that 
continue to perform well even under low tolerances for channel dimensions, which are 
oftentimes difficult to control. In addition to channel height, the system is flexible enough 
to vary any other system parameter such as channel widths and lengths or pressure drops. 
Furthermore, these parameters can be varied consistently for all channels or simply for a 
subset of channels. 
In this chapter, we simplify verify that the model agrees with manual calculations 
of flow through single channel, and furthermore compare those predicted values with 
observed flow rates on a microfluidic chip. A more detailed use of the multivariate 
analysis feature is demonstrated in Chapter 6. 
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4.2 Materials and Methods 
4.2.1 Hagen-Poiseuille model 
The Hagen-Poiseuille equation is used to analyze fluid flow and describes the 
dependence of pressure drop on the volumetric flow rate and hydraulic resistance: 
where RH is the hydraulic resistance and is defined as 
While the hydraulic resistance is straightforward to calculate for circular ducts, 
microfluidic channels are typically rectangular in geometry and cannot be defined by a 
diameter. Fortunately, an approximation for hydraulic radius in a rectangular duct is 
given by, 
Together with the Hagen-Poiseuille equation, this description was used for all flow 
calculations in the web application. 
To ensure that the model was correctly programmed into the application, 
comparisons of flow rates through single channels were compared between the software 
and manual calculations using the Hagen-Poiseuille equation. These comparisons 
matched exactly. Going one step further, a microfluidic chip was designed containing six 
channels of varying channel length ranging from 15-60 mm. These chips were used to 
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validate that analytical solutions of volumetric flow using the Hagen-Poiseuille law 
matched observed flow rates on a microfluidic chip. 
4.2.2 Chip fabrication 
Microfluidics chips were fabricated using polydimethylsiloxane (PDMS) cast on an SU8 
mold. The molds were made using two spin-coat layers consisting of SU8-2075 followed 
by SUS-2010, both spun at 2400 rpm. Each layer was exposed to a 350 nm light source 
through a chromium photo mask using the Siiss MicroTec MA6 mask aligner. The mold 
was developed using SU8 developer after both layers had been spun, and the channel 
heights were sampled across the mold using a Dektak 8 profiler. PDMS was mixed using 
the Sylgard 184 silicone elastomer kit at a 10:1 ratio and cured at 150°C for 10 min. 
PDMS chips were bonded to glass slides after 02 plasma exposure using the PV A TePla 
M4L plasma asher. 
4.2.3 Flow rate measurements 
The microfluidic chips were connected to a pressure source and tested at 5 and 10 psig 
using deionized water. Water was allowed to flow through the chip for 1 min before 
collecting a sample from the outlet into a microcentrifuge tube for 2 min. This sample 
was used to measure flow through the chip gravimetrically, where the weight of the tube 
was taken before and after sample collection and the density of water at 20°C was used to 
determine the sample volume. This volume was then divided by the collection time to 
yield the average flow rate through the microfluidic channel. 
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4.3 Results 
Comparisons of the software to manual calculations of volumetric flow through single 
and converging channels verified that the channel model correctly calculated flow 
through single channels and correctly accounted for conservation of mass in converging 
channels. The model was then compared to observed flow rates on a microfluidic chip 
with six different channels oflengths 15000, 24246, 32000, 42123, 50000, and 60000 Jlm 
(Figure 4.1). The results show a significant difference in absolute flow rate between what 
is predicted by the Hagen-Poiseuille law and what was observed on-chip: However, based 
on the equation, an inverse relationship is expected between flow rate and channel length. 
When the data was fit to a power law curve, the resulting exponentials were -0.953 and-
0.966 for the 5 psig and 10 psig data, respectively. Compared to the expected value of-
1.0, these values show and error of less than 5%. The average increase in flow rate 
observed on-chip as compared to the predicted value was 26.0% and 36.9% for the 5 and 
10 psig data, respectively. 
4.4 Discussion 
While the model was verified against manual solutions of the Hagen-Poiseuille equation, 
a discrepancy was observed between what the relationship predicts and what was 
observed on-chip. However, after fitting the data to power law functions, the resulting fit 
parameter for the exponential was within 5% of the expected value of -1.0 for both the 5 
and 10 psig data. This indicates that while the absolute flow rates are different, the 
relationship between flow rate and channel length remains inversely proportional. 
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The increase in the discrepancy between the 5 psig and 10 psig data suggests that 
the degree to which the observed flow diverges from the predicted value is pressure 
dependent. Several other works have demonstrated that, in fact, this phenomenon is due 
to deformation of the PDMS microchannels under pressure.166- 168 Unfortunately, the 
extent of the deformation is highly variable and depends on PDMS curing temperature 
and time. This means that for more accurate modeling of microfluidic designs intended 
for PDMS chips, further progress in this area is necessary. In particular, a model that can 
approximate the PDMS deformation based on curing temperature, time, and other 
process-related factors would be very useful increasing the predictive power of modeling 
software and decreasing the number of design iterations necessary to produce a 
microfluidic chip that behaves as intended. This is of great value to applications in which 
flow rate is a critical factor, such as diffusion-related designs and hydrodynamic 
focusing. However, for applications such as dilutions where chip performance is based on 
ratios of channel resistance, the effect of PDMS deformation is less critical to fluid 
behavior and modeling strategies such as the type presented in this work remain of 
tremendous value. 
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4.5 Figures 
Figure 4.1 
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Comparison of channel length dependence on volumetric flow rate (n=3) 
as predicted by the Hagen-Poiseuille law and as observed on a PDMS 
chip. The data was collected using a pressure driven system with a set 
point of 5 and 10 psig. The microchannel heights were measured using a 
microprofiler and found to be 71 f.!m. 
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Chapter 5: Continuous Flow Microfluidic Solution for Quantitative Analysis of 
Active Pharmaceutical Ingredient Content and Kinetic Release 
5.1 Introduction 
As we continue to celebrate decades of advancements in modern medicine, millions of 
sick around the globate find themselves amidst a world of failed treatments and false 
promises. In recent years, substandard and counterfeit medications have claimed the lives 
of close to 1M people around world and have crushed successful treatment plans for 
millions more. 1 In countries such as Nigeria and Pakistan, 40-50% of the medicines 
market is composed of adulterated medication1, and globally, the WHO reports numbers 
ranging from 10-50%.1 This black market is estimated to be worth $75B, and the 
numbers are only rising.4 
In light of the growing problem, numerous technologies have been used to 
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technologies that have aimed to qualitatively verify the presence of the correct active 
pharmaceutical ingredient (API) as well as screen against hazardous contaminants. Yet 
despite the gravity of the problem, there have not been any technologies that provide 
quantitative information regarding API content. Furthermore, there has been no focus on 
characterizing and verifying the release rate of APis from their tablet formulations. 
In this work, we present a fresh approach to this problem that uses a flow-through 
technique for quantitative analysis of both API content and release rate (Figure 3.13). To 
test a tablet using this approach, it is dissolved in a solution using mechanical agitation. 
During the dissolving process, the API concentration is continuously monitored, 
92 
ultimately providing the amount of API originally in the tablet as well as a plot of API 
release over time. The crux of the approach lies in the sampling method. We employ a 
microfluidic approach that can take continuous samples and analyze them in real-time 
using a fluorescence-binding assay. 
To test this approach, we conducted several studies that verified the use of a flow-
through system that is able to perform real-time analysis of dynamic analyte 
concentrations. We shall use the tenn dynamic solution to indicate a solution that exhibits 
this continuous change in analyte concentration. Initial tests were performed using 
streptavidin as a sample analyte and biotin-4-fluorescein (B4F) as a reporter that 
specifically binds streptavidin and provides a fluorescent signal. The streptavidin-biotin 
pair has been widely used due to both its bond strength and binding kinetics170, and B4F 
has also been found to be specifically quenched upon binding to streptavidin.171 •172 
Following these studies, we demonstrate that this approach can indeed be used to 
quantify a real drug. Tetracycline concentration was monitored in a dynamic solution 
using an aptamer as the reporter. Aptamers have emerged as a promising class of 
molecules that can provide high specificity, and more importantly, can be engineered for 
a specific target. 137•138 Ongoing research has also resulted in a shortened aptamer 
production time130•145, and the procedure itself provides a reliable means for producing a 
large library of reporter molecules which can be used to extend this monitoring approach 
to other drugs. The tetracycline aptamer itself has been studied extensively in literature, 
and studies have shown that the aptamer exhibits fast binding kinetics83 and triggers a 
dramatic increase in tetracycline fluorescence upon binding.84 
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5.2 Continuous Monitoring Approach 
In order to monitor analyte concentration, a reporter molecule is used that exhibits both 
fast binding kinetics and quick signal transduction .. Using such molecules, a dynamic 
solution is continuously pumped through a microfluidic chip, where it mixes with a 
reporter solution. Upon mixing, binding of the analyte to the reporter results in a 
fluorescence signal that can be recorded over time (Figure 3.14). A microfluidic mixer 
based on the work of Stroock et al. is employed to achieve this, with a longer mixing 
length to facilitate binding (Figure 5.1). In order to create a dynamic analyte solution, we 
titrate a concentrated stock into a dilution volume from which samples are continuously 
pumped through the microfluidic chip to rendezvous with the reporter solution. To 
simplify the system, the rate at which the titrant is added is equal to the rate at which 
solution is pumped from the dilution volume (FIG). 
5.3 Materials and methods 
5.3.1 Stock Solutions 
A streptavidin stock solution was prepared by dissolving 5 mg (Invitrogen, S-888) in 2 
ml of deionized water. A biotin-4-fluorescein (B4F) stock was prepared by dissolving 5 
mg (Invitrogen, B-1 0570) in 25 ml of IX PBS. A tetracycline stock solution was 
prepared by dissolving 7.8 mg (Sigma-Aldrich,T3383-25G) in 1.5 ml of deionized water. 
All solutions were aliquoted and stored at -20°C until required. The appropriate solutions 
were used as a starting point for all experiments 
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5.3 .2 Chip fabrication 
Microfluidics chips were fabricated using polydimethylsiloxane (PDMS) cast on an SU8 
mold. The molds were made using two spin-coat layers consisting of SU8-2025 (2600 
rpm) followed by SU8-201 0 (1200 rpm). Each layer was exposed to a 350 nm light 
source through a chromium photo mask using the Siiss MicroTec MA6 mask aligner. The 
mold was developed using SU8 developer after both layers had been spun. PDMS was 
mixed using the Sylgard 184 silicone elastomer kit at a 10:1 ratio and cured at 150°C for 
10 min. PDMS chips were bonded to glass slides after 0 2 plasma exposure using the 
PV A TePla M4L plasma asher. All chips were flushed with deionized water for 5 min 
just before use. 
5.3 .3 Streptavidin-biotin-4-fluorescein standard curve 
Prior work conducted by Kada eta!. demonstrated that biotin-4-fluorescein (B4F) was 
quenched by approximately 88% when bound to a pocket on streptavidin95 . While strong 
quenching was observed for all bound B4F molecules, it was found that the full extent of 
quenching was dependent on the number of bound ligands that were present for a given 
streptavidin molecule. This is illustrated in Figure 5.2, which shows that for ratios of 
biotin to streptavidin of less than 4, the fluorescence curve is nonlinear. However, as soon 
as this ratio exceeds 4, a sharp and linear increase in fluorescence for increasing 
concentrations of B4F is observed. This indicates that as long as the number of ligand-
binding sites is saturated with ligand, a linear response curve for B4F fluorescence can be 
used to quantify streptavidin concentrations. 
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Exploiting this property, streptavidin and B4F were used as a model drug and 
probe, respectively. To determine streptavidin concentration from B4F fluorescence, a 
standard curve was first formulated. Four 1 ml solutions of streptavidin were prepared 
with concentrations of 1-4 j..tM. An 8 ml working solution of 18 j..tM B4F was prepared 
using the stock solution. The 18 j..tM concentration was chosen so that it was just over 4x 
the maximum streptavidin concentration of 4j..tM according to the stoichiometry of the 
binding. Each streptavidin sample was successively pumped through the microfluidic 
chip along with the B4F solution using 2 channels of an 8-channel Ismatec peristaltic 
pump (Cole-Parmer, FF-7802312) operating at 10% power. 1.02 mm ID tubes were 
loaded on the pump. Fluorescence images were taken using a Leica confocal microscope 
with fluorescein filter cubes at a rate of 2 Hz for 1.5 min per sample. A 488 nm laser set 
to 44.9 m W was used as an excitation source, and images were captured using a 400 ms 
exposure and 4x4 binning. The resulting images were processed in Matlab to filter out 
cyclic artifacts due to pulsatile flow, and an average signal value from the resulting data 
for each sample was used to produce a standard curve. 
5.3.4 Standard curve signal processing 
Fluorescence signals of the standard curve samples measured from time-lapsed images 
were filtered using Matlab to remove cyclic peaks and valleys in the fluorescence 
intensity caused by out-of-phase pulsatile flow of the two solutions from the peristaltic 
pump. These peaks were identified and analyzed for the average peak separation, dp, in 
units of images; 1 Odp was used as the basis of a windowing algorithm used to analyze 
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local mean values over the full image set. These averages were used to discard local 
outliers beyond a 25% threshold between the mean and the extreme values of the data 
range. Once these outliers were removed, the surviving data was then further analyzed to 
identify data clusters within each pulsatile oscillation. These clusters represented the true 
fluorescence signal for the sample during steady flow, while the remaining data were 
snapshots of the signal departing from or returning to the steady-state fluorescence value. 
The data clusters were isolated by measuring the average distance between points and 
eliminating those whose distance lay outside of Y2 standard deviations from the mean. 
These thresholds were chosen empirically. The remaining data was then averaged to yield 
the mean fluorescence signal for the given sample concentration. Following this 
processing phase, more than 50 image points from the 1.5 m time-lapse remained, 
providing an ample sample size for averaging. 
5.3.5 Streptavidin-biotin dissolution 
The same 8 ml B4F solution from the standard curve experiment was used to perform this 
study. During the experiment, 2 ml of streptavidin stock was pumped into a stirring 30 ml 
dilution volume of deionized water using the same pump and power settings. A second 
pump line drew continuous sample from the dilution volume and pushed them through 
the microfluidic chip. A third pump line delivered the 18 f.!M B4F solution to the chip. 
1.02 mm ID tubes were loaded on the pump. Fluorescence readings were recorded at a 
rate of 2 Hz for 60 min using the same microscope and capture settings. While the 
titration time was estimated to take 20 min, data was collected over 1 hr to observe any 
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deviations from the expected plateau once the titrant had been depleted. Images were 
again processed to filter out artifacts due to pulsatile flow. 
5.3.6 Dissolution signal processing 
As time-lapsed images of a dissolution curve are not expected to yield a constant signal 
over time, a modified approach was taken to filter out the pulsatile flow artifacts. As 
before, a window-based approach was taken to remove large outliers from the data. Next, 
data clusters were again identified, but this time through the use of a density map. 
Regions of data were discarded where the density was outside a Yz standard deviation of 
the local mean density. Subsequent to the processing, a linear decrease in signal over the 
plateau region was observed for each experiment and was corrected by adding a constant, 
linear correction factor to the full dataset. 
5.3.7 BCA dissolution analysis 
An identical experimental setup to the streptavidin quantification study was used to 
collect fractionated samples from the microfluidic chip outflow. Each sample was 
collected for 1 min for the first 40 min, and for 1.5 min thereafter. The samples were 
plated on a 96-well plate, along with streptavidin standard curve samples. The standard 
Thermo Scientific™ Pierce™ BCA Protein Assay protocol was used for analysis, with 
the exception of performing an 80 min incubation at 3rC followed by an overnight 
incubation at 4 °C. 
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5.3.8 Dissolution theoretical model 
A computational model to describe the titration experiments was used to determine the 
theoretical concentration profiles under the experimental conditions. The assumptions for 
the model were that the flow rate of the titrant going into the dissolution vessel was equal 
to rate at which fluid was leaving the dissolution vessel. This allows for a constant 
volume approximation for the solution in the vessel, resulting in the description, 
where C(t) is the analyte concentration in the dissolution vessel, Q is the volumetric flow 
rate, V is the volume of the solution, and Cs is the concentration of the titrant solution. 
The solution to this equation is, 
where te signifies the time at the end of titration. The initial condition used to arrive to 
this solution was that C(O) = 0. 
5.3.9 Tetracycline aptamer preparation 
The aptamer sequence provided in a Promega SP6/T7 plasmid vector was used to 
transform competent E. coli cells. Plasmids were amplified and extracted from 4 ml tube 
cultures using a Qiagen miniprep kit (Qiagen, 12125). These plasmids were then 
linearized using a standard Hindiii digest (NEB, R3104T) and transcribed in vitro using 
T7 polymerase (NEB, M0251L) and a ribonucleotide mix (NEB, N0466L). The RNA 
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product was isolated with an ethanol precipitation, resuspended m UltraPure water 
(Invitrogen, 109770 15) and stored at 4 oc until use. 
5.3 .1 0 Tetracycline aptamer fluorescence studies 
According to the literature, binding of tetracycline to the aptamer results in enhancement 
of tetracycline autofluorescence by 2-3 orders of magnitude. To verify this behavior, a 
fluorescence study was performed using a spectrophotometer. The fluorescence intensity 
of tetracycline-aptamer complex was observed along with controls of solutions including 
a blank, tetracycline only, and aptamer only. The tetracycline solution was prepared at a 
concentration of 10 11M, and the aptamer solution was prepared at 6.4 11M, ensuring 
saturation of bound aptamer. A second study was performed using the same aptamer 
solution, but with tetracycline concentrations ranging from 0-10 11M. This provided an 
indication of tetracycline-aptamer stoichiometry, with the expectation of a saturated 
signal above 6 11M of tetracycline. 
5.3.11 Tetracycline standard curve 
A 100 11M working solution of tetracycline was prepared from the stock and used to 
create 4 samples of concentrations from 1-4 flM. A 10 ml aptamer solution of 7.16 11M 
was also prepared as the probe solution, where a concentration of just under double the 
maximum tetracycline concentration ensured saturation of tetracycline binding. Samples 
were pumped through the microfluidic chip with the probe solution, and images were 
taken using a fluorescence microscope with DAPI filter cubes, but no emission filter 
(appropriate filter cube was not available). Images for each sample were taken for 1.5 
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min at 2 Hz using a 250 ms exposure and 8x8 binning. The resulting data was averaged 
without signal processing, as spikes in fluorescence were not as pronounced as in the 
streptavidin studies. 
5.3 .12 Tetracycline dissolution 
A 48.64 !J.M tetracycline solution was prepared to approximately match the streptavidin 
stock solution concentration. The same procedure as the streptavidin quantification study 
was performed, but using this tetracycline solution and the same aptamer solution from 
the tetracycline standard curve study. Images were taken with the fluorescence 
microscope for ~35 min. Images were processed to remove artifacts due to pulsatile flow. 
Changes in dissolution apparatus and probe volumes over the course of the experiment 
were used to correct for any deviations from 1:1 mixing. 
5.4 Results 
5.4.1 Streptavidin-B4F studies 
An on-chip streptavidin-B4F standard curve was produced (Figure 5.3) and used for 
subsequent analysis of the streptavidin dissolution study. The curve demonstrated a 
perfect linear trend with an R2 value of 0.99. Large error bars were observed for each 
sample point, however this was due to the sharp fluctuations in signal caused by the 
pulsatile flow. In spite of this variance, average over more than 60 fluorescence readings 
per sample ensured a representative mean value. 
B4F was next use as a reporter for streptavidin to monitor a dynamic streptavidin 
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solution over a period of 60 min. Figure 5.4 presents the raw, unfiltered data, while 
Figure 5.5 shows the data resulting from Matlab processing. A 2.5 mg/ml stock of 
streptavidin was titrated into a dilution volume of 30 ml from which solution was pumped 
through the chip and mixed with an 18 ).lM B4F solution. The resulting concentration 
curve was corroborated with an independent BCA protein assay using discrete sampling. 
A theoretical model of our titration scheme was also used as a tertiary validation step. We 
found a 3.3% difference in concentration rate of increase between our approach (242.2 
nM/min) and the BCA assay (250.3 nM/min), and a 3.7% error from the theoretical value 
(251.5 nM/min). Integration of the signal yielded a total streptavidin content of 5.04 mg 
compared to an actual value of 5.0 mg, representing a 0.9% error. The data demonstrates 
that we are able to not only accurately monitor analyte concentration in a dynamic 
solution, but also accurately determine total analyte content. We are also able to do this . 
with higher precision than the BCA assay. 
5.4.2 Tetracycline studies 
The verification study of the aptamer behavior demonstrated that enhanced tetracycline 
fluorescence is only observed when both tetracycline and the aptamer are present in the 
same solution (Figure 5.6). The data confirms that virtually no fluorescence is detected 
in either a blank, tetracycline-only, or aptamer-only solution. In contrast, the solution 
with both the tetracycline and the aptamer showed over a 90-fold increase in signal. The 
subsequent stoichiometry study qualitatively confirmed a 1: 1 ratio, showing a plateau in 
the fluorescence signal at approximately 6 ).lM of tetracycline (Figure 5.7). However, the 
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linear range in the plot is observed from 0-4 ~J.M, which represents a maximum 
tetracycline concentration that is approximately 2h of the aptamer concentration. 
For the dissolution experiments, a 7.2 11M aptamer solution was prepared to ensure a 
linear standard curve for tetracycline fluorescence between 0-4 11M (Figure 5.8). The on-
chip standard curve demonstrated this linear trend, with an R2 value of0.99. The variance 
observed for each point on the plot was significantly less than that observed for the 
streptavidin study, which is an indication of the variability in the pulsatile nature of the 
peristaltic pump. The standard curve was then used to analyze fluorescence readings from 
the tetracycline dissolution experiment. Again, the raw data is provided in Figure 5.9 
while the processed data is presented in Figure 5.10. The results were again compared to 
a theoretical model of the titration. The concentration rate of increase was measured as 
245.5 nM/min, and integration of the signal gave rise to a calculated total API content of 
46.8 ~J.g. These values represent an error of 1.7% and 2.9%, respectively. 
5.5 Discussion 
The results of both the streptavidin and tetracycline experiments demonstrate that a 
microfluidic, flow-through method can be used to continuously monitor analyte 
concentrations. The streptavidin studies provided a general proof-of-concept for the assay 
design, and the tetracycline experiments showed that this method could be used to 
monitor a real drug. The study also demonstrated that aptamers could be successfully 
used as reporter molecules that provide an enhanced fluorescence signal upon binding, 
provided that binding kinetics are on the order of those published in literature for the 
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tetracycline aptamer. This provides a clear direction for future aptamer development with 
regards to the development of specific reporters that can be used to quantify APis other 
than tetracycline. 
One particular challenges that was observed in this work was the pumping. The 
use of a peristaltic pump showed high variability in the pulsatile nature of the 
microfluidic flow. This is demonstrated by the difference in the error bars between the 
streptavidin and tetracycline standard curves. The root cause of the fluctuations was out-
of-phase pulsing of the analyte and reporter solutions. Observed from the microfluidic 
chip, the consequence of this was a solution train during each pump cycle that showed 
two general variants. The first was a train composed of pure reporter, pure analyte; and 
then an appropriate mixture of the two. The alternative was a less severe version, with a 
train composed of mostly reporter, followed by mostly analyte, and then an appropriate 
mixture of the two. A detailed look at the at the junction on the microfluidic chip showed 
that at the begi1ming of each pump cycle, there was brief backflow in one channel 
· followed by a quick reversal before the flow stabilized and a mixture was sent down the 
mixing channel. 
The cause of this behavior was likely small variations in tubing diameter and length, 
which coupled with a high fluid resistance through microfluidic chip resulted in these 
brief backflows as the rollers of peristaltic pump released one tube slightly before the 
other. Compliance in the 1.02 mm ID tubing further store energy during the pumping 
process as they are put under stress as pressure builds to push fluid through the high-
resistance microfluidic channels. While in the present study, an open pumping system 
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was required in order to perform the titration to simulate tablet dissolution, future work 
using real tablets could employ a closed pumping method such as a pressure system. This 
would provide constant and continuous flow to the microfluidic chip, eliminating the 
fluorescence artifacts that were seen in this work. 
5.6 Concluding Remarks 
In spite of some of the shmt-term challenges, our results demonstrate an alternative 
approach to medicines quality screening that is capable of specifically and accurately 
quantifying drug API content and release rate. This brings a new tool to the field for 
quantitative testing that can provide more reliable information regarding medicines 
quality. Our microfluidic platform promotes minimal resource usage, cutting costs and 
weight. Furthermore, our single chip design can be used to quantify any analyte, simply 
with the change of the reporter solution. While requiring the development of an extensive 
reporter library, this modular design permits organization of specific kits that can cater to 
the testing needs of different areas. Furthermore, improvements in detection can continue 
to be made through enhancements to the specificity and responses of the reporter 
molecules themselves. This allows for quick and easy deployment of next generation 
reporters that provide improved results without any changes to the detection hardware. 
Our microfluidic approach presents an innovative solution that was guided and 
informed by the needs in the field. While there are still many challenges that must be 
addressed to mitigate the distribution of substandard medication, our goal is to provide a 
targeted solution for medicines quality testing. Beside the existing array of medicines 
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screening devices, this approach may help to provide a more dependable safeguard 
against adulterated medicines that continue to threaten the livelihood of millions around 
the world. 
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5.7 Figures 
Figure 5.1 Illustrates the mixing chip that utilizes the patterned herringbone design to 
adequately mix the API and reporter solutions in a microfluidic 
environment. A quarter is pictured as a size reference. 
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Figure 5.2 Figure by Kada et al. demonstrating the fluorescence quenching of B4F in 
the presence of avidin. The original figure caption is also provided. 173 
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Fig. 3. Titration of the biotin-binding sites in avidin with bio-
tin-4-FITC and biotin-4-ftuorescein. (A) Avidin (80 pmol, 2 ml) 
was titrated with nominally 22.5 ~ biotin-4-FITC by cumula-
tive additions at !-min intervals (o ). In a parallel control series, 
avidin had been presaturated with 8 nmol of o-biotin (o). The 
breakpoint at 13.5 ~ indicated an effective ligand concentration 
of 23.7 llM in the biotin-4-FITC stock solution. (B) Avidin 
(160 pmol, 2 ml) was titrated with nominally 16 f.LM biotin-4-
ftuorescein by cumulative additions at 1-min intervals (o). In 
parallel control experiments, avidin was either omitted (X) or 
presaturated with 1.6 nmol of o-biotin before titrating with bio-
tin-4-fiuorescein (o ). The breakpoint at 42.5 ~ indicated an ef-
fective ligand concentration of 15.1 f,LM in the biotin-4-fiuores-
cein stock solution. 
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Streptavidin-B4F standard curve for a single run obtained on-chip using 
18 J.!M B4F. This concentration was used to ensure saturation of all four 
biotin binding sites on each streptavidin molecule so as to avoid 
confounding data that would otherwise arise from differential quenching 
from streptavidin molecules with different numbers of bound ligand. Data 
for each point was collected and averaged over 90 s. Although the error 
bars are substantial, they are a consequence of the pulsatile flow in the 
system. The average value used in this plot was calculated from over 60 
samplings for each concentration over the 90 s duration. The coefficient of 
determination was 0.999. 
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Figure 5.4 Plot of raw streptavidin concentration curve consisting of fluorescence 
intensity plotted against image frame. Graph shows periodic fluorescence 
peaks and valleys that are artifacts of the pulsatile flow generated by the 
peristaltic pump. A closer look at the central region of the data reveals a 
higher density range of data that represents the true fluorescence reading 
between cycles of the peristaltic pump. 
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Figure 5.5 Streptavidin concentration profile using 18 11M B4F showing an 
increasing trend as streptavidin is titrated into the pill-dissolving vessel. 
Once the titrant has been consumed, the signal plateaus to a constant 
value. The initial decrease in concentration seen before the linear regions 
reflects the initial arrival ofB4F to the microfluidic chip. Linear regime of 
PharmaChk data shows an increase at a rate of 242.2 nM/min, as 
compared to 251.5 nM/min for the theoretical rate. Both the PharmaChk 
data as well as the independent assay show close agreement with the 
theoretical profile. (n=l) 
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Tetracycline (10 !JM) fluorescence measured with a spectrophotometer 
using an excitation wavelength of 360 nm and an emission wavelength of 
500 nm. A blank and two controls demonstrate that a 90-fold increase in 
fluorescence is observed only when tetracycline and 6.3 !JM aptamer are 
incubated together. 
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Figure 5.7 Concentration curve of tetracycline fluorescence with and without the 
addition of 6.4 f..LM aptamer (n = 3). Aptamer concentration was held 
constant for all samples regardless of tetracycline concentration. Plot 
shows a plateau region beginning at approximately 6 f..LM tetracycline, 
qualitatively demonstrating a 1: 1 binding ratio of tetracycline aptamer to 
tetracycline. 
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Standard curve of tetracycline fluorescence with 7.2 flM aptamer obtained 
on-chip. Each point was obtained by average data over 90s, and the error 
bars (representative of n= 180) are indicative of variations in signal caused 
by the pulsatile flow in the system over this time period. The coefficient of 
determination was 0.999. 
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Plot of the raw tetracycline concentration curve, showing fluorescence 
against image frames. Again there is the presence of periodic fluorescence 
peaks and valleys that are due to the pulsatile nature of the peristaltic flow. 
The extent of the variations is smaller in comparison to the streptavidin 
data as fluorescence in this experiment is only observed when both 
tetracycline and the aptamer are in solution together. 
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Figure 5.10 (red) Tetracycline concentration profile showing a linear rate of increase 
as solubilized tetracycline is titrated into the dissolution apparatus at a 
constant rate. The signal plateaus to a final value of 3.651J.M once the 
titrant has been consumed. The rate of increase in the linear regime is 
245.5 nM/min. (green) Expected concentration profile based on 
computational model of the titration. Linear regime shows an increase of 
241.5 nM/min and a plateau of3.74~J.M. 
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Chapter 6: Microfluidic Continuous Flow Dilution Strategy for Integrated 
Analysis of Medicines Quality 
6.1 Introduction 
Field-based technologies for the identification and screening of adulterated medicines 
abound. From handheld scanners to labs in a suitcase, these technologies bring 
laboratory-based interrogation techniques to the field and allow for rapid, high-
throughput tablet screenings. However, many only focus on chemical fingerprints or 
semi-quantitative · API measurements. Few field-ready technologies are capable of 
accurate API quantitation, and none can do so while also providing API release kinetics. 
In our prior work, we have presented PharmaChk, a microfluidic approach to 
analyte quantification that is able to measure API content and provide a continuous API 
release profile. We have also demonstrated that an aptamer reporter can successfully be 
used with this system, providing high specificity and sufficient binding kinetics to 
support real-time quantification. However, the demands of a field-capable system require 
high portability and an inexpensive approach. While the cost of producing aptamers is 
decreasing, the amount required for accurate API quantification in low-volume, high 
concentration tablet dissolutions is cost-prohibitive. 
One approach to limit aptamer demand is to simply dilute the API samples before 
quantification. Numerous microfluidic dilution strategies have been developed in recent 
years. 161-163•174•175 However, much of this work aims to create multiple dilutions that can 
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later be used for further analysis. More recent work by Ahrar et al. optimizes chip real 
estate, but requires valves that prevent continuous dilution. 176 
In this work, we explore the design of a microfluidic chip that is capable of 
continuous 1000:1 dilution and can be coupled with our prior analyte quantification 
designs. This will lead to the development of a single, integrated chip that will require 
1000 times less aptamer for analyte testing. The design of the dilution network was 
carried out using a circuit analogy and the resulting design was analyzed using a web tool 
for microfluidic chip designs. This analysis provided new insight into design sensitivities 
for channel widths and heights, proving important for understanding the specifications 
required for fabrication process parameters. 
6.2 Materials and methods 
6.2.1 Chip Design 
A three-step serial dilution was designed using a single diluent inlet channel to reduce 
tubing requirements and simplify chip interfacing. The design was modeled using a 
circuit analogy, where the Hagen-Poiseuille relation was likened to Ohm's law, revealing 
a linear dependence of pressure and volumetric flow rate on channel resistance. Figure 
6.1 presents a circuit diagram outlining the channel network. A simple analysis using 
Kirchhoff's rules was used to solve for channel resistance based on the intended flow 
rates. These resistances were then used to determine the appropriate dimensions in the 
channel network. The width and height of each channel was held constant at 100 f.J.m and 
70 f.J.m, respectively, allowing resistance control using channel length. This approach 
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provides more reliable chip performance, as channel length c·an be controlled with higher 
precision in comparison to width and height using standard photolithography methods for 
PDMS chip fabrication. These values were chosen due to pre-established process 
parameters for the fabrication procedure. Two exceptions were the inlet for the diluent 
solution and the outlet of the waste channel; these channels were made 200 11m to 
accommodate a larger flow rate without requiring more chip real estate. Larger widths 
were not explored due to the potential risk of channel collapses with decreased aspect 
. ratios. 
To ensure proper dilution across the chip, a staggered herringbone pattern was 
added after each dilution step. The resulting decrease in channel resistance was 
dete;mined from the web tool and used as an initial condition in the Kirchhoff analysis to 
refine the resistance calculations. These new dimensions were used to produce a final 
model in the web tool, which confirmed the predicted 1000:1 dilution based on the 
Hagen-Poiseuille model. The application was then used to interrogate design sensitivity 
to variations in channel dimensions. 
A new feature of the web tool enabled rapid analysis of chip performance under 
varying channel height and width conditions. This analysis revealed that the sensitivity of 
the dilution factor irtcreases with channel height (Figure 6.2) and decrease with channel 
width (Figure 6.3). Further focus on channel height showed that for a variation of only 
3%, the error in dilution becomes 14% for a height decrease and 16% a height increase. 
To ensure a variation in the dilution factor of less than 5%, the channel height must be 
maintained at 70.0 ± 0.6 Jlm. This provided valuable specification requirements for mold 
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fabrication, which is vitally important, yet typically not well understood for many 
microfluidic applications. 
6.2.2 Chip fabrication 
Microfluidics chips were fabricated using polydimethylsiloxane (PDMS) cast on an SU8 
mold. The molds were made using two spin-coat layers consisting of SU8-2075 followed 
by SU8-2010, both spun at 2400 rpm. Each layer was exposed to a 350 nm light source 
through a chromium photo mask using the Sliss MicroTec MA6 mask aligner. The mold 
was developed using SU8 developer after both layers had been spun, and the channel 
heights were sampled across the mold using a Dektak 8 profiler. PDMS was mixed using 
the Sylgard 184 silicone elastomer kit at a 10:1 ratio and cured at 150°C for 10 min. 
PDMS chips were bonded to glass slides after 0 2 plasma exposure using the PV A TeP1a 
M4L plasma asher. 
6.2.3 Dilution testing 
A fluorescein solution was pumped through the microfluidic chip together with deionized 
water at a pressure of 10 psig. Samples from the chip outlet were collected and tested on 
a spectrophotometer together with manual serial dilutions of the fluorescein solution. 
These dilutions provided a fluorescence standard curve that was used to interpret the 
signal observed from the chip-based dilution. Samples from the chip outlet were taken 
over 6 minutes and fractioned into two tubes to observe any time-dependent dilution that 
may occur as a result of flow stabilization. 
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6.3 Results 
Fluorescence readings of the manual dilutions provided a standard curve with points 
displaying a relative standard deviation of less than 2% and an overall linear character 
with a correlation constant of greater than 0.99 (Figure 6.4). The fluorescence readings 
of the chip dilutions are provided in Table 6.1. 
The difference in readings between the first and second fraction indicate that the 
microfluidic flow is still stabilizing after 3 min. If we take the second . fraction as a 
representative sample for chip performance, we observe a dilution factor of 1317:1 or an 
error of 31. 7%. However, sampling of the silicon mold used to fabricate the PDMS chips 
yielded an average channel height of 73.5 ± 0.51-lm. Based on the analysis performed 
using the microfluidics web tool, this deviation in channel height was expected to result 
in dilution factor of 1304 ± 50, representing an error ofless than 1%. 
6.4 Discussion 
Our three-step serial dilution chip demonstrated a design process that was informed by a 
more detailed microfluidic analysis based on Hagen-Poiseuille flow. The resulting chip 
showed a deviation in dilution factor of over 30%, but demonstrated an error of less than 
1% when the channel height was considered. Further sensitivity analysis of the dilution 
factor to changes in channel height and width indicated that a relatively small deviation in 
either parameter resulted in a notable change in dilution behavior. However, we see that 
while increases in channel height result in further dilution, increases in channel width 
result in concentration. While the changes in channel width were only evaluated for the 
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1 00 J..Lm channels, the result is far from intuitive and demonstrates the importance of a 
thorough microfluidic design review. Particularly when channel widths throughout a 
microfluidic network are not consistent, uniform channel deviations may drastically 
impact fluid flow in unforeseen ways due to the strong dependence of resistance on 
geometry. 
While an improvement in chip behavior may be achieved by modifying the process 
parameters and fabricating a mold with a channel height of 70.0 ± 0.6 J..Lm, the web-based 
modeling tool provides a powerful method for understanding the effect of parameter 
variations on chip performance. Using this tool, changes to the designed width and height 
could be made in a way that sensitivity to the dilution factor due to variations in these 
properties are diminished. This has important practical implications, as particularly for 
channel heights, spin coating processes are difficult to optimize to achieve a precise and 
uniform distribution of photoresist 
6.5 Conclusions 
In spite of the deviation in the dilution factor from the intended value, we have 
demonstrated a flow-through dilution system that can be easily integrated with our 
aptamer-based platform for analyte monitoring. While optimizations of channel 
geometries are still necessary in order to maximize device repeatability, the thousand-fold 
dilution delivered by the chip demonstrates a plausible design for the significant 
reduction of aptamer required for a single test. This has tremendous implications for 
associated cost reductions, transforming the analyte monitoring platform from an 
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expensive laboratory tool to an affordable field-capable method. Future work remains to 
integrate these designs, however the joined concept brings affordable testing for 
medicines quality one step further, and breathes new life to the potential of better 
securing quality medicines for millions of sick around the world. 
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6.6 Tables 
Table 6.1 
Fraction 
1 
2 
Presents the fluorescence signal obtained from both fractions of the diluted 
solution (n=1). These signals were compared against a fluorescence 
standard curve to deterimine the relative concentration and resulting 
dilution factor. An error is presented against the expected dilution of 1000. 
Signal Relative Cone. Dilution Factor Error(%) 
1722.234 0.6764 1478.30 47.83 
1929.763 0.7589 1317.72 31 .77 
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6.7 Figures 
Figure 6.1 Schematic of a microfluidic chip for continuous dilution of an incoming 
API solution 1000:1. Design enables easy integration with the aptamer-
based analyte monitoring platform, reducing the amount of the fluorescent 
tag solution required by the same factor. 
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Figure 6.2 Plot of the dilution factor produced by the chip as a function of 
microchannel height. Data indicates that the dilution factor becomes more 
sensitive to channel height as the channel height is increased. 
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Figure 6.3 
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Plot of the dilution factor produced by the chip as a function of 
microchannel width. Data indicates that the dilution factor becomes less 
sensitive to channel width as the channel width is increased. 
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Figure 6.4 
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Chapter 7: PharmaChk Miniaturization and Prototype Development 
In our previous chapters, we demonstrated the development of a new testing platform that 
utilizes microfluidics to monitor analyte concentration. We also showed that such a 
platform could be applied to medicines quality control, providing quantitative 
information for API content and release from tablets. We now turn our focus to the 
translation of that platform to a field-ready analysis that enables inexpensive, portable, 
and robust testing outside of the laboratory. To help explain our prototyping process, we 
will begin by reviewing the design considerations for a portable medicines screening tool. 
7.1 Design considerations 
Several field-based screening technologies are currently used to test drug quality. In 
particular, MiniLab®, Phazir, and TruScan are three products that have seen extensive 
uptake from medicines regulators across the globe. 
As we saw earlier, MiniLab® serves as an excellent first approach to the problem 
of field-based screening, but still only provides qualitative information that is difficult to 
standardize. We surveyed several individuals at the USP who have hired staff around the 
world completing MiniLab® tests. Their largest criticisms were that MiniLab®: 
1. Provides only qualitative information 
2. Requires technically trained staff to perform extensive sample preparation 
3. Involves laborious protocols even after sample preparation 
4. Packages a system that weighs close to 200 lbs and is difficult to transport 
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5. Limits practical testing to a single drug per day due to sample preparation time 
While in the face of these challenges, MiniLab® is still used extensively, the limitations 
of the system greatly hinder more extensive and precise testing. The World Health 
Organization defines good quality medications as those that contain 90-110% of the 
expected API content59 ; MiniLab® can only provide an indication as to whether API 
content is greater than 80%. The consequence is a decrease in field-based decision-
making power, and an increase in the number of samples that must be sent to national 
testing facilities for confirmatory analysis. Any future field-based technology must solve 
these setbacks in order to provide a more accurate and useful testing platform. 
Phazir solves several of these challenges. It is hand-held, requires no sample 
preparation, and can provide a chemical fingerprint of a tablet in seconds. Using NIR 
technology, it is a non-destructive test that uses absorption of light to determine tablet 
content while leaving the pill intact. However, the technology is costly and still does not 
solve the largest challenge for field-based methodologies-quantitation. It also has poor 
sample penetration and is sensitive to light, humidity, and sample position. 16 
TruScan uses Raman spectroscopy and provides several improvements over NIR. 
It is less susceptible to external conditions and is able to control for ambient light, 
humidity, and sample position. TruScan also shows superior sample penetration, allowing 
for the analysis of tablets through packaging. 16 This offers yet another improvement to 
sample preparation and general ease-of-use. However, Raman spectroscopy is extremely 
sensitive to fluorescent molecules, which are common among APis. 16•57 Furthermore, the 
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instrument still requires the development of an extensive reference library for calibration 
and comparisons to sample spectra. Most importantly, it also does not solve the problem 
of quantitation. 
7.2 PharmaChk needs and challenges 
PharmaChk as a laboratory-based method solves many of the problems typified by 
MiniLab®, Phazir, and TruScan. As a first measure of success, it provides quantitative 
information without the development of extensive reference libraries and training sets; it 
is expected to require only a single reference per API. Moreover, it eliminates sample 
preparation by dissolving the tablet itself and avoids a laborious testing protocol by 
performing automated sample processing and analysis. Due to these improvements, test 
time is minimized, allowing for analysis of multiple unique medicines per day. 
The remaining challenge lies in maintaining these advantages while translating 
the technology into a portable and robust field-based methodology. In the laboratory, 
precise fluorescence measurements were made using microscopy and scientific-grade 
photodetectors. Excitation light was also provided using finely tuned lasers that, while 
precise, were extremely sensitive, costly, and completely immobile. 
Additionally, sample delivery was accomplished using a bulky and heavy 
peristaltic pump. As we saw in Chapter 5, it also led to large and periodic spikes in the 
fluorescence signal, requiring extensive data processing. Alternative pumping strategies 
should be explored to address these problems. A quick and simple way to interface to the 
microfluidic chip with the pump tubing is also requisite. In the laboratory, this was 
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accomplished by manually inserting the individual tubes in the chip inlets and outlets; 
however this process is cumbersome and can sometimes lead to tube ejection from the 
chip due to high on-chip pressures. A robust and simple mechanism to eliminate that risk 
and enable a user to quickly interface to a chip is highly desirable. 
Lastly, a major challenge is providing the benefits that PharmaChk is capable of 
in an inexpensive platform. While MiniLab® exhibits many pitfalls, it continues to remain 
the most widely used technology, partly due to its reduced cost. 16 For PharmaChk to be 
competitively positioned, the system should be designed with a similar cost in mind. This 
will require creative and innovative solutions that will be able to encapsulate all of the 
advantages of the bench top PharmaChk system into a simple and portable device. 
Fortunately, several miniaturization schemes have been explored in the academic space 
over the past decade. For us to develop a successful platform, it would be prudent to 
review these developments. 
7.3 Current miniaturization schemes 
7.3.1 Optical detection strategies 
The largest challenge in translating the PharmaChk platform from the laboratory to the 
field is miniaturizing the detection system. Currently, the platform requires lasers and a 
large microscope setup. To make PharmaChk truly portable, this must be converted into 
an inexpensive and lightweight setup without sacrificing quantitative ability. 
Fortunately, this has been an area of extensive research. Early work involved 
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integrated systems that made use of embedded optical waveguides and detectors for 
direct and focused illumination of microchannels on chips. 177-180 Several groups also 
noted the feasibility of using light emitting diodes (LEDs) rather than lasers as a source 
of excitation light. This served the purpose of not only reducing the cost of the system, 
but also the portability and power consumption. While lasers are typically several 
thousand dollars, LEDs cost fewer than several hundred. Furthermore, an LED is orders 
of magnitude lighter and easier to integrate than a laser unit. However, embedded 
systems require more ·complicated fabrication techniques, and embedded photodetectors 
increase chip cost. 
Improvements in LED technology enabled the development of more effective 
platforms that were able to achieve quantitative measurements without the use of 
embedded system. These next-generation LEDs provided higher light intensities at a 
reduced cost, and led to the development of portable fluorescence microscopes. 181 - 183 
Miller et al. were able to show no statistical difference in the diagnosis of tuberculosis in 
sputum smears between a portable, low-cost, LED microscope and a conventional Nikon 
E400 microscope. 183 
Since the demonstration of LED-powered fluorescence measurements, numerous 
groups have developed new diagnostic tools and technologies that perform quantitative 
fluorescence measurements using chip-based devices. Myers et al. developed a point-of-
care instrument for multiplexed pathogen genotyping, 184 where a microfluidic assay is 
used to amplify and detect the presence of specific genetic markers for a variety of 
pathogens. More recently, Kostov et al. developed a portable system for the detection of 
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glucose levels in non-invasively collected biofluids such as saliva, tears, and sweat. 185 
The group demonstrated the ability to quantify concentrations of 0-5 flM glucose with a 
resolution of 0.07 flM. Furthermore, the detection system was designed into a housing the 
size of a hand-held gaming console. Compared to a conventional bench-top microscope, 
this work demonstrated just how portable a quantitative, fluorescence based system can 
become using simple LED and photodiode components. A similar configuration would 
serve as a promising starting point for the miniaturization of the PharmaChk system. 
7.3 .2 Chip interfacing strategies 
In spite of the burgeoning growth of microfluidic technologies over the last two decades, 
chip interfacing has remained a persistent and troublesome problem for device scale-up 
and commercial viability. The difficulty lies in the fact that while conventional fluid 
handling and storage typically involves milliliters to liters of fluid, microfluidic systems 
can only process pica- to nanoliter volumes due to their micron-sized channels. In the lab, 
a plethora of methodologies are used to enable this interfacing, but many of these 
techniques require additional preparatory steps that are laborious and not scalable. Any 
end-stage design must involve a simple and easy way for users to insert and connect 
microfluidic chips to quickly utilize the complete system. Here, we will review past 
techniques in order gain insight into opportunities for more scalable solutions. An 
excellent review is also available by Frederickson and Fan. 186 
The first macro-to-micro interfaces simply involved the fabrication of inlet and 
outlet wells. These wells were easily cored or drilled and interfaced with a reservoir of 
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solution connected by an appropriately sized micropipette or syringe tip. Tubing from 
fluid pumps could also be inserted into these wells, and glue was often used to secure 
these interfaces inplace.187-190 This technique continues to remain one ofthe most widely 
used methods due to a relatively simple chip preparation. 186 
To provide a more elegant solution to the intetfacing problem, some groups began 
using commercially available fluid connectors. 191 One example is Upchurch Scientific's 
Nanoport™. This connector is bonded to the chip surface using a supplied adhesive ring 
and clamped to allow the bond to fix. Once applied, the tubing can quickly and easily be 
connected to the device. However, common issues with these options included 
contamination of fluid channels with adhesive, failure of the bond due to incompatible 
solvents that are used with the microfluidic chip, or clogging of the channels. In more 
recent years, magnetic connectors have also been introduced that eliminate the need for 
cumbersome adhesives, and provide a quick and reusable solution. 192 
A final evolution in microfluidic interfaces is socket designs. These involve the 
development of customized sockets that are either held in place via a clamping 
mechanism or by vacuum. 193-195 Due to the designed fit and use of a clamping force to 
secure the interface over the microfluidic chip, these interfaces are typically the most 
leak-proof. However, the assemblies are often more complicated to design and fabricate, 
and typically require precision machining to ensure proper alignment between the socket 
ports and the microfluidic chip inlets and outlets. 186 Nevertheless, in commercial 
production, these socket designs can quickly become scaled and provide the most reliable 
solution for a leak-proof micro fluidic interface. 
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7.4 Prototype 1: A first crack at product design 
In Chapter 3, the PharmaChk system was broken down into four major components: the 
tablet dissolver, fluorescent tag, microfluidic chip, and signal detector. These components 
capture the essence of the project, but neglect outlining the key physical components of 
system. A more detailed breakdown includes: 
1. Tablet dissolver 
2. Fluid pump 
3. Chip interface 
4. Microfluidic chip 
5. Signal detector 
6. System housing 
During the early prototyping phase, the signal detector was, by far, the most restrictive 
component. All fluorescence measurements were conducted in the confines of a 
laboratory dark room that contained a confocal microscope setup and a laser light source 
for illumination. Imaging relied on a state-of-the-art Hamamatsu charged-coupled device 
(CCD) that was physically sensitive and came in a standalone and weighty housing 
assembly. All of these components were perfect for proof-of-concept studies, but were 
clearly too cumbersome, bulky, and expensive to utilize as part of a portable platform. 
This became this focus of the first prototype-development of a new detection system 
that was portable, reliable, and most importantly, still quantitative. 
In light of this, we began work on an initial prototype design, focusing solely on 
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the detection system. Based on the literature, it was clear that lab-on-a-chip devices using 
portable, fluorescence-based detection were quickly converging on high-powered LEDs 
as an illumination source. Ongoing improvements in UV and blue LEDs were making 
this option increasingly practical, both from a functional and financial position. This 
became the first component purchased for the PharmaChk prototype-a blue LED from 
Thor Labs (M490Dl). Corresponding excitation (FL05488-10) and emission (FEL0500) 
filters were also purchased to narrow the light bandwidth to 488 ± 2 nm and subsequently 
attenuate it to allow only green fluorescent light above 500 nm to reach the 
photodetector. An iPhone camera was selected for detection as it also used a CCD chip 
and provided a quick and ready-to-use solution. Furthermore, mobile phones were 
becoming increasingly popular in the global health technology space; m-health and 
telemedicine were the new buzzwords, ushering in a generation of ideas that allowed 
remote correspondence of health professionals based on data collected and sent from the 
field. 196-199 While PharmaChk did not have direct diagnostic relevance, real-time 
transmittance of medicines quality data coupled with GPS information had interesting 
implications for large-scale data collection and analysis. At the same time, numerous 
groups were demonstrating that mobile phone cameras were capable of microscopy and 
were a relevant technology for field use?00-203 
The use of additional lenses to focus down both the excitation light on the sample 
and the emission light on the iPhone camera were considered. Utilizing these optical 
components would greatly increase the efficiency and sensitivity of the assay. However, 
the power of a field-ready system lay within its simplicity. Using fewer components not 
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only directly reduced cost, but also reduced the complexity and number of parts that 
could have broken or required maintenance. A substantial cause for technology failure in 
in the field was the lack of parts and servicing expertise. Simplifying a device reduced 
this risk and increased the probability of technology success. Lenses would also required 
proper alignment, needing either a more rigid and reliable housing to maintain that 
alignment or more careful handling of the device. Neither was favorable for a successful, 
field-ready platform. Consequently, the initial prototype was developed without lenses, 
keeping in mind that if significant accuracy or sensitivity were lost, they may always be 
added to instrument. 
Given, these considerations, the final design idea consisted simply of the LED, 
excitation filter, microfluidic chip, emission filter, and CCD sensor stacked atop one 
another (Figure 7.1). This configuration lent itself to a simple design with minimal 
components to decrease the risk of device failure. The need for a lens to focus the 
emission light also became moot, as the CCD sensor was placed closer to the 
microfluidic chip to maximize light capture for intensity readings while disregarding the 
unnecessary need to resolve a focused image. 
With a clear design idea and the necessary components ready for integration, an 
AutoCAD design was drafted for the detection housing (Figure 7.2). The LED would be 
mounted on the underside of this housing, and a small cutout just above it held the 
excitation filter in place. Above this filter, a platform was incorporated to provide a 
location for the microfluidic chip to rest. This space was intentionally left open to allow 
chip repositioning in order to maximize the signal. Small openings were left on the sides 
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of the housing for the inlet and outlet tubing to pass through and connect the chip to an 
external pump. A lid would then close the assembly with a second cutout that would 
accommodate the emission filter. This would block any blue excitation light, so that only 
green fluorescence light from the microfluidic chip would pass through. Finally, the 
iPhone camera would be placed above the emission filter to capture the signal. The body 
of the iPhone would cover the opening to block out ambient light and ensure that only 
light from within the system was detected. 
The AutoCAD design was realized using a 3D printer to allow for rapid 
prototyping. Testing of the prototype found that the light from the LED was too powerful 
to be completely attenuated by the emission filter. Consequently, the excitation light 
dominated the signal seen by the camera. Figure 7.3 illustrates this result in a negative 
control where no signal was expected but bright blue light was still observed through the 
emission filter. In order to maintain quantitative power, either a new strategy for 
excitation had to be explored or a better emission filter was needed. 
7.5 Prototype II 
Rather than utilize more expensive filters to address the transmission of excitation light 
through the emission filter, a new design was considered to minimize this interference 
(Figure 7.4). In this design, two factors were changed. First, rather than maintaining the 
illumination source, sample, and detector on a single plane, the illumination source was 
moved by 90° to illuminate the sample transversely. Second, a black print material was 
used rather than white in order to facilitate absorption of stray light from within, and also 
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prevent transmission of external light into the housing. 
In this new configuration, the LED and excitation filter were moved to the side of 
the housing, while the emission filter and iPhone camera remained above. This design 
allowed the excitation light to shine through the sample and fall on an empty wall inside 
the housing. Using a black material resulted in absorption of much of the light, and most 
scattered light was similarly absorbed by the remaining surfaces. Any light that still made 
it to the emission filter was low enough in intensity to be successfully attenuated. 
An additional modification to the prototype was the design of a chip holder. 
Rather than having a fixed ledge printed into the housing for the microfluidic chip to rest 
on, this holder provides the freedom to not only move the chip side to side, but also 
adjust the chip vertically. This eliminated the need to print an entirely new housing 
simply to move the position of the chip. Furthermore, printing a ledge into the housing 
may have partially or completely blocked access to the cutout designed to accommodate 
the excitation filter, making it difficult or impossible to assemble the components. The 
holder was printed as two parts with insets designed to provide space for the chip edges 
to rest on. Once these components were fit together, the chip would sit neatly suspended 
at the appropriate height for illumination by the excitation light. 
Figure 7.5 depicts the printed prototype with a penny as a reference. Tests using 
the new design showed significantly improved results, with a negative control showing 
no noticeable transmission of excitation light through the emission filter. Video of a 
positive control was recorded to observe the consistency of the signal over time, however 
analysis revealed that the iPhone camera frequently adjusted the exposure time 
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automatically. While this programming was not directly controllable, the application 
CamLock was used to lock the exposure time so that it remained consistent throughout 
the duration of a video recording. With a locked exposure, a standard curve was obtained 
using samples of biotin-4-fluorescein (B4F) with concentrations ranging from 0-310 11M 
(Figure 7.6). However, higher concentrations than were typically used for the dissolution 
experiments were necessary in order to provide a quantifiable signal. The results showed 
an R2 value of 0.99. One data point was disregarded (248 J..LM), as it was a clear outlier in 
comparison to the remaining data. 
The data provided preliminary evidence than an LED could be used an excitation 
light source with a mobile phone as the photodetector. However, testing at lower 
concentrations of B4F was difficult to perform due to the inability to manually control the 
exposure settings on the camera. This indicated that a more reliable method of detection 
that provided this level of control was a requirement for the system. While the ability to 
immediately transmit test results via SMS was considered an advantage, it could not 
trump the accuracy of the assay. 
Overall, this prototype successfully demonstrated that the detection system could be 
moved from a laboratory-based microscope setup to a more portable LED and CCD 
configuration. Preliminary results indicated that a linear standard curve was still 
attainable, although a more sensitive photodetector with adjustable exposure settings was 
required to confirm this for lower concentrations. While this entailed future work for a 
more rigorous proof-of-concept with a miniaturized device, it provided a clear path for 
future experimentation. At this stage, What remained unclear was how to engineer a more 
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convenient world-to-chip interface to provide consistent placement of the microfluidic 
chip within the housing while simultaneously making connections with tubing quicker 
and easier for the user. This became the focus of the next prototype iteration. 
7.6 Prototype III 
Previous prototyping efforts demonstrated a clear path forward for miniaturizing the 
detection system to allow for a portable and quantitative fluorescence assay. We 
demonstrated that a linear curve could still be obtained using an LED with a consumer-
grade CCD sensor, albeit at higher sample concentrations. It was evident that a more 
sensitive and programmable photodetector was required to overcome this challenge and 
enable the same level of quantitation in less concentrated solutions. However, a parallel . 
hurdle was the development of a world-to-chip interface that allowed for a simple and 
robust interface to connect the microfluidic chip to the pumping system. Currently, this 
was achieved by manually inserting each tube into the corresponding inlet or outlet on the 
chip. This process was both cumbersome and unreliable, as tubing often popped out due 
to high on-chip pressures. In the laboratory, this was manageable, but in a portable and 
streamlined housing, this could result in unnoticed leaking and subsequent damaging of 
internal components. A more robust design was necessary that incorporated a lock-tight 
interface. 
With this in mind, a third-generation prototype was envisioned where needle 
connectors could be used to interface with the microfluidic chip (Figure 7.7). These 
needles protruded up from the bottom of the housing, and due to their rigidity, allowed 
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the user to quickly and easily press a microfluidic chip onto the assembly. Using a fitted 
space to accommodate the chip, the needles could automatically align with the inlets and 
outlets without any further intervention by the user. One immediate difficulty with this 
concept was safety. Exposed needles presented a health hazard making operation of the 
device more precarious. However, with an appropriate design, safety features could later 
be incorporated to ensure that no needles were exposed until after the user had placed the 
chip inside the housing and secured the lid. 
To quickly and easily couple the pump tubing with the needles, standard 
connectors (Cole-Parmer, EW-06473-00) with luer fittings (Cole-Parmer, EW-45505-82) 
were purchased. These connectors allowed quick attachment of the needles on one end, 
and compression-secured tube insertion on the other. With these components in hand, an 
AutoCAD design was developed (Figure 7.8). This design used the same trans-
illumination scheme as the previous prototype, but confined the microfluidic chip to a 
specific location in front of the LED. A removable chip nest accommodating an even 
smaller 18 x 18 mm chip was also designed to allow for access to the excitation filter 
cutout. Once the excitation filter was placed in the housing, the chip nest could be 
pressed down and secured. Alignment features on the housing and the underside of the 
chip nest ensured consistent placement. Three channels were also etched on the housing 
under the chip nest to accommodate the two inlet and single outlet needles. These needles 
entered horizontally, and then bent up 90° to protrude through guided features in the chip 
nest. The needles were cut to size with wire cutters in order to ensure that they each 
protruded the same distance from the chip nest despite varying path lengths to their 
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respective fluid connectors. 
A printed version of the prototype is pictured in Figure 7.9. While the majority of 
the space was occupied by the fluidic connectors, the full unit was roughly the size of a 
small jewelry box. As intended, the system was easily attached to the pump tubing, but 
testing demonstrated small and persistent leaks at the needle-chip interface. A closer look 
at the needles revealed that the ends were deformed due to the wire-cutters. While these 
needles could have been cut with greater precision using more sophisticated tools, this 
quick test revealed how dependent the interface was on intact needles. Slight deformation 
clearly resulted in fluid leaks, and while the needles could easily be replaced, the 
interface design needed to be one of the most rugged components of the system. 
7.7 Beta Prototype- PharmaChk 1.0 
Several prototype iterations provided tremendous insight and guidance as to how 
miniaturization of the PharmaChk system should proceed. We determined that consumer 
CCD chips, while sensitive, were difficult to configure and integrate into a larger system. 
Moreover, as an assay built around light intensity, the imaging capability provided by a 
CCD chip was unnecessary. A more relevant optical component for detection would be a 
photodiode. Photodiodes provide a current that is directly proportional to the intensity of 
light incident on its sensing region. As single components, they cannot be used to resolve 
an image, but therein lay their simplicity and value for an application such as ours. In 
addition to a more relevant detection component, we needed a more sophisticated world-
to-chip interface. Users should not have to manually insert the tubing into the 
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microfluidic chip, but a simple needle interface proved to be ineffective. Based on the 
literature, socket interfaces demonstrated the best performance in spite of requiring 
custom designing and precision tooling. 
As these results and conclusions began to materialize, it became apparent that the 
expertise that was required to design and integrate these components in a streamlined 
manner was not an available asset. If we were going to produce a robust and quantitative 
instrument quickly and expertly, we needed help. 
7.7.1 Fikst 
Fikst is a small product design fmn based in Woburn, MA. Founded by brothers Paul and 
Doug Sabin, the company offers a dynamic range of expertise and is capable of filling the 
role of anything from a facilitator for short-term requirements to an external wing for 
long-term technical development. We first met Fikst as we began searching for local 
expertise in product development. We had a technology that had been thoroughly tested 
in the laboratory, but after several iterations of prototyping, was proving complicated to 
miniaturize. Procuring external support became a high priority, as it would better serve 
our goal of developing a field-ready device rapidly and effectively. The company had an 
extensive and eclectic portfolio, demonstrating know-how in multiple areas including 
microfluidics. Furthermore, Fikst was very keen to the idea of an open collaboration 
rather than a complete outsourcing of the project. This was appealing on multiple levels, 
offering us more voice in the development of the system and simultaneously providing a 
unique learning experience. 
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Within a few weeks of meeting, we commenced a formal engagement and 
provided an outline of the technology and a requirements document that provided 
additional direction. The work was split into seven major components: 
1. Dissolution 
2. Probe delivery 
. 3. Pumping 
4. Chip interface and clamping 
5. Illumination/detection 
6. Control system 
7. User interface 
The goal was simple: to create a self-contained device that integrated these components 
into an easy to carry system. Fikst quickly identified a Pelican case as a rugged and 
dependable vessel for the alpha prototype. This enabled us to systematically approach the 
remaining tasks understanding our limitations for space and weight. While many of the 
components were already primed for use, development and integration of the outstanding 
work proved to be far from trivial. 
7.7.2 Tablet dissolver 
The tablet dissolver provided a container for the drug tablet to slowly dissolve in 
solution. While standardized USP dissolution vessels hold volumes approaching 1 L, we 
designed a compact container that could be used to dissolve tablets in 30 mL. To aid in 
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the dissolution process, a magnetic stir bar was added and actuated with a stir plate 
(Figure 7.10). For the alpha prototype, this design was quickly incorporated. However, to 
separate the stir bar from the tablet, a pill cage was designed and printed as an insert that 
pr~)Vided a distinct space for each component (Figure 7.11). The 30 ml solution would 
then fill the entire assembly, and tiny 1.5 mm diameter holes were designed into the base 
of the insert so that the rotation from the stir bar enclosure agitated the tablet solution 
above. 
The laboratory design of the tablet dissolver was intended for use with a 
peristaltic pump. The base was tapped to accommodate a fluid connector (Cole-Parmer, 
EW-06473-00) that allowed for easy connection of tubing via a compression fitting. This 
design was well suited for the application, however to incorporate future use of the 
dilution chip from Chapter 6 and to address the variability in signal observed in Chapter 4 
due to the peristaltic pump, a switch to a pressure-based pumping strategy was necessary. 
While this complication caused delays in several other aspects of the project, it simplified 
the tablet dissolver design. Instead of having a proprietary vessel that was capable of 
interfacing with tubing, the tablet dissolver could now utilize a simple plastic container in 
which the pill cage insert could rest. The advantage of this was that this container could 
now be disposable. Not only would this provide an additional source of revenue as a 
distinct consumable, it more importantly provided the opportunity to prepackage the 
vessels with clean, premeasured solutions. This would remove the possibility of assay 
variations due to both local water quality and solution volume while also making use of 
the system faster and more streamlined. 
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7.7.3 Probe delivery 
Packaging of the fluorescent tag also became a consideration that had important 
implications for easy-of-use and informed design considerations for the overall device. 
Numerous packaging methods have been utilized for portable systems, including blister 
packs that even eliminate the need for a pump204. However, our assays required upwards 
of 2 ml of the fluorescent tag per test, which was not amenable for packaging using 
typical blister packs. Furthermore, sophisticated packaging schemes were outside the 
scope of our current prototyping phase. For this reason, we chose to move forward with 
simply packaging the probe in 2 ml microcentrifuge tubes. 
7. 7.4 Pumping 
As previously mentioned, the use of a peristaltic pumping system led ~o a number of 
complications including additional signal processing requirements and incompatibilities 
with the dilution chip presented in Chapter 6. These problems are detailed below and 
informed the switch to a pressure-driven pumping solution. 
7.7.4.1 Peristaltic flow 
During the prototyping process with Fikst, pumping was quickly identified as one of the 
most high-risk aspects of the prototype. Up to this point, all experimental studies had 
been conducted using an Ismatec 8-channel planetary gear pump (Cole-Parmer, FF-
7802312). This pump provided eight separate, but codependent channels for pumping 
solutions at a constant volumetric flow rate. For the PharmaChk assay, we used two of 
these channels to pump API and probe solutions into our microfluidic chip at a 1:1 ratio. 
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On-chip, these solutions would converge at the SHM channel and mix together. In 
principle, this worked perfectly; in practice, it led to an unusual and unexpected 
problem-backflow. Peristaltic or positive displacement pumps are constant flow pumps 
that operate independent of downstream pressures. They function through the use of 
rollers that sequentially and repeatedly push solution forward through flexible tubing that 
is pinched and released (Figure 7.12). Ordinarily, this mechanism produces perfectly 
repeatable and consistent average flow rates; however, two causes of backflow were 
observed when these tubes were connected to a microfluidic chip with converging 
channels. 
The first resulted from air bubbles. Due to the compressibility of air, the presence 
of bubbles resulted in the loss of flow as more fluid was pushed behind it. Ordinarily, 
fluid that is pushed through the tubing can only cause downstream fluid to move through 
the high resistance channels of the microfluidic chip at the same flow rate. This is a direct 
result of the conservation of mass and the incompressibility of water. In the presence of 
air, mass must still be conserved. Thus, as fluid is pushed behind an air bubble, either an 
equal amount of fluid must move through the microfluidic chip, or the bubble must be 
compressed to accommodate more fluid mass in the same tubing volume. Of these two 
scenarios, the high resistance microchannels of the chip made it is easier to compress the 
bubble rather than cause downstream fluid movement. Consequently, fluid flow through 
the chip was greatly reduced. At same time, fluid that was pushed through the other tube 
flowed onto the chip and has two options when it reached the convergence point at the 
SHM channel-it could either continue down the high-resistance mixing channel, or flow 
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back through the lower resistance inlet channel that led to a compressible air bubble. 
Naturally, fluid traveled back toward the bubble in the other tube until the force required 
to further compress the bubble outweighed the fluid resistance across the SHM channel. 
Thus, during a single roller cycle, the air bubble was compressed from both directions. 
As soon as the roller was released from the tubing, there was no longer any pressure to 
maintain the compression of the air bubble. As a result, it expanded; however, it was 
easier for fluid to move back through the low resistance tubing toward the fluid source 
than move forward through the high-resistance microchannels. As a result of the 
phenomenon, there was a momentary negative displacement in the tubing. If the bubble 
was large enough, this negative displacement became larger than the positive 
displacement during each pump cycle, resulting in a net negative flow through the tubing. 
This posed a serious problem for any microfluidic chip that operated on the assumption 
of a 1:1 flow ratio of its incoming solutions. 
The second observed problem dealt with temporary backflow. Due to slight 
manufacturer variations in tubing diameters, as the rollers simultaneously move across 
two tubes, they reieased from one slightly before the other. On-chip, the result at the 
convergence point was that fluid from one channel flowed back down the inlet of the 
other channel. This motion then reverses when the next roller began to pinch the other 
tube. While this does not pose an immediate problem with the assay, it resulted in 
additional data processing due to signal spikes as were observed in Chapter 5. However, 
this did become an issue when independent peristaltic pumps were considered to pump 
fluid through each tube. If the rollers for each pump were not in phase, 1 : 1 mixing could 
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not be guaranteed. Moreover, the phase-sync of the two pumps would likely be variable 
from run to run. 
One solution that was explored to relieve the backflow was check valves. Check 
valves are one-way valves, similar to those observed in a heart that allow flow in one 
direction and prevent flow in the reverse. There are a wide variety of check valves that 
operate using different mechanisms, and several were trialed. However, while they 
helped significantly, some backflow was still observed. Ultimately, it was determined 
that for more reliable flow through the microfluidic chip, a pressure-driven pumping 
strategy was necessary. 
7.7.4.2 Pressure-driven flow 
In electronics, there are two main sources that drive electrical current through a circuit: 
current sources and voltage sources. In hydrodynamics, while peristaltic pumps are 
analogous to current sources, pressure-driven flow is analogous to voltage sources. In 
pressure-driven flow, the difference in pressure between the inlet and outlet of a channel 
drive fluid flow in the direction of less pressure. This forms the basis for the Hagen-
Poiseuille equation discussed in Chapter 4. Initially, the use of a pressure system for the 
PharmaChk system had been temporarily ruled out as it involved the design of a pressure 
vessel and a feedback loop to maintain a constant value. However, the advantage of a 
pressure-driven system was that it provided constant and continuous positive flow. As 
there were no cyclic rollers that relieved pressure as they released from the tubing, there 
was no oppmiunity for backflow. While the introduction of an air bubble may 
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temporarily slow down flow in the associated tubing, the bubble is quickly compressed 
and remains so until after it has passed through the chip. Thus, switching from a 
peristaltic system to a pressure system solved both sources of backflow that were 
previously observed. The trouble was simply integrating a pressure feedback loop. 
To make the switch to a pressure-drive system, a vessel was designed to contain 
the tablet dissolver, probe solution, and space for a third solution of water for future use 
with the dilution chip (Figure 7.13). The vessel was machined from a block of acrylic 
and fitted with a safety release valve with a set point of 30 psig. Additional pressure lines 
also connected the vessel to two pneumatic valves that allowed for controlled pressure 
relief. Finally, a pressure sensor was integrated, providing real-time readings of the 
internal vessel pressure. These components were controlled with a programmable 
microcontroller, allowing for a user-defined set pressure by specific actuation of the 
pump and controlled-release valves. Testing with this new pumping strategy confirmed 
consistent and positive flow without any backflow. 
7.7.5 Chip interface and clamping 
Prior work with earlier prototypes revealed that for a robust and reliable world-to-chip 
interface, a socket design had the highest probability of success. While brainstorming 
ideas, it was discovered that a commercial interface was available by Dolomite. Known 
as the Dolomite MultiFlux™ system, it provided a clamp-type system that rather than 
interfacing with the PDMS chip itself, instead interfaced with a glass slide. These slides 
were pre-drilled with 0.5 mm diameter holes that were intended to coincide with inlets 
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and outlets on the microfluidic chip. A specialized 0-ring assembly clamps down on the 
glass and provides a secure fit. There were two major drawbacks to using this interface. 
The first was that all of the chips would have to be redesigned so that the inlets and 
outlets matched the holes in the pre-drilled glass slides. The second was that the glass 
slides were over 1 Ox more expensive. However due to growing complications with the 
both the pressure and detection systems, we moved forward with this interface. 
Moreover, in spite of the cost, using predrilled slides eliminated the need to core PDMS 
inlets and outlets, saving valuable fabrication time. 
Looking forward, future costs can be mitigated by exploring protocols for 
bonding PDMS to plastic. Plastics are both easier to drill and are cheaper than glass. This 
would enable the use ofthe same interface but at a fraction of the cost. 
7. 7.6 Illumination/detection 
While prior work on the detection system had been conducted, our largest priority as we 
began work with Fikst was still miniaturization and self-enclosure of the signal detector. 
As we outlined our future plans to use aptamers as a platform for probe development, we 
had chosen a fluorescein signature as a basis for all probes. 
Fikst quickly began work on how to achieve an optimal signal using a compact 
assembly. As we had determined through our previous prototypes, Fikst agreed that 
photodiodes would be a more appropriate component for detection in comparison to a 
CCD sensor. However, unlike our original design, Fikst strongly suggested the use of 
focusing optics to enhance the signal. While high-power LEDs were proving themselves 
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as a useful alternative to laser excitation, we still needed to ensure that we collected as 
much light as possible from the sample to ensure that our results were as quantitative as 
possible. A design was consequently drafted using an LED, two filters, two lenses, and a 
photodiode (Figure 7.14). 
While this work was moving forward, the proof-of-concept studies at Boston 
University were ongoing. We had successfully fabricated tetracycline aptamers at a larger 
scale, and were beginning more dissolution tests. It was during this process that we 
determined that the API concentration of typical 50 mg tablets dissolved in 30 ml 
produced millimolar concentrations or higher; all of our past work was done with 
concentrations in the micromolar range. More importantly, millimolar concentrations for 
aptamers were unusually high, as the majority of aptamer research in literature was 
performed with nano- to micromolar concentrations. As we ran through the per-test cost 
estimates for using these high aptamer concentrations, we were running into numbers in 
the tens of dollars range; our target was less than $2. In the height of our prototyping 
working, we had stumbled into a serious roadblock. 
It was during this time that a secondary assay was being developed in the 
laboratory. Rather than using a binding probe to quantify APis, a chemical assay was 
being tested to specifically quantify artemisinin-derived active ingredients. A patiicular 
focus was put on artesunate, as the immediate need for a quantitative assay for the 
medication in the field was mounting. Compared tci the aptamer strategy, this new test 
was also luminescent. Rather than requiring an excitation light source to induce 
fluorescence, this assay generated light chemically and at a rate that was proportional to 
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the API concentration. While high concentrations were proving to be a detriment for the 
aptamer-based system, it had now become an advantage-the higher the concentration, 
the more luminescent light. For a detection system, luminescence also meant that no 
excitation light source would be needed, both cutting costs and freeing space. 
Unfortunately, the drawback was that the test was specific only to the artemisinin family 
of drugs. It was also more sensitive to reaction conditions and produced a lower light 
intensity than can be achieved with fluorescence. Still, it provided an alternative path 
forward. 
As the fmal stages of assay validation were being performed for the luminescence 
assay, parallel work was also conducted to solve the concentration problem for the 
aptamer-based system. The unique aspect of the dissolution chip was that it provided 
real-time and continuous monitoring of analyte concentrations. If the analyte solution was 
too concentrated for the fluorescent tag, a clear resolution was to dilute it. As we 
discussed in Chapter 6, a microfluidic dilution chip was developed to solve this problem, 
but the development time was taking too long, and there was an urgent need to complete 
and test a prototype system. The Center for Pharmaceutical Advancement and Training 
(CePA T) had just opened in Accra, Ghana, and OlJr collaborators at the USP were eager 
to test our method there. 
After carefully weighing the options, we switched our prototype strategy to 
incorporating the luminescence assay rather than the fluorescence, aptamer-based test. 
The remainder of the components would remain the same, and the additional excitation 
source could easily be added to the system later. Tests were initiated to assess the use of 
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the luminescence assay with the photodiode setup we had engineered for the fluorescence 
system. However, a significantly dimmer luminescence signal resulted in a second major 
design hurdle, as the most concentrated API solution provided a light intensity that was 
marginally higher than the background. 
To resolve this new problem, Fikst proposed a more complex approach that 
utilized a custom designed circuit board to filter and amplify the photodiode signal. This 
dramatically increased the photodiode sensitivity, now making it critical that minor 
cracks or gaps in the housing were addressed. After several design iterations, a magnetic 
enclosure was proposed that would allow the user to easily close the chip nest while 
keeping ambient light out. This enclosure was tested outside, under laboratory light 
conditions, and even directly under a lamp without any observed effect on the 
background signal from the photodiode. The final steps were to begin integrating the 
system components together. 
7.7.7 Control system: the Arduino heart 
The Arduino platform is an open-source system consisting of a single-board 
microcontroller and a software system that can be utilized to bring interactive hardware 
ideas to life. The board is based on an 8-bit Atmel ARV or 32-bit Atmel ARM chip, and 
integrates numerous pins that can be used to gather information from external sensors or 
send instructions to external hardware. Initially started in 2005 as a tool for students at 
the Interaction Design Institute Ivrea in Ivrea, Italy, the project has since gone viral, 
estimated to be in the hands of over 700,000 users in 2013.205 
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For PharmaChk, the Arduino platform provided the perfect balance of hardware 
control and flexibility. Built as a prototyping platform itself, the Arduino environment 
· provided us with the power to modify and fine-tune the response of the PharmaChk 
device as well as troubleshoot hardware-related issues. The Arduino provides a forgiving 
environment where hardware control code can be written and optimized before being 
finalized and hardcoded into a custom manufactured circuit board. 
Due to the open source nature of the platform, Arduino comes with many 
hardware extensions for which software libraries have already been written. One example 
is what is known as the Data Logger Shield. This piece of hardware easily interfaces with 
the Arduino board and provides the ability to timestamp data using a real-time clock. It 
also comes with an SD card interface, allowing the user to save and read data to and from 
an SD card. The Data Logger provided important features that were critical to the 
PharmaChk project. It allowed for data processing to occur onboard, while also providing 
the capability to later double-check it on a computer. It also enabled the use of logging 
files , which provided useful information about the device state as it ran. This was 
invaluable when troubleshooting hardware-related issues. 
The heart of the code used to program an Arduino board resides within the loopO 
function . As long as the Arduino is powered, the instructions within this function are run 
in a never-ending loop. While this is optimal for devices that perform repetitive tasks, 
procedural devices such as PharmaChk require a state structure that informs the code 
within the loopO function of the current device state and the respective set of instructions 
to perform. For instance, querying of the photodiode signal should only be done while a 
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test is running; it should not be perfonned while the user is selecting the test type or is 
reviewing the tests results. To build this structure into the Arduino code, the entire user 
experience from device power-on to shutdown was enumerated and organized. This 
experience was then split into a broad list of procedures that could each be defined as a 
unique device state. Finally, these states were programmed into the loopO function so 
that only code appropriate to the current state was executed during each run of the loopO 
function. 
7.7.8 User interface 
One of the most important aspects for any device from is the user interface-how exactly 
will the user interact with the system? As a field-based device for the developing world, 
one of our chief concerns for PharmaChk was ease-of-use. We wanted to design the 
system in a way that made it simple to use and required minimal training. 
With the Arduino platform, we were able to take advantage of yet another 
hardware extension to facilitate the development of a simple user interface-a 3.2" LCD 
touch screen. This was another programmable interface that allowed for custom screens 
to be presented to the user, and provided a means for user input to be communicated back 
to the Arduino microcontroller. Using this system, we designed a series of screens that 
walked the user through each stage of the test. Behind the scenes, these stages were what 
translated to device states. The screens provide all of the instructions that were relevant to 
the user, eliminating the need to refer to a separate manual for test procedures. 
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7.7.9 Putting it all together 
A photograph of the final system is provided in Figure 7.15. The completed device ran 
on a 12 V power source provided by an adapter that could be plugged into either 120 V or 
220 V wall outlets. The system weighed approximately 18 lbs, demonstrating a marked 
improvement over the 200 lb MiniLab® system. The onboard waste container was 
capable of supporting 1 0-15 tests before needing to be disposed of, providing the user 
freedom to run multiple tests in succession before emptying the waste. In total, over 40 
screens were programed into the unit, providing everything from test instructions to 
device status and error messages. 
7. 7.1 0 Prototype testing 
To verify that the final system could be used to accurately quantify artesunate, a series of 
dilutions were prepared and tested on the prototype. Tests were conducted on a well-
based microfluidic chip design demonstrated by Ho et al. and illustrated in Figure 
7.16.206 Dilutions of 0.4, 0.8, and 1.2 mg/ml were prepared using a 1.6 mg/ml working 
solution of artesunate (Sigma-Aldrich, A3731). The probe solution was prepared by 
dissolve 2 mg of luminal in 50 ml of 0.1M NaOH. Four replicates of these solutions 
were run through the PharmaChk system, in addition to two blanks (Figure 7 .17). While 
some points were discarded as clear outliers, the remaining data demonstrates clear 
separation between the different concentrations. Furthermore, the average blank value 
was 6.33x1 05 -fold smaller than the lowest prepared dilution, demonstrating good 
resolution. A plot of the average values for each concentration results in a clear linear 
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trend with a coefficient of determination of 0.992 (Figure 7.18). Additional work 
performed by Ho et al. demonstrates that no luminescence readings were registered when 
solutions containing isolated excipients were run through the system (Figure 7.19).206 
This demonstrates that the luminescence readings for artesunate are not affected by these 
common excipients. 
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7.8 Figures 
Figure 7.1 Conceptual diagram of a miniaturized fluorescence detection system 
focused on only detecting light intensity rather than resolving an image. 
The system contains an LED light as an excitation light source, an 
excitation filter to narrow the LED wavelength bandwidth, an emission 
filter to only allow fluorescence light to pass, and a light sensor to detect 
the resulting light intensity. This design eliminates the need for lenses, 
reducing cost, increasing handling robustness, and making alignment of 
optical components unnecessary. 
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Figure 7.2 Illustration of prototype I design. Housing focuses solely on miniaturizing 
optics, providing a space for an LED, the microfluidic chip, and the 
necessary light filters. Detection is performed using an iPhone camera that 
can sit atop the system. The LED sits below the housing and shines light 
up through the microfluidic. 
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Figure 7.3 Photograph of prototype I for a negative control where no sample was 
placed inside. Image clearly shows that blue light can still be seen through 
the emission filter that sits on the top of the housing. This filter is designed 
to attenuate blue light, however, the intensity of the LED is too high for 
the filter to completely block all blue light. 
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Figure 7.4 AutoCAD design of prototype II, where changes have been made to 
illuminate the microfluidic chip transversely. This allows the LED light to 
shine through the microfluidic chip, but fall on a rear wall of the housing 
rather than shine through to the emission filter. Sample that is excited in 
the microfluidic chip will emit light in all direction, which can be seen 
from above. An emission filter is still used to block out any blue light that 
may find its way to the detection opening. A separate holder was printed 
to position the microfluidic chip in the correct position in front of the 
LED. 
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Figure 7.5 3D Printed representation of prototype II, showing the housing lid with the 
emission filter inset and the separate chip holder containing an actual chip. 
Behind is the main housing, where the excitation filter is visible. Behind 
the filter rests the LED. 
L-- - 4 
165 
Figure 7.6 
1 
> 0.8 
+' 
·v; 
c 
Q) 
+' 
c 0.6 
Q) 
> ·~ 
(il 
~ 0.4 
0.2 
0 
0 
0 
(top) Images of B4F standard curve, starting with blank (top-left) and 
going up to 322 f.!M (bottom-right). (below) Plot of the standard curve 
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Figure 7.7 Design for prototype III chip interface. Syringe needles coupled to fluid 
connectors can more easily be inserted into a microfluidic chip than 
connecting the tubing directly. The needles can protrude up from the base 
of the new housing so that the microfluidic chip can just be pressed down 
onto the needles. This also puts the microfluidic channels, which are at 
surface with the glass slide, closer to the light sensor at the top of the 
housing. 
<E-- Microfluidic Chip 
Needles 
Needles/Tubing 
Adapter 
~ Tubing 
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Figure 7.8 AutoCAD design of prototype III with separate chip nest that aligns with 
features inside the housing base. This modular design provides access to 
the excitation filter inset, so that the filter can be easily inserted and 
removed. Three opening were designed into the anterior wall of housing as 
pictured below. These are sized to fit the fluid connectors so that the 
tubing can be easily connected on the outside out of the box. 
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Figure 7.9 3D printed representation of prototype III. Three syringe needles were cut 
to size and connected to the fluid connectors using luer lock adapters. A 
penny is pictured as a size reference. 
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Figure 7.10 Picture of compact dissolution vessel to dissolve a drug table. A magnetic 
stir bar coupled with a stir plate is used to agitate the solution within the 
vessel in order to accelerate dissolution. 
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Figure 7.11 Design of a pill cage that sits within the dissolution vessel. The cage 
separates the stir bar from the pill to prevent the two from colliding during 
the dissolution process. Holes were designed into the base of the cage to 
allow agitated flow to continue through into the body of the cage where 
the tablet is housed. 
Tablet 
Stir bar 
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Figure 7.12 Illustration of the mechanism of operation for a peristaltic pump. Several 
rollers sequentially collapse the tubing and roll forward and displace 
liquid. The tubing is then released before the next roller repeats the 
process.207 
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Figure 7.13 Solidworks design of the pressure vessel that houses all of the reagents for 
a test. This vessel is sealed and pumped full of air to a pressure set value 
in order to drive fluid flow through the microfluidic chip. 
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Figure 7.14 Solidworks design of miniaturized fluorescence detection unit containing 
an LED light source for excitation, two light filters, two focusing lenses, 
and a photodiode for detection. 
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Figure 7.15 Complete PharmaChk beta prototype. System is housed in a Pelican case. 
~ 
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Figure 7.16 Antimalarial luminescence-based chip with a pressure drop channel (a), 
the mixing channel with herringbone patterns (b), and the reaction 
chamber (c). Taken from Ho et a/.206 
A B c 
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Figure 7.17 Plots of artesunate dilutions run through the PharmaChk system along 
with a blank. The average signal for the blank across two runs was 
1.99xl o·4 with a relative standard deviation of 1.85xl o·5• This represents a 
signal increase of 6.33x104 between the blank reading and the 0.4 mg/ml 
peak value. 
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Figure 7.18 Standard curve of average readings from four dilutions of 1.6 mg/ml 
artesunate. Error bars are not provided for the 1.6 mg/ml concentration as 
the average value only represents two points. The coefficient of 
determination was 0.992, indicating a strong linear trend between 
artesunate concentration and observed voltage. 
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Figure 7.19 Spectrophotometric data presenting the observed luminescence of the 
artesunate probe mixed with common excipients in artesunate tablets. A 
positive control is included for comparison. The data demonstrates that the 
artesunate probe is not affected by the presence of common tablet 
excipients. Taken from Ho et a/.206 
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Chapter 8: Pilot Testing of PharmaChk System on Artesunate Medicines 
Quality in Accra, Ghana 
8.1 Introduction 
Substandard medication is a serious and growing public health concern. According to the 
World Health Organization 10-30% of medicines worldwide are adulterated.208 
Laboratory-based testing provides accurate analysis of drug samples, but is limited in 
throughput due to cost and logistics. Tum-around times for test results of tablets sent 
from the field can often approach months. For medicines awaiting customs clearance, this 
has significant impacts on procurement speed and efficiency. To combat this issue, an 
increase in the use and reliability of field-based screening tools is necessary. Several of 
h 1 ~ . d. . 1. . 209 2 10 b .11 . . 1 ~ t ese too s 10r testmg me 1cmes qua 1ty extst ' , ut many are st1 too 1mpract1ca 10r 
the field or provide only qualitative information that cannot be used to accurately identify 
substandard medication.52' 169 A quantitative, reliable, and field-ready screening tool 
remains a critical need. 
Previously, we presented a new and quantitative method for interrogating 
medicines and identifying substandard medication. The PharmaChk platform utilizes 
microfluidics to provide a method for specifically targeting a known API and analyzing 
its content within a pill. In our present work, we build on our well-based chip design to 
analyze artesunate tablets in the field. This design uses a simple staggered-herringbone 
(SHB) mixer to combine an artesunate sample with a reporter solution (Figure 7.16). 
This mixed solution fills an on-chip well of 5 x 5 x 3 mm, where it incubates to produce a 
luminescence signal. We have conducted initial field tests of the PharmaChk system 
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using this chip design to test three antimalarial field samples: Lever, Camosunate, and 
Glunate. These medicines were dissolved in phosphate-buffered saline (PBS) and the 
tests were conducted at the Center for Pharmaceutical Advancement and Training 
(CePAT) in Accra, Ghana. The samples were acquired locally and compared to results 
using the GPHF MiniLab® and HPLC. 
We show that the PharmaChk system provides precise results with relative standard 
deviations of less than 5%. Our results provide quantitative measurements for active 
pharmaceutical ingredient (API) content, but were inconsistent with both MiniLab® and 
HPLC testing. Further testing using an acetonitrile solvent system verified that these 
inconsistencies were due to incomplete and manufacturer-dependent dissolution of 
artesunate from the tablets. The substitution of acetonitrile for PBS as a tablet solvent in 
the PhannaChk system showed marked improvement in test accuracy. 
8.2 Materials and methods 
8.2.1 Chip fabrication 
Microfluidics chips were fabricated using polydimethylsiloxane (PDMS) cast on an SU8 
mold. The molds were made using two spin-coat layers consisting of SU8-2100 (1500 
rpm) followed by SU8-2025 (2000 rpm). Each layer was exposed to a 350 nm light 
source through a chromium photo mask using the SUss MicroTec MA6 mask aligner. The 
mold was developed using SU8 developer after both layers had been spun. 5 x 5 x 3 mm 
aluminum squares were machined and glued to the mold using superglue to cast wells. 
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PDMS was mixed using the Sylgard 184 silicone elastomer kit at a 10: I ratio and cured at 
80°C for 2 hr. The chips were bonded to Dolomite predrilled glass slides (Dolomite, 
3200275) after 0 2 plasma exposure using the PVA TePla M4L plasma asher. Chips were 
then incubated at 80°C for 6 h to deactivate plasma-activated surfaces. 
8.2.2 Probe preparation 
2 mg of hematin porcine (Sigma-Aldrich, H3281) and 2 mg of luminal (Sigma Aldrich, 
123072) were dissolved in 50 ml of 0.1 M NaOH using a stir bar for 30 min. A fresh 
probe solution was prepared at the beginning of each day of testing. 
8.2.3 Artesunate reference solution 
16 mg ofartesunate (Sigma-Aldrich, A3731) was dissolved in 1 ml of200-proofethanol. 
The solution was then diluted to 10 ml with IX PBS to yield a final concentration of 1.6 
mg/ml of artesunate. 
8.2.4 Tablet preparation 
16 mg of artesunate (Sigma-Aldrich, A3731) was dissolved in I ml of200-proof ethanol. 
The solution was then diluted to I 0 ml with IX PBS to yield a final concentration of 1.6 
mg/ml of artesunate. 
8.2.5 Liquid injectable preparation 
16 mg of artesunate (Sigma-Aldrich, A3731) was dissolved in I ml of 200-proof ethanol. 
The solution was then diluted to 10 ml with IX PBS to yield a final concentration of 1.6 
mg/ml of artesunate. 
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8.2.6 CePAT studies 
An artesunate reference, Lever, and Camosunate tablet samples were prepared and run on 
the first day. An 80% reference solution was also prepared and run by diluting the 700 Ill 
of the remaining reference sample to 900 !J.l with IX PBS. Filtered Lever and 
Camosunate tablet preparations were run on the second day along with a pure artesunate 
reference solution. On the fmal day, a Glunate sample was prepared and run. 
8.2.7 HPLC studies 
Tablet preparations and analysis were conducted using USP standard protocols at their 
facility in Rockville, MD. 
8.2.8 PharmaChk data processing 
Luminescence values sampled at 16 Hz were saved to an SD card in the form of comma-
separated values (CSVs). Plots of the resulting data provide a reaction profile of 
luminescence intensity over a capture period of 5 min. Several data processing strategies 
were tested to determine a reliable quantitative measure from the acquired data. Peak 
value was determined to be the most reliable in comparison to curve area and signal rate 
of increase, and was used for all analysis. 
8.2.9 Acetonitrile testing 
Tablet preparations were conducted following the same protocol used for testing in IX 
PBS with the exception of dissolving the tablet in 50% acetonitrile rather than PBS. 
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8.3 Results 
Tests at CePA T were successfully completed with minimal chip failures . Failed chips 
were considered ones in which the well did not fill completely in the allotted time due to 
channel blockages associated with fabrication. Data obtained from failed chips were 
discarded and are noted for relevant figures. 
The relative standard deviation (RSD) for all samples was found to be less than 
5%. Tablet to tablet tests from the same brand also showed consistent results independent 
of filtering, with percent differences of less than 4% (Table 8.1). Plots of the data are 
presented in Figures 8.1-4. The only samples that showed a notable difference from day 
to day were those for the artesunate reference solution. Although the peak values for each 
of the runs were consistent, data from the first day showed broader peaks. 
Comparisons of the PharmaChk results to HPLC are provided in Figure 8.5. 
MiniLab® results confi1m API content of between 80-IOO% for both Lever and 
Camosunate. As a protocol for liquid injectable medicines is not established for the 
MiniLab® test, Glunate was not tested on that platform. PharmaChk data showed 
inconsistent readings against the HPLC data for tablets dissolved in IX PBS. Percent 
errors were calculated to be 8.58% and 30.98% for Lever and Camosunate, respectively. 
Repeat tests conducting using 50% acetonitrile as a solvent rather than IX PBS showed 
improved results with an error of less than 4% when compared to HPLC data obtained 
from USP (Table 8.2). 
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8.4 Discussion 
We demonstrate that PharmaChk can reliably test samples with a relative standard 
deviation of less than 5%. This is further supported by tablet-to-tablet consistency, 
. despite testing on different days using fresh probe solutions for each day. However, 
comparisons of the tablet signals with the reference solution show unexpected results. 
While MiniLab® and HPLC results indicate API contents between 80-100% for both 
Lever and Camosunate, the Camsonunate signal using PharmaChk gave a result of 65%. 
Given the consistency of the signal obtained using PharmaChk for both tablets with and 
without filtering, the presence of any particles was ruled out as a cause. 
The use of 50% acetonitrile as a solvent rather than IX PBS showed marked 
improvement in results, with an error of less than 4% when compared to HPLC data. This 
not only indicates that the solubility of artesunate is poor even in tablet preparations, but 
also that its solubility is variable based on the manufacturer. While this could indicate 
differences in the API that was sourced, a more likely explanation for this is differenes in 
the relative concentrations of excipients within these tablets. Varying salt contents have 
an impact on solubility that could result in different dissolved concentrations of 
artesunate for tablets manufactured using different formulations. The use of acetonitrile 
demonstrates that with an appropriate solvent, these affects can be circumvented in order 
to obtain accurate measurements for API content regardless of tablet formulation. 
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8.5 Tables 
Table 8.1 
Sample 
Demonstrates the day-to-day repeatability in sample tablets on the 
PharmaChk system. Comparisons show a percent difference between days 
of less than 5%, which falls within the relative standard deviation of the 
individual data sets. Samples on day 1 were not filtered, while sample on 
day 2 were filtered through a 0.2 Jlm hydrophobic filter. The results 
indicate that the assay results are independent of the presence of 
particulate matter in solution. 
Day 1 Day2 % Difference 
Reference Solution 3.34 3.47 4.01 
Lever 3.54 3.44 2.99 
Camosunate 2.45 2.36 3.83 
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Table 8.2 
Sample 
Lever 
Camosunate 
Compares PharmaChk testing using 50% acetonitrile (n=3) against HPLC 
data obtained from USP (n=5). Results indicate a consistent error of 
approximately 3%, demonstrating a marked improvement over testing 
performed using lX PBS as a solvent. 
PharmaChk HPLC 0/o Error 
90.7% 88.0% 3.1 
97.8% 94.9% 3.1 
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8.6 Figures 
Figure 8.1 
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Plot of five replicates conducted of the artesunate reference tablet from the 
MiniLab® kit. 
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Figure 8.2 
a 
Plot of multiple replicates conducted of the artesunate reference solution 
(1.6 mg/ml) over two days. Trial 3 was discarded from the 3112 data due 
to a chip failure. The plot shows consistent peak values across the two 
days, although the peak width is greater for data obtained on 3/11. 
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Figure 8.3 
0 
Plot of multiple replicates conducted of the Lever tablets across two days. 
A different tablet was tested each day, but the plots show consistent peaks 
across all tests. The RSD for replicates within a tablet was less than 5% 
for both. 
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Figure 8.4 
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Plot of multiple replicates conducted of the Camosunate tablets across two 
days. A different tablet was tested each day, but the plots show consistent 
peaks across all tests. The RSD for replicates within a tablet was less than 
5% for both. Trial 5 of the Camosunate tablet tested on 3/12 was discarded 
due to a chip failure. 
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Comparison of PharmaChk results to HPLC. API percentages for 
PharmaChk results were normalized to the pure artesuante reference. 
While the tablet results (Lever and Camosunate) in IX PBS show 
inconsistencies with the HPLC results, the Glunate liquid injectable 
exactly matches HPLC data. PharmaChk results represent an average of 5 
replicates. HPLC data is representative of 20 samples crushed together and 
sampled using 5 replicates for testing. 
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Chapter 9: Cc;mclusions and Future Work 
Decades of studies and reports have proven time and again that counterfeit and 
substandard medicines are a terrifyingly immense problem. Some studies have shown 
that in a few areas of the world, up to 60% of medicines are adulterated. Millions of sick 
continue to search for treatment, but in a growing economy for essential medicines, they 
are increasingly met with fake and poor quality alternatives. Policy-makers on both the 
national and international scale are diverting more of their efforts to solving this problem, 
however the lack of specific information regarding the extent of the problem makes a 
difficult case for targeted and focused policies. While we see the burden of a large 
problem on our hands, we remain unaware of how it fell and continues to fall upon us. 
The use of quantitative, field-based methods for medicines testing is essential for 
resolving this issue and obtaining hard numbers for what per~entage of medicines are 
fake, what percentage are substandard, and where along the global and local supply 
chains these drugs are entering the stage. While laboratory tests have begun to help 
elucidate this problem, testing is not widespread and is not designed to handle the scale 
and throughput necessary to obtain a comprehensive understanding of the problem. 
Furthermore, as pieces of equipment that require permanent homes, they require 
additional resources in the form of logistics in order to have samples sent from the field 
and results sent back. Inexpensive field-based analysis is the only suitable way for scaling 
testing in a controlled and manageable way. The same price tag will buy more field-based 
devices than mammoth laboratory instruments, already increasing throughput. Moreover, 
as field-based alternatives, they are able to test on the spot, removing logistical 
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complications and enabling immediate data collection at the source. From a policy 
standpoint, this allows for informed decision-making on a local level. Portable, field-
based technologies can also be used to travel up and down the supply chain and probe it 
for leaks; however, without quantitative methods, these results are inconclusive, 
demonstrating wasted eff01is rather than valuable information. The current technology 
landscape for field-based approaches illustrates tremendous improvement over the last 
decades; however, a truly quantitative methodology remains elusive. 
Through the course of this work, we have made tremendous strides in specifically 
confronting that problem. Using a holistic approach, we demonstrated the design and 
implementation of a quantitative, inexpensive, and robust technology that addresses many 
of the technical and user-based problems that are commonly encountered in the field. In 
addition to assessing API content, our approach also provides the capability of 
determining API release kinetics. This has never been done before in the field. In addition 
to the contributions that this technology can offer to this larger problem, this thesis also 
demonstrates scientific contributions to both microfluidics and biomedical engineering at 
large. 
9.1 Microfluidics model 
Microfluidics continues to grow as an area that not only provides alternative assays to 
existing bench top tests, but also is exploring novel applications.211 However, progress in 
this field is requiring increasingly more complex microfluidic designs. To aid in this 
design process, many are using CFD simulations and application such as pSpice that 
194 
solve equivalent networks represented as circuits. However, CFD simulations are 
computationally expensive, and applications such as pSpice require manual conversion of 
microfluidic channel dimensions into equivalent electrical resistances. These approaches 
are being less suitable for thorough analysis of large network designs. 
9 .1.1 Major contributions 
The web-based software system developed as part of this thesis provides a new 
opportunity to directly analyze a microfluidic network for the first time. Based on a 
simple Hagen-Poiseuille model, this analysis provides quick solutions to fluid flow in 
complex and interconnected microchannels. Furthermore, it allows direct control of 
microchannel geometries, allowing users to specifically analyze how channel height, 
width, or length individually impact system-wide fluid behavior without requiring any 
manual conversions to equivalent electrical resistances. The interface is extremely easy to 
use, providing quick and easy creation and placement of new channels and pressures. 
Furthermore, it supports the establishment of named variables that are graphically 
represented onscreen and can be used to set values for microfluidic component 
properties. This allows the user to quickly change a property that is shared by multiple 
channels in one location, and minimizes the risk of forgetting a component when such a 
change is made. 
In addition to the power provided by analyzing the fluid flow in a single click and 
without any manual conversions, the system allows for tabulation of a custom formula 
while a single component property is varied. In Chapter 6, this feature was used to 
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analyze how the overall dilution factor provided by the chip was affected by varying 
channel heights; a custom formula was entered that takes the ratio of flow rates 
throughout different channels in the network and yields the overall dilution factor. This 
formula was automatically parsed by the system and evaluated for different channel 
heights. The range of channel heights evaluated was user-defined, and the results were 
outputted in a user-defined format that in addition to the function value, also included 
specific component properties. Using this feature, the resulting output can easily be 
copied to applications such as Excel to perform additional analysis or simply plot the 
results. In applications such as pSpice, this analysis would require manual conversions of 
all channel geometry changes to electrical resistance each time a new channel height was 
to be analyzed. Using the tool developed in this thesis, the analysis instead took minutes. 
9 .1.2 Future investigations 
Built as a modular software platform, there are many additions to the system that would 
add tremendous value to microfluidic modeling. One example is including a model for 
the pressure drop across a herringbone-patterned microchannel. Micromixers are a 
common component in many integrated rnicrofluidic chips, and having the power to more 
accurately account for their effect on fluid behavior would provide a more accurate 
description that can be exploited in the design phase to develop precision microfluidic 
networks. Another example is the effect of serpentine channels on flow rate. Serpentine 
channels are commonly used in designs were chip real estate is valuable, but long 
channel are necessary. The ability to account for any effects they have on bulk fluid 
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behavior would be valuable m order to generate a more accurate model for design 
purposes. 
Beyond more accurate descriptions of fluid behavior as a result of channel design, 
another important area for further investigation is the effect of pressure on PDMS 
channel deformation. While much work has been performed by others confirming PDMS 
deformation as a result of pressure or fluid flow, it is critical to understand to what extent 
this occurs. Many alternative materials to PDMS chips are being explored, but most are 
typically used once the design phase has been completed. The fact remains that PDMS 
and soft photolithography provides one of the cheapest and fastest methods for rapid 
prototyping. While PDMS may not be suitable for large-scale manufacturing of chips, it 
is invaluable in the design phase. By incorporating a modular component into the web-
tool developed as part of this thesis, microfluidic designs could take PDMS deformation 
into account during the prototyping phase. Once the design concept has been proven and 
actualized, the same concept can be used to quickly build a microfluidic design for a 
different chip material that is not susceptible to these deformations. 
9.2 Continuous analyte monitoring 
Monitoring of analytes in solution is used in many fields ranging from medicine to water 
treatment. A plethora of methods and techniques are employed to perform this 
monitoring for different types of analytes. Some examples are optical, electrochemical, 
and colorimetric analyses. In this thesis, we demonstrated that binding-based methods 
can also be used to monitor analyte concentration. 
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9.2.1 Major contributions 
While binding-based methods have been used in analyte quantification or years, they 
have typically been used for single sample analysis. ELISA assays are a perfect example, 
where antibodies to a target analyte are used to quantify analyte concentration in a single 
sample. However, methods such as these typically require incubation times for accurate 
analysis. In this thesis, we presented a flow-through design using aptamer binders that is 
capable of performing the same level of quantification without requiring incubation 
times. In addition to reducing assay length, the test provides a method for continuous 
monitoring, which has many applications including therapeutics. Furthermore, because 
the aptamer probe solution is stored separately from the analyte, the two are only in 
contact for the few seconds they mixed together and analyzed on the microfluidic chip. 
Consequently, the presence of RNAse and DNase enzymes that can degrade aptamers are 
of little concern as the kinetics of those reactions cannot produce significant degradation 
on the time scale of the microfluidic chip. This can oftentimes be a problem for other 
testing approaches that require extended incubation times. Additionally aptamers are 
significantly more stable than antibodies as they can refold into their original 
conformation even after denaturing. A key contribution during this work was the 
demonstration that aptamer binding kinetics can be sufficiently fast to support 
quantification in a flow-through system without requiring any incubation time. 
In addition to demonstrating continuous analyte concentration, this thesis also 
explored the potential for continuous dilution of the analyte prior to analysis. A 1000:1 
dilution chip was designed and tested demonstrating this dilution, and the resulting 
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design enables easy integration into the existing quantification chip. Together, the use of 
analyte dilution prior to quantification means that the amount of aptamer required for a 
single test is reduced by a thousand-fold, having significant implications for cost and 
aptamer production. 
9 .2.2 Future investigations 
While continuous dilution was demonstrated and the design easily lends itself to be 
integrated with the quantification chip, further work is still necessary to perform this 
integration and analyze design sensitivities for the complete chip. Additional work could 
also be performed to optimize the channel dimensions to minimize this sensitivity. 
In addition to this work in single analyte quantification, multiplexed analysis of 
multiple analytes would be extremely powerful. Such an analysis would require the 
development of aptamers that utilize different fluorescence signatures so that a single 
solution containing aptamers for multiple analytes could be used to perform 
quantification. Using this approach, a rotating filter wheel could be used to single out a 
single fluorescence signature at a time, but do so at a high frequency so as to maintain 
continuous monitoring for all analytes. 
9.3 Quantitative approach for medicines quality testing 
This thesis provides numerous contributions to further scientific inquiry; however, its 
conception and impetus came from a larger, global problem. As highlighted numerous 
times, counterfeit and substandard medicines are a public menace that kill hundreds of 
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thousands every year and threaten millions more. A quantitative, field-based testing 
approach is desperately needed in order to more precisely defme the problem. In this 
work, our aim was to directly address this technology gap by designing and developing 
such a methodology. 
9.3.1 Major contributions 
Above all else, this work enables a quantitative approach to medicines quality testing-
something that has never been done before. While many technologies have provided 
semi-quantitative readings, none specifically focus on API content and kinetic release. 
The result has been a plethora of technologies that require trained users to interpret 
results and draw conclusions. With the quantitative methodology provided in this thesis, 
no specific expertise is required to interpret results. Instead, hard numbers for API 
content are provided that can be directly compared to indications on the medicine 
packaging. While certainly making the user experience easier, this has more important 
implications for data comparisons. Using technologies such as MiniLab®, results are 
completely dependent on user competence and interpretation. Furthermore, the 
specifications for a good quality medicine versus a poor quality medicine are completely 
different when compared to other technologies such as TruScan or Phazir™. This has 
made it extremely difficult to compare data from different studies. Quantitative 
measurements of API content do not suffer from this problem. Results based on percent 
API can be directly compared from different studies, providing an intuitive and universal 
platform for assessing the extent of poor quality medication in different parts of the 
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world. This represents a tremendous step forward in providing policy-makers with 
relevant information that can be used to devise informed strategies to mitigate and 
ultimately eliminate this problem. 
9.3 .2 Further investigations 
Through the development of this work, we demonstrated translation of a laboratory-based 
methodology to a field-ready platform; however, in order to complete this process and 
provide a useful tool to medicines regulatory authorities, a number of refinements and 
additional work is necessary. 
9.3.2.1 Probe development 
A key component of the PharmaChk system is the fluorescent tag or reporter molecule. 
These aptamer solutions are specific to a particular API, conferring the testing platform it 
specificity and accuracy. In Chapter 5, we demonstrated the use of aptamers to quantify 
the antibiotic tetracycline. This provided an important proof-of-concept, but to provide a 
complete system that is capable of testing multiple drugs, more aptamer probes must be 
developed. Fortunately, the SELEX approach provides a platform upon which this 
development can take place, but in order to take advantage of it, an aptamer design and 
selection system for produce binders with fluorescent reporting must be finalized. 
The SELEX process is crucial next step for the PharmaChk platform, but technology 
development is only half of the picture. In order to make a quick and important impact on 
the substandard medicines problem, APis for which aptamers are developed must be 
carefully and strategically selected. Antimalarial medicines represent a class of drugs that 
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see one of the highest rates of counterfeit and substandard manufacturing. The 
development of aptamers for these medicines would be of tremendous value. 
Additionally, oxytocin, a leading drug used for post-partum hemorrhaging is also one of 
the most poorly stored medicines in the developing world. With the potential to save 
millions of lives, it is often stored at ambient temperature where it quickly degrades and 
becomes useless. Nevertheless, this drug continues to be shuffled down the supply chain, 
finding its way into the bloodstream of mothers around the world. An aptamer probe to 
ensure oxytocin efficacy is critical to saving lives in these areas of the world, and should 
be another important focus for aptamer development. 
9.3.2.2 Prototype refinement 
The beta prototype developed with the help of Fikst represented a leap forward on the 
path of technology translation from the laboratory to the field. However, this prototype 
still only performs luminescence readings. While the chemiluminescent assay that was 
developed for antimalarials provided an opportunity to push prototype development while 
also addressing an important class of drugs, it's use is limited to the artemisinin family of 
medicines. Long-term use of the PharmaChk system relies on fluorescent aptamers that 
can be designed for any API. A fluorescence detection system must be incorporated into 
the prototype in order to enable this testing. Fortunately, this does not require the 
modification of existing components. Instead, it simply requires the addition of an LED 
light for excitation and excitation and emission filters to facilitate sensitive readings. 
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Additionally, our time in Ghana provided the fortunate opportunity of receiving 
user feedback. Overall, the response was extremely positive, but minor improvements 
such as a larger screen and smaller form factor were suggested. Addressing these 
comments will be paramount to providing a system that is both useful and well received. 
9.4 Concluding Remarks 
In providing a quantitative, field-based method for substandard and counterfeit medicines 
testing, this thesis provides an important contribution to the existing toolset that is used to 
safeguard the supply of essential medicines. PharmaChk offers a unique testing platform 
that can be used to test any drug and obtain both API content and kinetic release from a 
dissolving tablet. These are critical quality parameters that are not tested by any other 
technology in the field and represents essential information to policy-makers that can 
devise strong and strategic approaches to solving this problem. With our experience in 
Ghana and with the USP, we have heard time and again that a testing method that 
provides this type of information is desperately needed. By devising an inexpensive, 
portable, accurate, and robust technology that offers this data, PharmaChk has the 
potential to rapidly identify poor quality medicines and ultimately save the lives of 
millions around the world . 
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